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ABSTRACT 
The global outbreak of Severe Acute Respiratory Syndrome which began in 2002 and ended in 2003 
resulted in over 8000 cases in 29 countries, causing an atypical pneumonia which resulted in a case 
fatality rate of ~10%. The etiological agent of this disease was found to be a novel coronavirus dubbed 
SARS Coronavirus (SARS-CoV). One of the distinguishing features of this virus is the presence of 
several accessory genes in its positive-stranded RNA genome which have no known homologs in the 
coronavirus family. In this thesis we examine virus host interactions in the context of SARS 
coronavirus in order that some insight may be gained into the biology of this virus, which is still the 
subject of investigation.  
 
A lot of work has been done to study the function of SARS-CoV accessory proteins. One of these is 
the ORF6 accessory protein, which has been shown to accelerate infection, interfere with interferon 
production and signaling by impeding nuclear translocation, induce membrane rearrangements in the 
host cell and induce ER stress and subsequent caspase-mediated apoptosis. Examination of the ability 
of ORF6 to interact with other virus proteins by a yeast-two-hybrid assay showed an interaction with 
the nsp8 replicase protein. A direct interaction was shown using a cell-free system, and subsequently, 
transient transfection and immunoprecipitation experiments in Vero E6 cells showed that these 
proteins interacted in mammalian cells, which was confirmed in SARS-CoV infected cells. 
Examination of the co-localisation of these proteins in infected Vero E6 cells also showed a subcellular 
localization of the ORF6 protein to a intracellular vesicular population which was Lamp1- and CD63-
positive.  
 
The impedance of nuclear translocation by the ORF6 protein is linked to its ability to function as an 
interferon antagonist. A plasmid-based system comprising a CMV-derived promoter was used to 
replicate this impedance, and it was found that the impedance is dose-dependent. Additionally, 
plasmid-expressed ORF6 was shown by immunofluorescence to colocalise with an intracellular 
vesicular population positive for Lamp1 and CD63. Alanine substitution of a putative diacidic motif in 
the ORF6 protein showed a reduction in the impedance of nuclear translocation and when examined by 
immunofluorescence also showed clustering of ORF6-stained vesicles, suggesting that the impedance 
of nuclear import by ORF6 and its localisation to this specific vesicular population are linked.  
 
In order to characterize the differential expression of genes in host cells which might lead to ORF6-
mediated apoptosis, a defective recombinant vaccinia virus expressing ORF6 was generated. Analyses 
were performed using a QPCR array specific to human apoptotic signaling as well as microarray 
analysis for examination of genome-wide differential expression. Subsequent analysis of these results 
suggested that the extrinsic pathway of apoptosis was upregulated in cells expressing ORF6, and that 
intracellular calcium flux might have a role to play in ORF6-mediated apoptosis.  
 
The introduction of an exogenous nitric oxide donor into Vero E6 cells infected with SARS-CoV has 
been shown to exert a negative effect on viral replication. Here an attempt was made to explore the 
mechanism of this inhibition. Nitric oxide can exert an effect on viruses either directly or through 
several redox intermediates, one of which is peroxynitrite, which is formed through the reaction of 
nitric oxide and superoxide. It was shown that the effect of the exogenous nitric oxide donor SNAP on 
SARS-CoV replication was not due to the effect of peroxynitrite, but probably through direct action of 
nitric oxide or another derivative. Examination of the palmitoylation of the S protein in SNAP-treated 
cells showed that SNAP treatment was able to reduce S palmitoylation and consequently its binding to 
the ACE-2 receptor in an in vitro cell-cell fusion assay. Also, QPCR analysis of viral RNA production 
showed a significant reduction in SNAP-treated cells. Examination of the cleavage of viral replicase 
polyproteins in these cells showed an alteration in the cleavage pattern of the replicase polyproteins.  
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1 INTRODUCTION 
 
Coronaviruses are a family of enveloped, positive-stranded RNA viruses. These viruses are 
classified under the order Nidovirales, within the family Coronaviridae. The other family of 
viruses under this order are the Arteriviridae, which comprise viruses of veterinary importance, 
such as equine arteritis virus (EAV). Other members of the coronavirus family include the 
porcine virus transmissible gastroenteritis virus, (TGEV), the avian virus infectious bronchitis 
virus (IBV), feline infectious peritonitis virus (FIPV), mouse hepatitis virus (MHV) and the 
human coronaviruses 229E and OC43 which are well documented in the literature. The name 
Coronavirus is derived from the characteristic appearance of these viruses in electron 
micrographs, which resemble a solar corona. These viruses have among the largest genomes of 
any virus family, and encode a variety of proteins. Up till recently, the only coronaviruses known 
to be pathogenic to humans were 229E and OC43, and these were only responsible for mild flu-
like symptoms in patients.  
 
With the onset of the Severe Acute Respiratory Syndrome (SARS) epidemic in 2003, 
coronaviruses attained an unprecedented notoriety in the eyes of the public, and coronavirologists 
accordingly attained an unprecedented popularity. By most accounts, the outbreak of SARS 
began in Guangdong Province in Southern China in late 2002. By the time the World Health 
Organisation (WHO) office in Beijing had been notified of a strange respiratory disease spreading 
through the province in the same year, there were rumoured to be over 100 fatalities in 
Guangdong alone. Official statements released in February of 2003 described approximately 300 
cases of this respiratory disease. By the time the WHO had called an end to this epidemic in July 
2003, there had been 8096 documented cases with 774 deaths, indicating a case fatality rate of 
about 9.6% (http://www.who.int/csr/don/2003_07_04/en/index.html). But these numbers did not 
just arise from Guangdong - during the course of the epidemic, 29 different countries were 
affected by SARS. While most of the documented cases were in China, there were significant 
numbers of SARS cases in Hong Kong, Singapore, Taiwan and Canada, mostly related to the 
Chinese diaspora. Travellers to China and emigrants who had returned home for the Lunar New 
Year in early 2003 had brought this disease back with them, resulting in the global spread of a 
disease that brought death, widespread panic and an economic toll of approximately US$ 20bn 
over the course of just a few months. Hong Kong was considered to be the epicenter of the global 
spread of SARS, and it was from here that the first clinical reports of the outbreak emerged, 
describing an 'atypical pneumonia' that attending physicians were confronted with. Reports from 
the WHO document the role of one hotel where travellers from Singapore, Vietnam and Canada 
all came into contact with infected individuals from Guangdong province and became index 
patients in their respective countries.  In April that year, just a month after the initial reports of the 
outbreak in Hong Kong, a novel coronavirus was described as being the etiological agent of this 
disease (Peiris et al 2003b, Ksiazek et al 2003, Drosten et al 2003).  
 
Clinically, SARS resembled the symptoms of influenza - indeed, when SARS emerged, infectious 
disease physicians thought that this was the emergence of a human strain of highly pathogenic 
avian influenza (HPAI, personal communication). Along these lines, the WHO published a case 
definition of SARS in order to differentiate potential SARS cases from other illnesses resulting in 
respiratory syndromes. However, in the interest of prudence, the case definition was itself vague: 
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"A suspected case of SARS is an individual with fever (temperature 38°C 
[100.4°F]), cough or dyspnea, and contact with an individual believed to 
have SARS or to have traveled to a region where there has been documented 
transmission of the disease. A probable case is an individual meeting 
criteria for a suspected case along with radiographic features of 
pneumonia, respiratory distress syndrome, or an unexplained respiratory 
illness resulting in death with autopsy results demonstrating pathology of 
respiratory distress syndrome without an identifiable cause." 
       - WHO Global Alert and Response, May 2003 
 
The progression of the disease itself was triphasic. Infected individuals underwent an incubation 
period of about 1-11 days, before the presentation of the first phase of symptoms which included 
fever, myalgia and lung radiographs which showed air spaces. Within the first week, most patients 
showed incremental improvement which was widely attributed to the administration of a 
combination of ribavirin and corticosteroids by attending physicians (Peiris et al 2003a, Tsang  
2003, Tsui et al 2003). However, into the second week, symptoms usually began to worsen, with 
the recurrence of fever and the onset of diarrhea. Lung radiographs also show increasing 
consolidation of air spaces during this phase of the disease. By the 10th day after initial 
presentation, most patients were observed to undergo IgG seroconversion (Peiris et al 2003a). The 
onset of the third and severe phase of SARS in marked by acute respiratory distress syndrome 
(ARDS), oxygen desaturation, severe lymphopenia and thrombocytopenia, which was suspected 
to have resulted in nosocomial sepsis in several patients, and eventually death (Peiris et al 2003a, 
Lew et al 2003). This phase was seen as a turning point in the disease as far as patient prognosis 
was concerned, and many patients were observed to not progress to this stage, eventually going 
into recovery. Complicating this was also reports of toxicity in patients due to the administration 
of ribavirin (Booth et al 2003). Because of the unknown nature of the disease, several 
combinations of therapies were used in diverse settings, with some reporting limited success. An 
example of this was interferon Alfacon-1, which showed promise in combination with 
corticosteroids in the Toronto SARS cohort (Loutfy et al 2003), with a later study also showing 
potential with the use of interferon treatment on SARS isolates in in vitro experiments (Cinatl et al 
2003). 
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2 THE SARS CORONAVIRUS 
 
2.1 IDENTIFICATION OF A NOVEL CORONAVIRUS 
 
During the initial phases of the outbreak both in Asia and globally, the medical community was 
racing against time to treat SARS patients, but the cause of the disease itself was unknown. But 
there were clues to the infectious nature of the disease, in particular the fact that several cases of 
the disease came from unrelated individuals who were staying at the same hotel in Hong Kong. In 
order to identify the etiological agent of a disease, Robert Koch devised a series of postulates in 
the 1880s, which in modern-day science came to be known as Koch's postulates. These 
postulates, while initially developed with bacterial diseases in mind, were subsequently modified 
by Thomas Rivers for viral diseases in 1936. In order for a virus to be proven as the etiological 
agent of a given disease, the burden of proof rests on: 
 
1) Isolation of virus from a diseased host 
2) Cultivation of virus in host cells 
3) Proof of filterability 
4) Production of comparable disease in the original host species or a related one 
5) Re-isolation of the virus 
6) Detection of a specific immune response 
 
It was eventually in June 2003 that several groups identified a novel coronavirus as having 
fulfilled these requirements to be deemed responsible for the SARS epidemic (Drosten et al 2003, 
Fouchier et al 2003, Ksiazek et al 2003, Peiris et al 2003b, Poutanen et al 2003). The coronavirus 
responsible for the outbreak of SARS was first imaged when it was isolated from patient samples 
in Vero E6 cells in Hong Kong, and carried this characteristic corona appearance: 
 
Figure 1. Structure of the SARS Coronavirus as seen by (a) electron microscopy, (b) stylized 
diagram of virus structure showing structural proteins and viral RNA genome.  Reprinted by 
permission from Macmillan Publishers Ltd: Nature Reviews Microbiology (Stadler, K., et al. 
SARS - Beginning to Understand a New Virus. Nature Reviews Microbiology 2003, 1(3): 209-
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218), copyright (2003). 
 
 
The identification and subsequent isolation of the virus, changed the face of the outbreak and 
heralded a surge in antiviral research targeted at gathering information on disrupting the virus' 
natural cycle and slowing down or inhibiting its transmission altogether. However, to date, no 
efficient therapeutic or prophylactic vaccine has been found for the SARS Coronavirus.  
 
The outbreaks at the Metropole Hotel and Amoy Gardens apartment complex in Hong Kong, 
when considered in the light of the discovery of this novel coronavirus shed more light on the 
transmissibility of the virus. At the sites of both community-based outbreaks, contact-tracing 
determined that infected individuals did not come into contact with each other in most instances. 
Because of the respiratory pathology of the virus, it was suspected to be  a respiratory virus, but it 
is well-documented that coronavirus tropism extends beyond the respiratory system - the 
gastroenterological nature of many coronaviruses suggests that the community-based outbreaks in 
Hong Kong may have been due to fecal-oral transmission of the virus, thanks to faulty sewage 
systems (Peiris et al 2003a, Drosten et al 2003). The respiratory nature of the virus meant that it 
was easily transmitted through the kind of aerosolization caused by coughing and sneezing. 
Along these lines, nosocomial infections in the sterile environment of a hospital where one could 
expect that the fecal-oral route of transmission would be minimal, were responsible for most of 
the infections observed in many of the countries affected, particularly where infections among the 
healthcare community were concerned. Respiratory equipment used in hospitals were deemed to 
have aided the aerosolization of the virus, which could have been a significant factor in the 
nosocomial transmission of the virus (Lee and Sung 2003). Given this information, a huge effort 
was put into the containment of the spread of SARS - the efforts of governments to screen and 
quarantine the symptomatic was crucial in halting the spread of the virus in its tracks, far before 
any significant progress had been made towards understanding the virus and designing 
therapeutic interventions. 
 
 
2.2 THE SARS-COV GENOME 
 
One of the first steps towards our understanding of the SARS coronavirus was attained with the 
sequencing of its genome in May of 2003, barely 3 months into the global outbreak. The initial 
characterization of the SARS-CoV genome was carried out through sequencing of 14 different 
virus isolates - from the Singapore index case, 3 primary strains in the Singapore outbreak, as well 
as other strains from Hong Kong and China, in an effort to examine the mutational dynamics of 
the virus as well as to carry out a more detailed study of the virus genome (Ruan et al 2003). This 
was followed soon after by almost simultaneously published sequencing reports of the Urbani 
strain (Rota et al 2003), the Tor2 strain (Marra et al 2003) and the Frankfurt-1 strain (Thiel et al 
2003). The genome of the prototypical coronavirus is, as in the case of SARS-CoV, a positive-
stranded, polyadenylated RNA genome.  The layout of the SARS-CoV genome is shown below: 
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Figure 2. Diagram of the SARS-CoV genome showing virus genes (above) and subgenomic 
RNA (sgRNA) species (below). Red denotes Replicase genes and sgRNAs. Blue for structural 
genes and sgRNAs and white denotes accessory genes and sgRNAs. Adapted from Thiel et al 
(2003).  
 
 
The SARS-CoV genome is an approximately 29.7kb long polyadenylated RNA genome. It can be 
seen that the virus genome contains 2 large replicase genes at the 5' end of the genome; Orf1a and 
Orf1b encode for the replicase polyproteins pp1a and pp1b. The replicase gene Orf1b is located -1 
to the reading frame of Orf1a. Downstream of these genes are prototypical coronavirus structural 
genes - spike (S), envelope (E), membrane (M) and nucleocapsid (N). It was also noticed that 
encoded amongst these structural genes were other open reading frames which were assumed to 
encode for nonstructural genes. These were eventually labeled 'accessory genes', and their 
nomenclature, which differed between reports on the sequences, was eventually resolved. Also 
observed on the SARS-CoV genome were a 72nt leader sequence at the 5' end of the genome and 
a terminal sequence at its 3' end. The examination of the SARS-CoV genome led to a great deal of 
discussion over the classification of SARS-CoV within the three existing phylogenetic groups of 
the Coronavirus family. It was initially postulated that SARS was phylogenetically dissimilar to 
other coronaviruses and therefore ought to be classified in a group unto itself (Rota et al 2003, 
Marra et al 2003). This initial determination was carried out by either antigenic cross-reactivity or 
the examination of viral proteases as well as structural proteins. Based on these analyses, the 
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SARS_CoV genome did not fall into any of the three existing groups of coronaviruses. Based on 
analysis of the proteolytic cleavage and domain organization of the replicase polyproteins of 
SARS-CoV, a third proposal was posited - that SARS-CoV was an early split-off from the Group 
2 coronaviruses, which included mouse hepatitis virus (MHV) and bovine coronavirus (BCoV). 
While this sparked considerable debate in the coronavirus community, the classification of SARS-
CoV was eventually settled and the virus denoted part of the Group 2 coronaviruses, albeit as a 
subgroup - Group IIb. The prolonged (and contentious) classification exercise of the SARS-CoV 
genome was later noted as being beneficial to the entire coronavirus family, as it resolved many of 
the discrepancies and inconsistencies in the classification of these viruses (Gorbalenya et al 2004). 
 
The accessory genes encoded within the SARS-CoV genome were of particular interest to many 
coronavirologists as well as other virologists who took an interest in this novel coronavirus. The 
existence of accessory genes in coronaviruses is not novel in itself; other coronaviruses such as 
MHV encode for accessory genes within their genomes. However, the fact that SARS-CoV is a 
human coronavirus of moderate pathogenicity lends credence to the study of these accessory 
genes in particular. There are a total of 8 putative accessory genes encoded with the genome of 
SARS-CoV, 3a, 3b, 6, 7a, 7b, 8a, 8b and 9b, which is a hidden reading frame within the 
nucleocapsid gene. Antibodies against the protein products of all of these accessory genes were 
detected in human patient sera, indicating that these genes code for actual proteins and that these 
are actively expressed during infection (Guan et al 2004a,b, Guo et al 2004, Tan et al 2004b, 
Chow et al 2006). The interest taken in these genes by coronavirologists has led to a large number 
of varied observations of the characteristics of their protein products, and these are summarized in 
Table 1. 
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                  Table 1. Observed characteristics of SARS-CoV accessory proteins 
 
One of these accessory genes, ORF6, encodes for a ~7kDa protein with a hydrophobic N–terminal 
and that has been suggested to have a N-endo-C-endo conformation (Netland et al 2007). Several 
Gene Characteristics of Protein Product References 
3a • Pro-apoptotic, Induction of mitochondrial death 
pathway 
Law et al 2005, Chan et al 2009, Padhan 
et al 2008 
  • Immunogenic, elicits humoral and cellular 
responses 
Lu et al 2009, Åkerström et al 2006, 
Zhong et al 2006,  
  • Promotes membrane rearrangement Freundt et al 2010 
  • Downregulation of Type I IFN receptor Minakshi et al 2009 
  • Induces G1 cell cycle arrest Yuan et al 2007 
  • Interacts with 5' UTR of SARS-CoV genome Sharma et al 2007 
  • Interacts with caveolin Padhan et al 2007 
  • Potassium-permeable ion channel activity Lu et al 2006 
  • Structural contribution to virion Ito et al 2005, Shen et al 2005 
  • Localizes to cell surface, undergoes endocytosis Tan et al 2004 
  • Upregulates fribrinogen in lung epithelia Tan et al 2005 
3b • Activation of JNK/ERK pathways Varshney et al 2011 
  • Induction of cell death Khan et al 2006 
  • Localizes to nucleolus Yuan et al 2005 
  • G0/G1 cell cyle arrest Yuan et al 2005 
  • Interferon antagonism Kopecky-Bromberg et al 2007 
ORF6 • Acceleration of infection in a recombinant murine 
coronavirus 
Pewe et al 2005, Tangudu et al 2007, 
Netland et al 2007 
  • Required for optimal SARS-CoV replication Zhao et al 2007 
  • Interacts with nsp8 replicase protein Kumar et al 2007 
  • Antagonism of STAT1 nuclear import Frieman et al 2007, Hussain et al 2010 
  • Promotes membrane rearrangment Zhou et al 2010 
  • Localises to lysosomal compartment Kumar et al 2007, Gunalan et al 2011 
  • Interferon antagonism Kopecky-Bromberg et al 2007 
  • Induction of JNK-dependent apoptosis  Ye et al 2008 
7a • Induction of apoptosis Tan et al 2004, Schaecher et al 2007 
  • RNA silencing suppression Karjee et al 2010 
  • Interaction with human Ap4A-hydrolase Vasilenko et al 2010 
  • Interaction with Bcl-XL Tan et al 2007 
  • Contribution to virus structure Huang et al 2006 
  • Interaction with hSGT Fielding et al 2006 
  • Inhibition of cellular protein synthesis Kopecky-Bromberg et al 2006 
7b • Attenuates viral replication Pfefferle et al 2009 
  • Induction of apoptosis Schaecher et al 2007 
8a • Induction of apoptosis Chen et al 2007 
8b • Proteasome-dependent downregulation of E 
protein 
Keng et al 2006, Keng et al 2011 
9b • Shuttling across nuclear membrane Moshynkyy et al 2007, Sharma et al 2011 
  • Association with virion Xu et al 2009 
  • Lipid binding Meier et al 2006 
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groups have undertaken to characterize the protein product of the ORF6 gene and found that it 
interacts with the nsp8 protein from the SARS replicase complex (Kumar et al 2007), is able to 
increase infection titer during early infection at low MOI (Zhao et al 2009), increase the rate of 
cellular gene synthesis (Geng et al 2005), inhibit interferon production (Kopecky-Bromberg et al 
2006), and inhibit the nuclear translocation of STAT1 by interacting with karyopherin α2 
(Frieman et al 2007). Most recently, the ORF6 protein has been suggested to induce intracellular 
membrane rearrangements resulting in a vesicular population in the infected cell which could 
possibly serve some role in increasing replication (Zhou et al 2010). Such virus-induced or virus 
associated vesicles have previously been shown in other viral infections, such as protein 
trafficking in Herpes simplex virus (Miranda-Saksena et al 2009) and Sendai virus (Chambers & 
Takimoto 2010). Members of the coronavirus family have been shown by several groups to also 
utilize vesicular structures within the infected cell; most of these studies suggest that vesicles play 
a role in viral replication (Sims et al 2000, Snijder et al 2006, Knoops et al 2008). 
 
 
2.3 VIRUS LIFE CYCLE 
 
The infection process for any given virus begins with the binding of the virus to its cognate 
cellular receptor. In the case of SARS-CoV, this receptor was identified as the angiotensin-
converting enzyme 2 (ACE-2) receptor. Mass spectrometry analysis of proteins bound to a 
pulldown complex using the spike protein of the virus identified this receptor as also being the 
receptor for virus entry (Li et al 2003), and this finding was subsequently confirmed by other 
groups (Wang et al 2004). It was also shown shortly afterwards that L-SIGN could function as a 
SARS-CoV receptor as well (Jeffers et al 2004), although subsequent work showed that L-SIGN 
promiscuously binds to many viruses outside the coronavirus family such as Human 
Immunodeficiency virus (da Silva et al 2011), Hepatitis C virus (Gardner et al 2003) and 
Ebolavirus (Alvarez et al 2002), and that L-SIGN could have a protective effect against SARS-
CoV infection by mopping up virus particles for internalization and subsequent degradation by 
proteasomes (Chan et al 2006).  
 
Upon binding of the S protein to the ACE-2 receptor, the virus is internalized by endocytosis and 
presumably undergoes pH-dependent uncoating within endosomes in order to release the viral 
genome as well as viral proteins. From here, viral RNA undergoes replication and the expression 
of viral genes commences. It has been suggested on the basis of experiments showing the 
incorporation of accessory protein ORF6 into the virion that the surface of the virus contains 
several proteins other than the main structural proteins such as S, E and M and these other 
proteins, including accessory proteins, might be able to exert an immediate host effect instead of 
undergoing the usual lag time between uncoating, mRNA synthesis and translation of viral 
proteins (Huang et al 2007), which taking into account the expression of late viral genes, takes up 
to 12 hours from the point of infection (unpublished observations).  As the SARS-CoV genome 
was positive-stranded, it was assumed that a negative strand template was transcribed from this 
positive-stranded genome to serve in the replication of the genome, although none of the initial 
sequencing work looked for the existence of a negative-polarity template for the virus genome. 
The transcription of the open reading frames in the virus genome, however, were much more 
complex than its replication. According to the existing model of coronavirus transcription, genes 
are transcribed as a set of nested subgenomic mRNAs, each encoding for a different gene or set of 
genes(Sawicki and Sawicki 2007). Through the use of Northern hybridization using probes 
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targeted at the terminal sequence of the coronavirus genome, a series of RNA fragments of 
varying lengths were discovered, confirming that this mode of transcription also applied to SARS-
CoV (Marra et al 2003, Rota et al 2003, Thiel et al 2003). The mechanism behind the creation of 
these subgenomic mRNAs is predicted to be a discontinuous synthesis model, which leads to the 
generation of a subgenomic mRNA containing a leader sequence known as a transcriptional 
regulatory sequence (TRS) at the 5' end, a terminal sequence at the 3' end just upstream of the 
polyadenylated tail, and the body of which contains the gene to be expressed at the 5' region 
downstream of the leader sequence, followed by the genes downstream of it (see Fig 2). A total of 
7 subgenomic mRNAs were detected in the case of SARS-CoV, and eventual sequencing 
identified the genes expressed from each of these mRNA species, with the exception of the 
replicase genes, which were presumed to be expressed from the genome itself  (Thiel et al 2003), 
which differs from its subgenomic mRNAs only by inclusion of the replicase genes. This 
determination was consistent with the prevailing idea that the replicase genes carried the highest 
priority of expression, as the virus genome encoded for these genes at its 5' end, downstream of 
the primary TRS sequence in the genome. Translation of the replicase genes from the SARS-CoV 
genome produces 2 replicase polyproteins, pp1a which contains nsps 1-10 and and pp1ab which 
contains nsps 1-16. Autoproteolytic cleavage of the replicase polyproteins yields the nonstructural 
proteins nsp1 to nsp16, which contains proteases, two RNA-dependent RNA polymerases, and a 
host of other enzymes crucial to viral replication (Snijder 2003). It is assumed that the heteromeric 
nature of the expressed polyproteins is indicative of a dependency relationship between the 
various nonstructural proteins which dictates that they be expressed simultaneously. To this end, 
replicase polyproteins have been found to localize at the same subcellular compartments (Prentice 
et al 2004) and structural studies have elucidated a torus-like structure for the nsp7-nsp8 complex 
(Zhai et al 2005). This putative complex of nonstructural proteins, referred to as the replication 
complex, is thought to localise in the infected cell to particular vesicular compartments. The 
strategy of employing vesicular compartments to facilitate viral replication is a well-known 
strategy used by several viruses, among these other coronaviruses such as MHV and EAV, which 
have been suggested to utilise the autophagic pathway for the generation of these vesicles 
(Prentice et al 2004). Recent evidence has shown that SARS-CoV utilizes a modified 
reticulovesicular network derived from the ER to encapsulate and protect these replication 
complexes (Knoops et al 2008), and no evidence of autophagy has been found in SARS-CoV 
infection (Snijder et al 2006), although it can be argued that this simply reflects the diverse 
strategies by which different viruses generate vesicular compartments for use in replication, even 
within the same virus family.  
  
The assembly and egress of progeny virions was first shown using electron microscopy of SARS-
CoV infected cells (Ng et al 2003), showing nascent virus particles budding from swollen Golgi 
sacs. Other efforts soon followed and were consistent with initial findings (Goldsmith et al 2004). 
However, electron microscopy is of limited value in deciphering the actual mechanism as well as 
the sites of assembly, as well as the viral and host determinants of this process. One useful strategy 
to address this issue is to use VLPs, or virus-like particles, as a least common denominator of a 
virus particle. Given that SARS has 4 canonical structural proteins, S, M, E, and N, VLPs were 
constructed by adding different combinations of viral structural proteins in order to determine the 
exact mechanism of virus assembly. VLPs have been constructed using a combination of M and N 
or M, E and N (Siu et al 2008) or using all 4 structural proteins (Nakauchi et al 2008). It is clear 
from these studies that the M protein seems to be the common denominator of viral assembly, a 
point which was reinforced by the finding that the M protein is able to homoploymerize (Tseng et 
al 2010), suggesting that the M protein forms the backbone for virus assembly. Clues as to the 
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sites of SARS assembly have come from the detection of a Golgi targeting signal in the E protein 
(Cohen et al 2011) and the observation of a dibasic COPI-binding ER retrieval signal in the spike 
protein which also promotes the interaction of the M and S proteins (McBride et al 2007). The 
COPI retrieval signal carries the canonical KKxxx motif and aids in the retrieval of ER-resident 
proteins from the Golgi complex to their proper locations in either the ERGIC or ER (Lee et al 
2004). This suggests that the site of SARS assembly could be the ERGIC, and this is supported by 
immunogold EM and immunofluorescence studies which have placed the structural proteins in the 
vicinity of cellular markers corresponding to the Golgi and the ERGIC (Stertz et al 2006). As the 
sites of SARS replication are thought to have been ER-derived, it makes sense to postulate that the 
assembly compartments in the ERGIC and Golgi are closely connected to these replication sites. 
However, it is unclear if the assembly of progeny virions depends only on the 4 canonical 
structural proteins - accessory proteins of the virus have been suggested to make structural 
contributions to progeny virions. By studies of incorporation in VLPs and purification and 
immunoanalysis of  SARS-CoV particles, the 3a, ORF6, 7a and 9b proteins have been found to be 
associated with virions (Ito et al 2005, Shen et al 2005, Huang et al 2006, Xu et al 2009).  In the 
case of 3a, it has also been suggested to affect virus release by forming putative postassium-
permeable ion channels at the plasma membrane of the host cell (Lu et al 2006). The use of 
siRNA against the 3a protein also exhibited a dose-dependent reduction in virus release, 
suggesting that the 3a protein modulates virus release, although it is unclear if the ion channel 
activity of the protein is directly responsible for virus release. 
  11 
3 RESPONSE TO INFECTION 
The characteristic clinical presentation in SARS patients was an atypical pneumonia with 
symptoms including fever, myalgia, and the progressive consolidation of lung space with later 
symptoms including lymphopenia, thrombocytopenia, diarrhea and eventually acute respiratory 
distress.  While these are easily observed pathological changes which can be attributed to 
infection, there are several processes in infected cell of the host which underly these pathological 
outcomes.  A lot of work done towards our understanding of SARS has been accordingly 
focused on the pathogenicity of the virus in an attempt to elucidate the pathogenic determinants 
of SARS-CoV infection. While there have been pathological features observed in the course of 
characterisation of several viral proteins, the response of the host to infection can also be an 
important determinant of pathogenicity. 
 
 
3.1 THE INNATE IMMUNE RESPONSE IN SARS 
 
A study performed in the early days of the outbreak looked at viral load and IgG seroconversion 
in 14 SARS patients over the course of infection. The study showed a peak in viral load in 
almost all of these patients at day 10 after the onset of symptoms, with viral load subsequently 
dropping off at 15 days. Coincidentally, IgG seroconversion also began to increase greatly 
around the 15th day, when viral load was observed to undergo a reduction. While the reduction 
in viral load is easily attributable to the increasing IgG seroconversion and thereby the activation 
of the adaptive immune response in these patients, it was also noted that the patients exhibited 
clinical worsening (Peiris et al 2003a). At the same time, a study done on a lung biopsy from a 
SARS patient who had succumbed to the disease showed predominantly macrophage-based 
infiltration in the lung which was deemed responsible for the diffuse alveolar damage which was 
observed (Nicholls et al 2003), a finding that was echoed in other pathological studies performed 
on lung tissue from SARS patients (He et al 2006, Lang et al 2003). These studies lent credence 
to the possibility that the immune response might have been partially responsible for the 
pathology of SARS. Concomitant with this, the overproduction of pro-inflammatory cytokines 
such as TGF-β1, TNF-a, IL1β and IL-6 was also observed (He et al 2006) as well as 
inflammatory chemokines such as MIP-1a, RANTES, IP-10 and MCP-1 from infected DCs 
(Law et al 2005), and also from in vitro infected macrophages (Cheung et al 2005). However, 
the magnitude of the alveolar damage seen in the lungs of SARS patients cannot easily be 
explained by the secretions of a few proteins. One model proposed for this immune-mediated 
lung pathology involves 2 steps: firstly, lung epithelial cells infected with SARS-CoV were 
found to secrete chemoattractant proteins such as MCP-1 and IL-8, which could recruit 
monocytes and macrophages to the site of infection. The same study then found that a THP-1 
monocyte line could secrete more chemoattractants which were observed to attract monocytes 
and macrophages, along with neutrophils and activated T cells in a chemotactic assay. This 
would form the second step of immune infiltration into the lungs, exacerbating the damage 
already done by the first wave of immune cell infiltration (Yen et al 2006). This line of thinking 
was strengthened by the finding that PBMCs infected with SARS-CoV exhibited the 
upregulation of similar sets of proinflammatory cytokines and chemoattractants as observed in 
previous studies. It was proposed that these served as attractant factors for the infiltration of 
immune cells such as monocytes and macrophages to the lungs, acting in a similar fashion to 
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infected lung epithelial cells to initiate a 'second wave' of infiltration (Ng et al 2004).  
 
The same studies examining the secretion and differential expression of various cytokines and 
chemokines in infected tissues from patients as well as in vitro studies noticed a very interesting 
feature of the immune response to infection - a lack of IFNα/β. This difference has been cited as 
the reason for the longer time taken for virus load in SARS-CoV infection to peak (at 10 days) as 
opposed to other respiratory infections such as influenza A, which has been known to achieve 
peak viral load within a day of infection. By comparison, the magnitude of IFNβ downregulation 
by influenza A was not as great as it is in SARS-CoV infection, and the peak virus load coincides 
with the secretion of interferon as opposed to the peak of SARS-CoV coinciding with IgG 
seroconversion (Cheung et al 2005, Kaiser et al 2001). Subsequent studies have shown that 
SARS-CoV does indeed inhibit the interferon response actively, and several proteins encoded 
within the SARS-CoV genome have been shown to downregulate the expression of interferons at 
different steps of the induction pathway. Using a plasmid construct utilizing an interferon-β 
promoter tagged to a GFP reporter gene, it was shown that the accessory proteins ORFs 3b and 6, 
and the nucleocapsid protein were able to block the expression of IFNβ (Kopecky-Bromberg et al 
2007). The ORF6 protein has been shown to prevent the nuclear localization of STAT1 in order to 
inhibit the downstream effects of interferon signaling via the JAK/STAT pathway (Frieman et al 
2006). The papain-like protease domain of the SARS-CoV replicase complex as well as the 
accessory proteins ORF3a and ORF6 have been shown to inhibit the phosphorylation and 
subsequent nuclear translocation of IRF-3, thereby inhibiting its ability to induce the expression of 
interferons (Devaraj et al 2007, Kopecky-Bromberg et al 2007). In addition to the induction of 
interferon expression by phosphorylated, nuclear translocated IRF-3, a second method of 
induction exists via the nuclear translocation of NFkB. Using an NFkB-responsive promoter, it 
was shown the the SARS-CoV nucleocapsid protein was able to block NFkB-dependent activation 
of interferon expression (Kopecky-Bromberg 2007). Thus it is clear that SARS-CoV possesses 
several mechanisms to inhibit the interferon response. However, it is possible to overturn this 
multi-faceted inhibition of the IFN response. Priming of non-lymphatic cells with small amounts 
of IFNa was shown to induce a sufficient IFN response during SARS-CoV infection (Kuri et al 
2009).  
 
 
3.2 ADAPTIVE IMMUNE RESPONSE 
 
The adaptive immune response to infection comprises of the humoral immune response, mediated 
by B lymphocytes, and the cellular response, mediated by T lymphocytes. Both of these responses 
were observed in SARS patients. The humoral response to SARS-CoV infection was observed in 
the IgG seroconversion of patients at an average of 2 weeks after the first signs of symptoms 
(Peiris et al 2003a). Studies examining the antibody response in SARS patients in China showed 
that this antibody response was able to neutralize pseudotypes viruses containing spike proteins 
from different strains of SARS-CoV (Nie et al 2004). However, it was also found that a 
correlation existed between IgG levels in patients and the severity of disease (Lee et al 2006), 
suggesting that the humoral response to the virus might be part of the immunopathogenesis of 
SARS, and not necessarily protective. In order to determine the relative immunogenicity of 
proteins encoded by the SARS-CoV genome, various recombinant viral proteins were tested for 
reactivity against patient sera from both acute and convalescent phases of infection. Reactivity of 
all the sera to the nucleocapsid proteins suggested that it was the most immunogenic of viral 
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proteins. Interestingly though, acute phase sera did not show reactivity to the S proteins where 
convalescent phase sera did (Tan et al 2003). Based on these results, an ELISA-based diagnostic 
kit was designed to detect anti-N IgG in patients, using a recombinant N protein (Guan et al 2004).  
 
One of the hallmarks of SARS-CoV infection is observed lymphopenia in patients. A study 
looking at T lymphocyte subsets in a cohort of 271 patients in China found decreases in several 
lymphocyte subsets, particularly in CD4+ and CD8+ T lymphocytes. The researchers also found a 
correlation between the severity of disease in this patient cohort and and levels of CD4+ and 
CD8+ lymphocytes, with patients who recovered showing a restoration of lymphocyte levels (He 
et al 2005). However, an earlier study of a cohort of 50 patients in Hong Kong did not observe a 
similar correlation between lymphocyte count and progression to ARDS (Peiris et al 2003a). In 
parallel to these results, it was found that BALB/C mice infected with a mouse-adapted strain of 
the virus developed a poor T-cell response (Zhao et al 2009). An adoptive transfer of SARS-CoV 
immune splenocytes from infected BALB/C mice or in vitro generated T-cells from these mice to 
severe combined immunodeficiency (SCID) or naïve BALB/C mice resulted in enhanced survival 
and reduced virus titers in the lungs of these mice, suggesting that T lymphocytes might be 
important for viral clearance in vivo (Zhao et al 2010).  
 
Several studies on the cell-mediated immune response also examined immunological memory 
against SARS-CoV in recovered patients. Using a peptide library comprising fragments of 
different viral structural proteins to stimulate peripheral blood mononuclear cells (PBMCs) from 
recovered patients, it was found that central memory CD4+ and effector memory CD8+ were 
elicited in these  individuals against the S, M, E and N proteins, suggesting that these responses 
were part of the response against initial infection (Peng et al 2006a, Peng et al 2006b, Yang et al 
2006, Yang et al 2007). However, no comparison was made between these responses to 
determine the magnitude of the response to different structural proteins . It is also not known if 
these long-term memory responses would be sufficient in the event of re-infection.  
 
 
3.3 APOPTOSIS IN SARS-COV INFECTION 
 
Apoptosis is a genetically controlled form of eukaryotic cell death which is evolutionarily 
conserved, having been observed in an array of cell types from budding yeast to mammalian 
cells. The genetic coordination of apoptosis is seen in 3 different cellular pathways towards this 
end: 1) the intrinsic or mitochondrial pathway, 2) the extrinsic or death-receptor mediated 
pathway, and 3) the caspase – independent pathway which is mediated by the action of 
granzymes where the intrinsic and extrinsic pathways are dependent on the action of cellular 
proteases known as caspases. The hallmarks of apoptosis are a series of morphological events: 
nuclear condensation, DNA fragmentation, ‘blebbing’ of the plasma membrane and eventual 
phagocytosis. Apoptosis, as morbid as the implications of this term are, also has a role to play 
during the course of morphogenesis and development. However, apoptosis is also a valuable tool 
in countering microbial infection. Elimination of the infected cell and eventual phagocytosis is a 
known element of the immune response to infection.  
 
Viral apoptosis is an intriguing aspect of the infection process, as viruses can induce apoptosis 
towards different, and opposing ends. Viruses may inhibit apoptosis in order to prevent the use 
of the apoptotic program by infected cells or immune cells to halt the spread of infection, and at 
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the same time, apoptosis may be a useful tool used by viruses either to neutralize cells of the 
immune system or to aid viral spread by the breakdown of infected cells (Best et al 2008, 
Galluzzi et al 2008). In SARS-CoV infection, viral apoptosis has been postulated to form part of 
the pathogenic mechanism of infection. One of the hallmarks of SARS-CoV infection was 
observed to be lymphopenia, as observed in studies of different patient cohorts (Wong et al 
2003, Cui et al 2003, He et al 2005). It was subsequently suggested, by analogy to lymphopenia 
observed in measles infections, that apoptosis might be the underlying cause for this observed 
lymphopenia (O'Donnell et al 2003), although this was countered by the argument that the 
lymphopenia might have arisen out of adrenal insufficiency and glucocorticoid treatment 
(Panesar 2003). Evidence of apoptosis related to SARS-CoV infection was found though, in 
hepatocytes (Chau et al 2004) as well as in thyroid tissue (Wei et al 2007). The induction of 
apoptosis was also detected in Vero E6 mammalian cell cultures infected with SARS-CoV (Ren 
et al 2005, Yan et al 2004), and it was suggested that the phosphorylation of p38MAPK might be 
involved in this apoptotic induction (Mizutani et al 2004). However, the role that apoptosis 
might play in SARS -CoV infection was not clear. Inhibition of apoptosis in Vero E6 cells either 
by blocking p38MAPK phosphorylation or Bcl-2 overexpression did not seem to have an effect 
on the replication of the virus but it was observed to reduce the cytopathic effect of infection 
(Bordi et al 2004, Mizutani et al 2004). 
 
Despite this, the idea that apoptosis was a crucial part of SARS pathogenesis remained popular, 
and several laboratories published work that pointed to the pro-apoptotic nature of several SARS 
proteins, and in some cases there were indications that apoptosis had a distinct role to play in the 
function of a given pro-apoptotic SARS-CoV protein. The 3a protein of this virus was shown to 
induce apoptosis in Vero E6 cells (Law et al 2005) and this induction was linked to the 
mitochondrial death pathway though p38MAPK activation (Padhan et al 2008). In addition, 
blocking of the ion channel activity of the 3a protein abolished caspase-dependent apoptosis 
(Chan et al 2009). It was also shown that ER stress induced by the 3a protein resulted in PERK 
activation which in turn caused a downregulation of the interferon alpha 1 receptor (Minakshi et al 
2009), suggesting that the pro-apoptotic nature of the 3a protein had a discrete function in terms of 
immune evasion. The 7a protein of SARS-CoV was also the subject of several studies on the 
induction of viral apoptosis. In addition to a demonstration of the pro-apoptotic activity of 
overexpressed 7a protein in Vero E6 cells (Tan et al 2004), it was also shown by the same group 
that this apoptotic activity is linked to its interaction with prosurvival proteins such as Bcl-XL, 
MCL-1, Bcl-2, Bcl-2w and A1 (Tan et al 2007). In addition, the 7a protein was also shown to 
inhibit cellular protein translation and initiate apoptosis via p38MAPK activation but not through 
JNK activation (Kopecky-Bromberg 2006). Construction of viruses with disruptions in the ORF7 
reading frames encoding for the 7a and 7b proteins showed a reduction in apoptotic induction by 
the virus as compared to the wildtytpe virus, indicating that these genes have a role to play in 
virus-induced apoptosis (Schaecher et al 2007). However, the same study also showed that 
deletion of ORF7 from the virus did not have an effect on viral replication or on the observations 
of early markers for apoptosis, but rather markers for the terminal stages of apoptosis such as 
DNA fragmentation, indicating that other proteins encoded within the SARS-CoV genome are 
responsible for induction of apoptosis by the virus. In this respect, 2 other accessory proteins have 
been observed to induce apoptosis. A GFP-tagged ORF6 fusion protein has been shown to induce 
apoptosis in Vero E6 cells via the induction of ER stress and the activation of the JNK pathway 
(Ye et al 2008) and a YFP-tagged ORF9b fusion protein was observed to induce caspase-
dependent apoptosis when its active nuclear export was inhibited using Leptomycin-B (Sharma et 
al 2011). In the case of 9b, a causal relationship between protein function and apoptotic induction 
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was shown, albeit not in the classical sense as the inhibition of function led to the induction of 
apoptosis in this instance. Another such unorthodox observation of a causal relationship between 
the induction of apoptosis and protein function was observed for the nucleocapsid protein of 
SARS-CoV. Using caspase inhibitors specific to effector caspases, it was found that the N protein 
of SARS-CoV induced the intrinsic pathway of apoptosis and the resulting  activated effector 
caspases cleaved the N protein. However, this phenomenon did not occur in all cell lines, only 
being observed in Vero E6 and A549 cells but not in CaCo2 or N2a cells (Diemer et al 2008).  
 
 
 
3.4 NITRIC OXIDE 
 
Nitric oxide in an important intracellular messenger involved in several cellular processes such as 
the modulation of blood flow, thrombosis, and neural activity. It also forms part of the host 
defense against pathogens, with documented antimicrobial activity against bacteria and some 
viruses. There exists a fine line between the physiological and pathological activity of nitric oxide. 
Nitric oxide by itself is relatively unreactive, which may go some way towards explaining its 
suitability as an intracellular messenger in diverse physiological processes. However, the reaction 
of nitric oxide (NO) with the superoxide (O2-) anion produces peroxynitrite (ONOO-), which is a 
potent reactive nitrogen species (RNS). The formation of peroxynitrite is thought to a 
spontaneous, constitutive reaction in steady-state physiology. However, the redox potential of 
peroxynitrite is governed by biological minimization of the compounds which form this reactive 
species. NO itself rapidly diffuses through tissues (another reason for its suitability as an 
intracellular messenger) into red blood cells where it forms nitrates by reacting with 
oxyhaemoglobin, effectively scrubbing available nitric oxide and limiting the half-life of this 
molecule. The superoxide anion is physiologically limited through the action of superoxide 
dismutase (SOD), an enzyme which catalyzes the breakdown of superoxide to yield oxygen and 
hydrogen peroxide. This also aids in protecting cells from the oxidative damage potential of 
superoxide radicals. The balance, then, between the physiological concentrations of both NO and 
O2- are rate-limiting for the spontaneous formation of peroxynitrite, and this limitation forms that 
fine line between physiology and pathology where reactive nitrogen species are concerned. One of 
the ways in which this fine line can be crossed is through the overproduction of nitric oxide by 
nitric oxide synthases (NOS).  
 
There are 3 kinds of NOS enzymes, originally dubbed eNOS (epithelial NOS), iNOS (inducible 
NOS), and nNOS (neuronal NOS) - in light of their detection in tissues other than those they 
were named, for, these are now known as NOS-1, NOS-2, and NOS-3 respectively. These 
enzymes catalyze the oxidation of L-arginine to yield nitric oxide and L-citrulline. NOS-1 and 
NOS-3 are calcium sensitive, constitutively expressed nitric oxide synthases. NOS-2, however, 
is inducible and has a very low constitutive level of expression, and is triggered during periods 
of cellular stress, for example during the immune response to infection by bacterial, fungal and 
viral pathogens. The TLR signaling pathway activates NOS-2 expression by way of activated 
MAPKs and NFκB, and cytokines such as TNFα and IL-1β are also able to activate such 
expression as part of this response to infection. IFNγ is also able to activate NOS-2 expression 
via the JAK-STAT signaling pathway (Lowenstein & Padalko 2004). The expression of NOS-2 
by these pathways then results in the overproduction of nitric oxide in order to tip the 
equilibrium in favor of peroxynitrite production, which is thought to mediate the effects of nitric 
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oxide (Pacher et al 2007). And in this regard, nitric oxide has been shown to exert antiviral 
effects on a number of viruses. Nitric oxide has been shown to exert antiviral effects on Japanese 
encephalitis virus (Saxena et al 2001), hantaviruses (Klingström et al 2006), Crimean-Congo 
haemorrhagic fever virus (Simon et al 2006), and even against SARS-CoV (Åkerström et al 
2005). An interesting aspect of the antiviral activity of nitric oxide was shown in 
coxsackieviruses. Two different groups showed that nitric oxide was able to inhibit the 3C and 
2A proteases of coxsackievirus by S-nitrosylation of a cysteine residue at the active site of each 
of these proteases (Saura et al 1999, Badorff et al 2000). It has been quite a while since the S-
nitrosylation of proteins was described (Stamler et al 1992), but since then, it has been observed 
in a variety of intracellular processes, including the regulation of gene transcription by directly 
modifying transcription factors such as NFκB (Sha et al 2011).  
 
In addition to the induction of NOS-2 expression by the immune system, such expression has 
also been shown to be induced directly by viruses themselves. The gp41 glycoprotein of HIV-1 
and infection of A549 cells with respiratory syncitial virus have been shown to directly induce 
NOS-2 expression. It is believed that this sort of induction has a role to play in virus-induced 
cytotoxicity (Akaike et al 2000). Where pathogenicity did not involve the generation of nitric 
oxide by the virus to a cytotoxic end, the interactions of virus and host often induced sufficient 
levels of NOS-2, and thereby nitric oxide and reactive nitrogen species to induce cytotoxicity. It 
was shown that nitric oxide had a role to play in the pathogencity of influenza-induced 
pneumonia (Akaike et al 1996). Nitric oxide also has also been shown to be a pro-apoptotic 
factor, possibly in viral infections. Activated macrophages are thought to release large amounts 
of nitric oxide and superoxide, and this is believed to induce apoptosis in both the producing 
macrophages as well as in neighboring cells (Hortelano 1999). Even without the contribution of 
macrophages or viral infection, nitric oxide might be able to induce cytotoxic effects such as 
apoptosis and necrosis. S-nitrosylation of cysteine-450 on the RING domain of X-linked 
inhibitor of apoptosis  (XIAP) was shown to inhibit its E3 ligase activity and thereby stabilize 
caspase-3, allowing for pro-apoptotic signaling in neurons (Nakamura 2010).  Nitric oxide 
signaling has also been consistently observed to upregulate pro-apoptotic factors in the intrinsic 
pathway of apoptosis such as TP53, Bax and other pro-apoptotic members of the Bcl-2 family 
(Bosca et al 1999).  
 
 
3.5 ANIMAL MODELS 
 
In the course of the study of a microbe, the use of animal models is crucial. Animal models allow 
for for the study of systemic, pathologic characteristics of infection, as well as giving researchers 
insight into viral replication kinetics and the dynamics of viral spread within an organismal host. 
There is also valuable information to be gleaned about the host response at the systemic level, for 
example in the nature and magnitude of the immune and inflammatory response to such infection. 
Such information can be multi-faceted, from morphological studies to expression profiling of 
genes in different tissues. A second, yet equally important value of an animal model is that it 
allows for the evaluation of antiviral strategies and vaccines against a microbial pathogen, 
something which would only yield very limited information in a monolayer of cells. Given the 
urgency of the SARS epidemic and the realization of a definite zoonotic pattern of transmission, 
the need to study all these aspects of SARS-CoV infection as well as to evaluate novel antivirals 
and vaccines to prepare against future outbreaks, was of utmost importance.  
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The first demonstration of SARS pathology in an animal model was made in 2003, when 
cynomolgus macaques were infected with SARS-associated coronavirus (as it was originally 
dubbed after isolation from patients) passaged in Vero E6 cells. The infected macaques displayed 
pulmonary lesions and dysfunction similar to human patients, with the diffuse alveolar damage, 
necrosis of alveolar epithelium, multinucleated alveolar syncitia, and macrophage/neutrophil-
containing proteinaceous lung exudate that was characteristic of the disease in humans. These 
pathological features allowed for the fulfillment of Koch's postulates, indicating that the SARS-
associated coronavirus was the etiological agent of the disease (Fouchier et al 2003). The first 
attempt at a mouse model was reported shortly afterwards - BALB/C mice were infected with 
SARS-CoV to determine if the inbred mouse would prove a suitable model. Surprisingly, it was 
found that the mice showed little sign of pulmonary disease, and peak viral titers were achieved 
within the first 2 days post-infection before being cleared by day 7. Determination of immune 
response in the mice showed that neutralizing antibodies were developed, rendering them resistant 
to reinfection. Transfer of serum into naive mice was also able to confer resistance in these mice 
to virus challenge (Subbarao et al 2004). The same group also attempted to establish a mouse 
model in a different inbred mouse strain, C57BL/6. Similar to observations in the BALB/C mice, 
the virus was cleared within 9 days of infection, with peak titer established at day 3. It was 
observed that several pro-inflammatory chemokines were upregulated, along with their cognate 
receptors; however pro-inflammatory cytokines were not observed to be upregulated, and levels of 
pulmonary dysfunction remained low (Glass et al 2004). A subsequent model of pathogenesis was 
eventually found in aged BALB/C mice, which was based on the idea that advanced disease was 
observed in aged patients as compared to other age groups. Infection of aged BALB/C mice 
showed similarities to human disease, and early upregulation of pro-inflammatory cytokines such 
as IFNα, IFNγ, and TNFα which the researchers postulated to be responsible for pathological 
differences between these mice and previous attempts at adolescent BALB/C and B6 mice 
(Roberts et al 2005a). A second study on these aged mice also demonstrated an interesting pattern 
of cytokine production in aged mice - while the initial observations of pro-inflammatory cytokine 
production concur with the original study, at around day 7 post-infection a second wave of pro-
inflammatory cytokine production was observed, with concomitant infiltration of T-lymphocytes. 
This second wave was found to be dependent on CD4+ T cells (Chen et al 2010).  
 
While the various attempts at a mouse model were being worked out, a separate study using both 
cynomolgus and rhesus macaques found little correlation between pulmonary and systemic 
disease in these macaques and the previous studies of SARS-CoV infection in cynomolgus 
macaques which were used to fulfill Koch's postulates (Rowe et al 2004). What was found, 
though, was that there were pathological differences between rhesus and cynomolgus macaques, 
with more advanced signs of disease in cynomolgus macaques. The study also highlighted that 
technical differences in the execution of the animal studies could have an effect on observations of 
pathology and thereby in the interpretation of these observations in terms of SARS-CoV 
pathology in these macaques. It was suggested that pathology was more pronounced at the earlier 
timepoint of 4-6 days post-infection used by other groups, and at later timepoints such as 12-14 
days post-infection, the infection (along with pathology) is largely resolved, leading to the 
interpretation that cynomolgus macaques only display mild lung pathology.  
 
An interesting approach to the generation of a SARS animal model was shown with the report of 
SARS-CoV infection of a mouse line transgenic for the human ACE-2 receptor. Infection of this 
transgenic line resulted in consistently higher viral titers than in non-transgenic control mice, and 
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lethality occurred in almost all mice within 5 days post-infection. Upon examination of mice, it 
was found that the lungs and brains were the major sites of viral replication. Histologic 
examination of lungs showed the characteristic diffuse alveolar damage seen in SARS patients, 
and proinflammatory cytokines and chemokines such as IL-1β, RANTES and MCP-1 were 
observed to be upregulated in the lungs of these mice (Tseng 2007). But the problems with this 
transgenic line were evident in the high levels of pathology in the brain, which seemed to make a 
significant contribution to mortality, and the observation that a similar transgenic line with a 
lower hACE-2 expression level showed lesser pathology with the eventual recovery of infected 
mice. The results of this study could simply be interpreted as the consequences of the level to 
which cell lines are permissive to infection with a particular virus - the mouse line with higher 
hACE-2 expression underwent a greater level of mortality and a low level of viremia where the 
line with lower levels of hACE-2 showed no viremia and lower levels of mortality. This study 
could help explain the results from the previous studies performed with juvenile BALB/C and 
C57BL/6 nice.  
 
While these animal models proved useful in highlighting aspects of SARS-CoV pathology, their 
underlying purpose is considerably more important - the evaluation of potential antivirals and 
vaccines in a mammalian organism. Several different groups have attempted to evaluate vaccine 
candidates in animal models of SARS-CoV infection in order to arrive at some measure of their 
efficacy either as therapeutic or prophylactic agents. One of the first uses of animal models to this 
end was the evaluation of recombinant adenoviruses encoding the SARS-CoV structural proteins 
S, M and N in evoking an immune response in rhesus macaques. Intramuscular immunization of 
the macaques with a combination of all three recombinant adenoviruses was observed to generate 
neutralizing antibodies which were shown to inhibit lysis of SARS-CoV infected Vero E6 cells. 
No challenge experiment was performed, with the authors citing the need for a clinically relevant 
animal model (Gao et al 2003). Since then, several groups have attempted to evaluate vaccination 
strategies and vaccine candidates in different species, chiefly among them inbred mice. Mice 
immunized with a fusion protein comprised of the receptor-binding domain of the SARS-CoV S 
protein elicited protective effects in a mouse challenge model (Du et al 2007), and a prime-boost 
strategy using T-cell-specific S-protein epitopes was found to elicit both CD4+ and CD8+ T 
lymphocyte responses in mice (Huang et al 2007). Some groups also examined the use of 
recombinant viruses as vaccine delivery systems, such as modified vaccinia Ankara (Bisht et al 
2004) and vesicular stomatitis virus (Kapadia et al 2004) expressing the S protein. One study even 
compared the protective response elicited by S and N-expressing recombinant adenoviruses 
against whole killed virus in a mouse challenge model (See et al 2006). While the results of these 
vaccine experiments are promising, the mouse model used by most of these groups has not been 
shown to be clinically relevant, as different juvenile mouse models have been observed to show 
no overt signs of disease (Roberts et al 2008).  
 
In addition to the mouse models, a hamster model of SARS was shown using Golden Syrian 
hamsters. Infection of hamsters was observed to peak around 2 days post-infection, with eventual 
clearance of virus about a week later. While no overt signs of clinical disease were observed, lung 
histology showed similarities to pathological manifestations observed in human patients, and 
persistence of viral infection was longer than in juvenile mouse models. Hamsters were also 
shown to produce neutralizing antibodies against the virus, and were resistant to reinfection 
(Roberts et al 2005b). This model was used to evaluate the therapeutic potential of a human 
monoclonal antibody against SARS-CoV (Roberts et al 2006), and also to evaluate the 
immunogenicity and efficacy of a live attenuated virus lacking the E gene (Lamirande et al 2008). 
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4 RESULTS AND DISCUSSION 
 
4.1 CELLULAR EFFECTS OF THE ORF6 PROTEIN (PAPERS I, III, IV) 
 
The ORF6 protein of SARS-CoV is a relatively small gene of just 63 amino acids. Initial 
characterization of this protein showed that it was found to be expressed in the lungs and intestinal 
tracts of SARS patients, and that at the cellular level, this expression was localized to the 
endoplasmic reticulum, by means of colocalisation studies using a ORF6-GFP fusion protein and 
a dsRed marker for the ER (Geng et al 2005). Another study performed at around the same time, 
using reverse genetics to selectively remove accessory genes from the SARS-CoV genome, 
showed little effect on virus replication in most cells when infected with a recombinant SARS-
CoV lacking ORF6, suggesting that the ORF6 gene encoded for a protein of nonessential function 
(Yount et al 2005). However, the OR6 protein attracted a lot of interest when it was shown that a 
recombinant neurotropic mouse hepatitis virus (strain JHM) encoding the ORF6 gene turned an 
otherwise sublethal infection of the wildtype virus into a fully lethal infection, increasing virus 
titer by 101.5 (Pewe et al 2005). This finding suggested that the ORF6 protein might indeed have a 
role to play in viral replication. While the effect seen might not be due to a direct effect on viral 
replication, it might have been due to a virus-host interaction that was beneficial to viral 
replication. This observation of a stimulatory effect on MHV replication piqued the interest of 
several groups working on SARS accessory proteins, ourselves included.  
 
We set about to characterize the interaction of ORF6 protein with other SARS proteins to examine 
the possibility that an interaction between ORF6 and another viral protein might have an effect on 
replication. In Paper I, a yeast-two-hybrid assay was used to examine a subset of such potential 
interactions, and found that ORF6 interacted with the nsp8 protein of the virus. In order to further 
study this interaction, an in vitro, cell-free transcription/translation system expressing His6-nsp8 
and myc-ORF6 was set up in rabbit reticulocyte lysates. Using antibodies against both the His6 
and myc epitope tags, it was determined that both proteins were co-immunoprecipitated with the 
use of each of these antibodies, indicating that these 2 proteins did indeed interact. Given that the 
co-immunoprecipitation experiment was performed in a cell-free system expressing these 2 
proteins, the result also indicated that the ORF6 and nsp8 proteins interacted directly. In a system 
that utilized mammalian cells, such a confirmatory experiment would cast doubt on whether the 
interaction was direct as the possibility would exist that an intermediary factor could bind both 
proteins, showing an interaction, albeit not necessarily a direct one.  
 
Next, mammalian expression constructs were made to express ORF6 and nsp8 in mammalian 
cells. Vero E6 cells were co-transfected with these constructs, which expressed untagged ORF6 
and myc-nsp8. Co-immunoprecipitation experiments using a rabbit antibody against the ORF6 
protein and a mouse monoclonal antibody against the myc tag fused to nsp8 showed that ORF6 
did not co-immunoprecipitate with a control myc-GST protein, but did indeed co-
immunoprecipitate with myc-nsp8. Given this, we sought to determine if the 2 proteins interacted 
when expressed from SARS-CoV during the course of infection. Vero E6 cells were infected with 
SARS-CoV for 24 hours or uninfected and lysates were subjected to immunoprecipitation using a 
rabbit polyclonal antibody against the ORF6 protein. Western blotting using a monoclonal 
antibody against the nsp8 protein showed that ORF6 and nsp8 interacted when expressed from 
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SARS-CoV, and presumably, therefore, interacted during the course of infection. We also tried to 
determine if the 2 viral proteins colocalised in infected cells. The same antibodies that were used 
for the co-immunoprecipitation experiments were also used to examine the colocalisation of the 
ORF6 and nsp8 proteins in SARS-CoV-infected Vero E6 cells, and it was observed that the 2 
proteins did indeed colocalise in infected cells. This colocalisation was particularly interesting – it 
has been shown that coronavirus replication complexes localize to intracellular double-membrane 
vesicles which are a subset of the vesicular trafficking system (Jackson et al 2005). The SARS-
CoV replication complex has also been shown to localise to punctate structures in infected cells 
(Prentice et al 2004). Given this, we sought to determine if the site of ORF6-nsp8 colocalisation 
was indeed the same vesicular structures. According to Jackson et al, Lamp1 is a marker for the 
replication machinery for coronaviruses, and using a monoclonal Lamp1 antibody, we showed 
that ORF6 colocalised with Lamp1 in SARS-CoV infected cells. Taken together, these results 
illustrate that the ORF6 protein might exert its effect on SARS-CoV replication by interaction 
with the replicase complex of ORF6. The nsp8 protein has been shown to act as a primase, 
generating short oligonucleotides of less than 6 residues for priming viral RNA synthesis (Imbert 
et al 2006), and subsequent work has shown that features of the nsp8 protein important to this 
function are conserved in other coronaviruses, including MHV-A59 (Li et al 2010). Given this, it 
seems likely that the stimulatory effect of ORF6 on viral replication might rely on its interaction 
with the nsp8 primase, both in SARS-CoV and MHV infection.  
 
Another function of ORF6 was elucidated by the demonstration that it could function as an 
interferon antagonist. Using a plasmid construct expressing ORF6, it was shown that 293T cells 
infected with Sendai virus, a known inducer of the interferon response, failed to synthesis IFNβ. 
This was subsequently shown to be due to the inhibition of IRF-3 phosphorylation (Kopecky-
Bromberg et al 2007). In addition, it was shown that ORF6 could interact with karyopherin α2 
(KPNA2), which forms part of the importin-β superfamily of nuclear import factors. This 
interaction was deemed to have inhibited the nuclear translocation of STAT-1, which is dependent 
on KPNA1, another import factor that competes with KPNA2 for a crucial KPNB1 factor to 
achieve nuclear translocation. The nuclear import of STAT1 transduces the IFNβ signal and 
initiates a transcription cascade of interferon-sensitive response elements (ISREs) in order to 
initiate the antiviral response (Frieman et al 2007). We had observed, around this time, that the 
ORF6 protein had an unusual downregulatory effect on the expression of genes from co-
transfected plasmids. Transfection experiments in Vero E6 cells coupled with Western Blotting 
using relevant antibodies against ORF6 and myc-tagged nsp8 or GST showed that 1) ORF6 
downregulates the expression of myc-nsp8 and flag-GST, 2) this effect was dose-dependent, and 3) 
the effect seems to be specific to ORF6 as flag-GST titrated against myc-nsp8 by transfection did 
not result in a downregulation of myc-nsp8 expression. Given that ORF6 could downregulate the 
expression of 2 different transgenes with 2 different epitope tags, it was unclear if this effect might 
be global. In order to address this, we transfected Vero E6 cells with different amounts of ORF6-
expressing plasmid or empty plasmid and labeled the cells with 35S at 16 hours post-transfection. 
Radiolabelled lysates were PAGE-separated and exposed to film. The resulting autoradiographs 
showed that no significant change was observed in total protein production between cells that had 
been transfected with ORF6 or cells that had been transfected with empty vector. Therefore the 
effect of ORF6 on myc-nsp8 was not a global one, yet as the downregulation of flag-GST showed, 
not specific to nsp8 either.  
 
While the downregulatory effect of ORF6 on co-transfectant expression was clear, it was unclear 
if this effect manifested itself at the transcriptional, translational or even post-translational level. In 
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order to address this, we examined nsp8 mRNA levels in Vero E6 cells that has been transfected 
with mammalian expression constructs expressing either ORF6 or myc-nsp8. Quantitative realtime 
PCR analysis of nsp8 mRNA levels showed a significant reduction, using specific primers 
targeting nsp8 and SYBR Green chemistry. This indicated that the effect of ORF6 on transgene 
expression manifested itself at the transcriptional level. In the context of findings that ORF6 
inhibited STAT1 mediated nuclear translocation (Frieman et al 2007), this was very interesting as 
the promoter used in our mammalian expression constructs was a CMV promoter, and required 
nuclear translocation in order to drive transgene expression. It might be possible that the CMV 
promoter required KPN-mediated nuclear translocation (Lischka et al 2003), and given what has 
been shown with regard to the perturbation of KPN-mediated activity by the ORF6 protein, these 
results are consistent with such a model. Indeed, it has been observed that ORF6 is able to impede 
expression of transgenes encoded in constructs requiring nuclear translocation for expression 
(Hussain et al 2008).  
 
In order to dissect the ability to the ORF6 protein to selectively impede nuclear translocation, we 
mutated select motifs in the ORF6 protein. Using the CBS prediction server 
(www.cbs.dtu.dk/services/), a few select regions of interest were identified from the amino acid 
sequence of the ORF6 protein. 2 of these, a putative lysosomal targeting motif YSEL from amino 
acids 49-52, and a putative diacidic motif DDEE from amino acids 53-56, were substituted with 
alanine residues and resulting mutants were assayed for their ability to impede the nuclear 
translocation of a mammalian expression plasmid encoding myc-nsp8 and thereby its expression. 
Western Blotting of lysates from cells co-transfected with ORF6A53-56, but not ORF6A49-52, 
showed a decrease in the impedance of nsp8 expression as compared to cells that had been co-
transfected with wildtype ORF6 and myc-nsp8. However, this difference in impedance was 
deemed to be too small to be entirely certain that the ORF6A49-52 mutant did not exhibit a 
decreased impedance of myc-nsp8 expression when examined by Western Blotting. In order to 
generate quantitative data that would better highlight the differences in impedance between 
wildtype ORF6 and its 2 mutants, we employed the use of QPCR to examine the difference in 
myc-nsp8 mRNA levels between Vero E6 cells that had been co-transfected with myc-nsp8 and 
either ORF6 or the 2 mutants. It was observed from the QPCR results that the difference, while 
more evident, was not convincing. In order to strengthen the determination of these differences, 
we repeated the experiment 5 times and the resulting differences in myc-nsp8 mRNA levels as 
compared to cells which were not transfected with ORF6 was subjected to a Student’s two-tailed 
T-test. The T-test showed that the difference in impedance was significantly different in cells 
transfected with ORF6A53-56, but not in cells that had been transfected with ORF6A49-52, 
although a discernible difference was also observed in these cells. These results indicated the 
diacidic motif DDEE from amino acids 53-56 in the C-terminal of the ORF6 protein is involved in 
its ability to impede nuclear translocation. 
 
It has also been shown that the ORF6 protein induces membrane rearrangements in mammalian 
cells (Zhou et al 2010). We had also previously observed the localization of ORF6, and the np8 
replicase protein, to punctate structures in SARS-CoV-infected Vero E6 cells in Paper I of this 
thesis. To determine if the expression of ORF6 in our system could induce similar membrane 
rearrangements, we examined the localization of ORF6 in Vero E6 cells transfected with a 
mammalian expression plasmid expressing ORF6. It was observed that ORF6 did indeed localize 
to vesicles in these cells, and we determined that these vesicles were positive for Lamp1, as 
observed in infected cells, as well as CD63, a marker for late endosomes. It was not clear if these 
vesicles were induced by ORF6, as has been previously suggested (Zhou et al 2010) or simply a 
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pre-existing site of ORF6 localisation. If these vesicles were indeed induced by ORF6, mutants 
which might be able to disrupt this putative function would also alter the subcellular localization 
of ORF6 as well as possibly the morphological characteristics of these vesicles. With this in mind, 
the same ORF6 alanine substitution mutants ORF6A49-52 and ORF6A53-56 were transfected into 
Vero E6 cells and analysed by confocal microscopy, using a rabbit polyclonal antibody against 
ORF6. It was observed that in the ORF6A49-52 mutant, which disrupts a putative lysosomal 
targeting motif, no obvious difference in morphology was observed, only a slightly more diffuse 
cytoplasmic localization. The ORF6A53-56 mutant, however, showed a more dramatic difference 
in localization, with clusters of vesicles positively stained for the ORF6 antibody. While this 
finding suggests that the diacidic motif of the ORF6 protein exerts some influence over its 
subcellular localization, given that this same mutant was observed to significantly alter the ability 
of the ORF6 protein to impede nuclear translocation, the finding also suggests that the subcellular 
localization of the ORF6 protein is linked to its ability to impede nuclear translocation. A previous 
study which looked at the membrane rearrangement by ORF6 suggested on the basis of N-
terminal mutants that the N-terminal was sufficient for this function (Zhou et al 2010). With this 
study, we show that motifs at both termini of the protein might exert an effect on the same 
functions, and that the 2 halves of the protein do not necessarily carry out independent functions, 
as was previously suggested (Zhou et al 2010). More evidence of this comes from the same study 
that examines the ability of ORF6 to impede the nuclear translocation of STAT1 by interaction 
with KPNA1 (Frieman et al 2007). It was shown in this study that an alanine substitution mutant, 
ORF6Ala54-58, had an effect on ORF6-mediated impedance of STAT1 nuclear import. This 
mutant disrupts the same diacidic motif that was observed in our study to decrease the ORF6-
mediate impedance of nuclear import as well as its subcellular localization, suggesting that 
perhaps the localization, or generation of vesicles the ORF6 protein is linked is some way to its 
ability to impede nuclear transport. Interestingly, several groups had previously looked at ORF6 
subcellular localization (Geng et al 2005, Pewe et al 2005, Frieman et al 2007, Netland et al 2007, 
Zhou et al 2010). All of these groups reported the localization of the ORF6 protein, in a variety of 
different conditions and utilizing a variety of cellular/infection systems, to be confined to the ER 
and Golgi compartments. However, none reported any change in subcellular localization of the 
ORF6 protein caused by mutating any residues on the protein or by deletion of specific C-terminal 
regions of the protein. None of these studies have also reported the localization of the ORF6 
protein to any compartment other than those in the ER or Golgi, although none had reported the 
use of any markers for other cellular compartments besides dsRed, giantin or other markers for 
these compartments. A crucial difference between these studies and ours seems to be that most 
other studies examining the subcellular localization of ORF6 used a GFP tag fused to the ORF6 
protein. In our studies, we used an untagged ORF6 protein in our constructs because it had been 
determined that a commercially available rabbit polyclonal antibody against ORF6 was suitable 
for detection by both Western Blotting as well as immunofluorescence. The use of an untagged 
ORF6 protein might explain the differences between our observations.  
 
The generation or subversion of intracellular vesicular populations is a running theme in the study 
of virus-host interactions. Various viruses have been observed to utilize vesicular populations in 
several viral infections. For example, proteins from several picornaviruses have been observed to 
localize to intracellular vesicles, such as polioviruses and coxsackieviruses. The flavivirus 
Hepatitis C virus has also been observed to utilize vesicles for replication (Pierini et al 2009). The 
use of intracellular vesicles presents advantages for viral replication: vesicles could provide a 
microenvironment for viral RNA synthesis, provide an anchoring point or scaffolding for viral 
replicase complexes, and aid in concealing viral RNA intermediates, from recognition by the host. 
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Interestingly, similar observations of subversion of vesicular populations have been observed for 
coronaviruses. It has been shown that MHV replication complexes localize to double membrane 
vesicles (Gosert et al 2002) and subsequently it was suggested that these vesicles might have their 
origins in cellular autophagy (Prentice et al 2004b), although this claim has been contested by 
others (Zhao et al 2007). One of the earliest studies of SARS replicase proteins showed the 
colocalisation of nsp8 with the LC3 protein, which is a marker for cellular autophagy (Prentice et 
al 2004). The implications of this are that like a few other viruses, SARS-CoV might induce 
autophagy in order to generate vesicles for viral replication. But a later study examined the 
colocalisation of SARS replicase proteins with GFP-tagged LC3 expressed from a mammalian 
expression plasmid and found no evidence of colocalisation (Snijder et al 2006). The researchers 
suggest instead that SARS replication vesicles (the existence of which was confirmed using 
electron microscopy of SARS-CoV infected Vero E6 cells) are derived from the ER. In this vein, 
the localization of the ORF6 protein is similarly contentious, with most groups reporting ER/Golgi 
localization as opposed to our findings of colocalisation with Lamp1 in SARS-CoV infected cells 
and Lamp1 and CD63 in cells transiently transfected with a plasmid encoding ORF6. The finding 
that nsp8 was able to colocalise with a marker for the LC3 protein was indeed received with great 
interest; however, as several groups have pointed out, the LC3 antibody resulted in high 
background and difficulty in imaging, something which we had also encountered. Our use of a 
GFP-LC3 plasmid to determine if the ORF6-positive vesicles were of autophagic origin proved 
inconclusive (data not shown), and identity of the ORF6-positive vesicles remains uncertain. One 
possible approach to study vesicle generation by the ORF6 protein comes from a recent study that 
suggests MHV is dependent on EDEMosomes, part of the cell’s ER associated degradation 
pathway (ERAD) for generating a vesicular population for viral synthesis (Reggiori et al 2010). 
EDEMosomes are positive for nonlipidated LC3 (the pre-autophagic precursor of LC3) and yet do 
not form part of the cellular autophagic machinery, failing to colocalise with GFP-LC3. The 
eventual destination of these degradatory vesicles is late endosomes, although this pathway is 
poorly characterised. This might help to explain the colocalisation of LC3 with SARS nsp8 
(Prentice et al 2004) and reconcile this with an apparent lack of autophagic markers colocalising 
with these viral proteins. Until further experiments can be done, the possibility that this might 
represent the origin of ORF6-positive vesicles remains just a possibility, albeit an exciting one. 
 
Adding to the plethora of cellular functions attributed to the ORF6 protein, it was demonstrated 
that ORF6 could induce ER stress in cells, along with JNK- and caspase-dependent apoptosis (Ye 
et al 2008). A similar, albeit independent observation was made in our group, by employing the 
use of fluorometric detection kits for caspase activity in Vero E6 cells that had been transiently 
transfected with ORF6. In order to further characterise the induction of apoptosis by ORF6, in 
Paper IV of this thesis we decided to examine the differential expression of host apoptotic genes in 
cells expressing ORF6. Several medium to high throughput technologies exist for the purpose of 
examining the differential expression of genes in a system, such as microarrays, deep sequencing, 
and QPCR arrays. The study of differential expression of genes in a system using these 
technologies allows for the determination of mechanisms leading to changes in cellular 
physiology at the transcriptional level, although such examination at the protein level is also 
possible with these systems. In order to identify differentially expressed genes in these systems, it 
is necessary to achieve a comprehensive background of expression of, in this instance, the ORF6 
gene. Typically the introduction of transgenes into mammalian culture systems uses various 
chemical or electrical transfection systems to transport an expression plasmid encoding the gene 
of interest across the plasma membrane of the host cell. While this method has enjoyed substantial 
popularity for its ease of use and reliability, the efficiency of transfection varies from cell line to 
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cell line, and is typically observed to be around 50-70 percent, which is deemed suboptimal for the 
requirements of expression profiling of a cell population. One approach to achieving this 
expression background would be to employ the use of a recombinant virus, which would infect 
target cells and express a gene of interest. For these purposes, however, the contribution of the 
virus to host gene changes could potentially complicate the results of the analysis. Keeping this in 
mind, we prepared a recombinant vaccinia virus encoding the ORF6 gene, dVV-L-ORF6 in order 
to create a thorough expression background. This defective vaccinia virus is derived from the 
Lister strain, and is replication-defective owing to the deletion of a crucial uracil DNA glycosylase 
from the D4R locus of the virus genome. This D4R locus is replaced with a recombination 
cassette allowing for genes of interest to be recombined into the virus genome for expression 
(Holzer and Faulkner 1997). In parallel to the recombinant vaccinia virus expressing ORF6, a 
second, empty vaccinia virus dVV-L-empty was prepared to serve as a control for vaccinia-
induced background.  
 
In order to assess the functionality of virally-expressed ORF6 from this vaccinia system, in 
particular its ability to induce caspase-dependent apoptosis, we infected Huh7 and Vero E6 cells 
with either dVV-L-empty or dVV-L-ORF6. A third virus, dVV-L-7a, expressing the known pro-
apoptotic 7a gene from SARS-CoV, was used as a positive control for apoptosis. Using a 
fluorometric assay for caspase activity, we determined that both ORF6 and 7a expressed from 
recombinant vaccinia viruses were able to induce capase-dependent apoptosis, as compared to the 
empty virus. This indicated that the ORF6 protein as expressed by the vaccinia system was 
functionally intact, and allowed us to proceed with characterization. Because of their ability to 
undergo caspase dependent apoptosis from a much earlier timepoint (12 hours) as opposed to 
Vero E6 cells which only showed significant caspase activity at 24 hours post-infection, Huh7 
cells were infected with dVV-L-ORF6 at an MOI of 5, with total RNA extracted at 6, 12 and 24 
hours post-infection. Following reverse transcription, total cDNA was subjected to analysis using 
a commercially available QPCR array for apoptosis containing primers for 84 human genes 
involved in either the positive or negative regulation of apoptosis. Analysis of fold changes in 
these apoptotic genes following a second experiment serving as a biological replicate revealed the 
differential expression of a total of 14 genes. In order to validate these genes, we employed the use 
of quantitative realtime PCR (QPCR) using pre-fabricated Taqman-based assays specific to each 
of the 14 genes. The validation results indicated that a total of 7 genes were reproducibly 
upregulated or downregulated as a result of ORF6 expression in the host cell population. These 
genes were observed to fall into 2 categories – BNIP3, CIDEB, DAPK1 and TP53 form part of the 
intrinsic or mitochondrial death pathway and GADD45A, LTA and TNF form part of the extrinsic 
pathway of apoptosis. The results here pointed to a possible induction of the apoptotic pathway by 
the ORF6 protein via the extrinsic pathway, given the upregulation of TNF and the concomitant 
downregulation of the TP53 gene, which is considered the master regulator of the mitochondrial 
death pathway. Indeed, the upregulation of the TNF gene is very interesting, as it points to a JNK-
dependent mode of apoptotic induction, consistent with previous findings (Ye et al 2008). In order 
to assess if these observed transcriptional changes were consistent with ORF6-mediated apoptosis 
in other cell lines, we used the same validation gene assays to examine the differential expression 
of these genes in Huh7.5 and CaCo2 cells which had been similarly infected with either dVV-L-
ORF6 or dVV-L-empty. The results were largely consistent with what we had observed in Huh7 
cells, although there were a few interesting differences. Where the FAS gene was observed to be 
downregulated in Huh7, it was observed to be upregulated in Huh7.5 as well as CaCo2 cells. The 
same extrinsic-pathway genes observed to be upregulated in Huh7 cells were also observed to be 
upregulated in these cell lines. On the other hand, the TP53 gene was observed to be upregulated 
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in CaCo2 cells. While the level of upregulation was low, given the magnitude of downregulation 
in other cell lines, this result was surprising. However, put together, the results suggest that ORF6 
activates the extrinsic pathway of apoptosis, in more than just one cell line.  
 
 A previous study of ORF6 apoptosis showed that ORF6 induced JNK-dependent, caspase-3 
mediated apoptosis. We have observed from the fluorometric caspase assays that in our vaccinia 
expression system, ORF6 is able to induce caspase-3 dependent apoptosis as well. The 
observation that a few genes from the extrinsic pathway of activation were upregulated matches 
the JNK-dependence observed by others. The TNF gene, which has been observed in this study to 
be upregulated, is a known transcriptional target of both JNK and p38 MAPK, which are both 
mediators of apoptotic signaling in either direction – pro and anti-apoptotic, but in this case, pro-
apoptotic. From here, the binding of TNFα to the TNF receptor initiates the activation of caspase-
8, which eventually results in the execution of the death program by the activation of executor 
caspases such as caspase-3. However, pro-apoptotic signaling by JNK can occur via both the 
extrinsic or intrinsic pathways. While it was observed that one member of the intrinsic pathway, 
BNIP3, was reproducibly upregulated, a key component of the intrinsic pathway, the TP53 gene, 
was observed to be significantly downregulated in cells expressing ORF6. This could mean that 
ORF6 induces apoptosis exclusively via the extrinsic pathway, but it could also mean that ORF6 
could activate the intrinsic pathway of apoptosis independently of TP53, along with a concomitant 
activation of the extrinsic pathway. In order to shed further light on this mode of activation, the 
protein levels of proteins involved at this stage of apoptotic signaling need to be examined. This 
especially applies to p53, the protein product of the TP53 gene, as it cannot be assumed that a lack 
of TP53 transcription equates to a loss of p53 activity.  
 
While the QPCR array examining apoptotic genes gives us an idea of the transcriptional changes 
occurring in these pathways, it is limited in its format (current restrictions of the QPCR plates 
limits the number of genes to a maximum of 384) and cannot yield information on cellular 
processes that might be activated upstream of the apoptotic pathway which might lead to ORF6-
mediated apoptosis. In order to examine the cellular transcriptional changes in cells expressing 
ORF6, a portion of total RNA was used from the QPCR array experiments and subjected to 
microarray analysis using a commercially available microarray chip containing gene-specific 
probes corresponding to the human genome. Following data normalization and fold change 
calculations, we sought to compare the microarray data to the QPCR array data by direct 
comparison of fold changes in the 7 validated apoptotic genes from the QPCR array. It was 
observed that the fold change trends for these genes from the microarray concurred with those 
from the QPCR array: CIDEB, DAPK1 and TP53 were observed to be downregulated and BNIP3, 
GADD45A, LTA and TNF were observed to be upregulated. A fold change threshold of 5 was 
selected and genes exhibiting fold changes of greater than 5 or lesser than -5 were intersected 
between 2 biological replicates to arrive at a list of genes which were reproducibly differentially 
expressed in ORF6-expressing cells relative to cells infected with the empty vaccinia virus. A 
functional profile of these genes was then obtained using DAVID, an online toolset for gene 
functional assignment from microarray data ((http://david.abcc.ncifcrf.gov) with parameters 
accordingly set to yield high-level functional assignments for each gene, clustering the results by 
pathway. Similarities were observed between the clusters for functional assignments of 
upregulated and downregulated genes, suggesting that ORF6 had an effect on specific cellular 
pathways. Interestingly, it was observed that 3 candidate genes which were downregulated 
according the microarray results were annotated as being related to (positive regulation of 
apoptosis). These genes were not represented in the QPCR array, but remain of interest given their 
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putative function.  
 
The results of the functional analysis of the microarray study, while yielding a myriad of different 
pathways, exhibited a very interesting commonality – these were largely calcium-dependent 
processes. The presence of so many pathways that are calcium-dependent points to a possible 
upregulation of calcium in cells infected with dVV-L-ORF6. A great deal of published work has 
implicated calcium levels in the ER as a putative ‘trigger’ that initiates apoptotic signaling. Such 
work has also shown that JNK activation in apoptotic cells correlates to sustained elevated ER 
calcium levels, leading to the transcriptional activation of TNF, downstream signaling of the TNF 
receptor and subsequent caspase recruitment and activation (Brnjic et al 2009). This observation 
of elevated ER calcium levels corresponds to the activation of the ER stress pathway, which has 
been observed in the induction of apoptosis by different viral proteins, including the 3a protein of 
SARS-CoV (Law et al 2005, Minakshi et al 2009). Consistent with this model, we have observed 
the upregulation of several genes related to calcium influx and the cellular response to calcium 
such as CACNA1D, CACNA1E, CACNA1F, CACNA1G, and CACNA1S, which encode for 
subunits of L-type calcium channels and other genes involved in the transduction of calcium 
signals such as CAPN3 (calpain 3). Taking these results together, a putative picture of ORF6-
mediated apoptosis begins to emerge: ER stress results in elevated calcium levels in the ER, 
invoking JNK activation which in turns transcriptionally activates TNF and consequently other 
members of the extrinsic pathway, resulting in caspase-3 dependent apoptosis. However, it must 
be taken into account that these candidate genes from the microarray have not been validated, and 
with the gene lists being quite long (>200 genes), candidates for validation should be deliberated. 
Also, ER stress has not been directly observed in this study, although examining GRP78 or 
GRP94 protein levels should address this uncertainty. Lastly, and quite importantly, most 
apoptotic signaling occurs at the protein level and not at the transcriptional level, and involves 
several protein-modification steps such as phosphorylation and proteolytic cleavage of precursors 
of apoptotic proteins leading to their activation or inhibition. It would prove quite useful to 
examine the protein products of genes involved in the induction and regulation of apoptosis in 
order to arrive at a clearer picture of this process.   	  	  
4.2 MECHANISMS OF INHIBITION BY NITRIC OXIDE (PAPER II) 
 
Work done by several groups has shown that nitric oxide and its derivatives have an effect on the 
replication of several viruses that can be either stimulatory or inhibitory. It was shown that SARS-
CoV is one such virus that is affected in an inhibitory manner. The use of S-nitroso-N-acetyl 
penicillamine (SNAP) was observed to cause a dose-dependent reduction in SARS-CoV titer, with 
a concomitant reduction observed in the expression of viral proteins, as exemplified by an 
observed reduction in expression of the N protein. It was shown that cytokine-dependent NOS-2 
activation reduced viral yield significantly, suggesting that NOS-2 activation held antiviral 
potential against SARS-CoV (Åkerström et al 2005). Mechanistically, this suggests a potential 
action of peroxynitrite (ONOO-), which is formed by the rapid reaction of superoxide (O2-) and 
nitric oxide (NO). The use of increasing concentrations of SIN-1, a peroxynitrite donor, in Vero 
E6 cells infected with SARS-CoV showed no discernible effect on virus titer, suggesting that 
peroxynitrite did not have a role to play in the inhibition of SARS-CoV replication by nitric oxide. 
Moreover, a superoxide scavenger MnTBAP, when used in conjuction with SIN-1, was observed 
to restore the inhibition of viral replication as determined by virus titer. Because the formation of 
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peroxynitrite is a reversible reaction, the scavenging of superoxide shifts this reaction in the 
direction of excess nitrix oxide production. This result indicated therefore that the inhibition was 
due to nitric oxide or another derivative of this compound, rather than peroxynitrite.  
 
The inhibition of SARS-CoV replication by nitric oxide or its derivatives could manifest itself at 
several different steps in the viral life cycle, beginning with the process of infection itself, where 
the S protein of the virus binds to its cognate ACE-2 receptor and undergoes endocytosis into the 
host cell. To examine the possibility that the S protein might be affected by nitric oxide, we treated 
cells infected with a replicative recombinant vaccinia virus expressing the S protein (rVV-L-S) 
and treated these cells with either SNAP or NAP. Nitrotyrosine immunoprecipitation was able to 
pull down the S protein from lysates, indicating that the S protein was indeed reacting with nitric 
oxide when infected cells were treated with SNAP. However, there are 2 different residues which 
can react with nitric oxide or its derivatives. In addition to tyrosine nitration, which allowed for the 
pulldown of the S protein, cysteine residues on the S protein are also able to react with nitric 
oxide-based compounds. The S protein of SARS-CoV is known to undergo a few post-
translational modifications such as glycosylation and palmitoylation. Of these palmitoylation, 
which is the addition of a 16-carbon saturated fatty acid chain, is interesting as palmitate links to 
the S-protein via thiol groups on cysteine residues, and has been implicated in membrane fusion 
by the S protein after receptor binding (Petit et al 2007). In order to determine if palmitoylation of 
the S protein was affected by nitric oxide, Vero E6 cells infected with rVV-L-S were treated with 
SNAP, NAP, SIN-1 or SIN-1 with MnTBAP and labeled with [3H]-palmitic acid. Subsequent 
pulldown of labeled S using a rabbit polyclonal antibody against this protein showed that the 
amount of palmitoylated S was noticeably reduced in cells treated with SNAP, as compared to 
cells which had been treated with NAP or left untreated. SIN-1 treatment was not observed to 
have an effect on S palmitoylation, an effect that was restored with the combined use of SIN-1 and 
MnTBAP. These results indicated that the palmitoylation of the S protein was indeed adversely 
affected by nitric oxide or its derivatives, and additionally, that peroxynitrite did not have a 
noticeable effect on this modification. The functional consequence of the interference of nitric 
oxide on this modification was examined using a cell-cell fusion assay based on the fusion of 
293T cells stably expressing S with Chinese hamster ovary (CHO) cells stably expressing the 
ACE-2 receptor (Lip et al 2006). The treatment of S-expressing cells with SNAP was observed to 
inhibit the formation of syncytia where similar cells treated with NAP were not hindered in terms 
of cell-cell fusion.  
 
While it had been shown that nitric oxide or its derivatives might have an effect on the post-
translational modification of the S protein, it was unclear if this was the extent of the mechanism 
of nitric oxide-mediated inhibition of SARS-CoV replication. To address this, Vero E6 cells were 
infected with SARS-CoV and treated with SNAP, NAP or left untreated. QPCR analysis of RNA 
isolated from these cells using Taqman probes and primers specific to the N gene of SARS 
showed a significant decrease in cDNA encoding the N gene in cells treated with SNAP. Pre-
treatment of Vero E6 cells with SNAP did not result in a further decrease in N amplification. This 
indicated that nitric oxide had an effect on the production of viral RNA. This finding presented a 
myriad of possibilities as to the nature of inhibition of viral RNA production by nitric oxide – an 
effect on the viral replicase proteins seemed a likely explanation for the observed decrease. 
Additionally, it was known that the replicase proteins of SARS-CoV are expressed as 2 
polyproteins pp1a and pp1ab which are then autoproteolytically cleaved by 2 cysteine proteases, 
PLpro and 3Cpro, encoded within these polyproteins. It has been previously shown that nitric oxide 
or its derivatives could have an effect on the activity of cysteine proteases by modifying thiol 
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groups on the cysteine residues at the active sites of these proteases (Saura et al 1999, Cao et al 
2003a). In the case of SARS-CoV, modification of the cysteine residues on the replicase 
polyproteins would likely result in an alteration of the activity of these proteases. In order to study 
this possibility, Vero E6 cells were infected with SARS-CoV and treated with SNAP, NAP or left 
untreated for 24 hours and harvested lysates were examined by PAGE separation and Western 
Blotting using a mouse monoclonal antibody against nsp8 (see Paper I). While no difference was 
observed in the levels of nsp8 protein, there were observed differences in other bands on the 
Western Blot. When matched against calculated permutations of replicase polyprotein cleavage 
intermediates, these bands represented the calculated molecular weights of cleavage intermediates, 
suggesting that while nitric oxide did not completely inhibit the cleavage of the replicase 
polyproteins, it may have altered the cleavage patterns produced. Such polyproteins are indicative 
of a stoichiometric relationship between different proteins, and presumably an alteration in 
cleavage of this polyprotein could result in a perturbation of this relationship, adversely affecting 
viral RNA production. A study of 11 unique sites on the SARS-CoV replicase polyprotein cleaved 
by 3Cpro suggested that these 11 unique sites were cleaved with different efficiencies (Fan et al 
2005). Given that an altered pattern of cleavage was observed with SARS-CoV replicase 
polyproteins in the face of SNAP treatment, it would be interesting to examine the possibility 
these efficiencies might accordingly be altered. Also, all these results point to a significant 
antiviral activity of nitric oxide, or a derivative of nitric oxide. However, it is not known if NOS-2 
is activated during SARS-CoV infection, and whether such an effect plays a role in natural 
infection in vivo, or if NOS-2 might be inhibited in some manner by the virus, as has been 
previously described in the case of adenovirus E1A infection (Cao et al 2003b). These are among 
the interesting possibilities that might merit further study.  
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Abstract
Severe acute respiratory syndrome (SARS) coronavirus (SARS-CoV) caused a severe outbreak in several regions of the world in 2003. The
SARS-CoV genome is predicted to contain 14 functional open reading frames (ORFs). The first ORF (1a and 1b) encodes a large polyprotein that
is cleaved into nonstructural proteins (nsp). The other ORFs encode for four structural proteins (spike, membrane, nucleocapsid and envelope) as
well as eight SARS-CoV-specific accessory proteins (3a, 3b, 6, 7a, 7b, 8a, 8b and 9b). In this report we have cloned the predicted nsp8 gene and
the ORF6 gene of the SARS-CoV and studied their abilities to interact with each other. We expressed the two proteins as fusion proteins in the
yeast two-hybrid system to demonstrate protein–protein interactions and tested the same using a yeast genetic cross. Further the strength of the
interaction was measured by challenging growth of the positive interaction clones on increasing gradients of 2-amino trizole. The interaction was
then verified by expressing both proteins separately in-vitro in a coupled-transcription translation system and by coimmunoprecipitation in
mammalian cells. Finally, colocalization experiments were performed in SARS-CoV infected Vero E6 mammalian cells to confirm the nsp8–
ORF6 interaction. To the best of our knowledge, this is the first report of the interaction between a SARS-CoVaccessory protein and nsp8 and our
findings suggest that ORF6 protein may play a role in virus replication.
© 2007 Elsevier Inc. All rights reserved.
Keywords: SARS coronavirus; Protein–protein interaction; Yeast two-hybrid system; Non structural protein; Accessory protein; Immunoprecipitation
Introduction
Severe acute respiratory syndrome (SARS) is a newly
emerging infectious disease. The etiologic agent of SARS has
been identified as a novel coronavirus, namely SARS-associated
coronavirus (SARS-CoV) (Ksiazek et al., 2003; Marra et al.,
2003; Peiris et al., 2003; Rota et al., 2003). As of June 30th,
2003, 8447 probable SARS cases including 811 deaths were
reported by the World Health Organization (WHO) from 32
countries or regions worldwide. The significant morbidity and
mortality, and the potential for re-emergence, makes SARS-CoV
a continued worldwide public health threat.
Like other known coronaviruses, SARS-CoV is an envel-
oped, plus-strand RNA virus that features the largest RNA
genomes currently known. The SARS viral genome comprises
approximately 30,000 nucleotides, which are organized into 14
functional open reading frames (ORFs) (Rota et al., 2003; Thiel
et al., 2003). Analysis of the nucleotide sequence of this novel
coronavirus revealed a similar pattern of gene organization
typical of coronaviruses (Marra et al., 2003; Rota et al., 2003).
Two large, 5′-terminal overlapping ORFs, 1a and 1b of the
replicase gene encode two polyproteins, pp1a and pp1ab (Fig. 1)
(Rota et al., 2003; Thiel et al., 2003). Like other coronaviruses,
the nascent SARS-CoV replicase polyproteins are processed by
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virus-encoded proteinases, and in this case, two proteinases
have been identified: a 3C-like proteinase (3CLpro) and a
papain-like proteinase (PLP) (Denison et al., 1992; Snijder et
al., 2003; Ziebuhr, 2004). The processed end products of pp1a
are designated nonstructural proteins (nsp) 1 to nsp11 and those
of pp1ab are designated nsp1 to nsp16. Cleavage by the viral
main protease, 3CLpro results in generating the nsp8 protein
which is currently of undesignated function. The nsp8 protein
has been shown to associate with several other nsps and to
colocalize with these nsps in cytoplasmic complexes that are
important for viral RNA synthesis (Prentice et al., 2004a,
2004b; Sutton et al., 2004; Zhai et al., 2005). The +RNA
coronavirus usually encode a non-structural protein (nsp12 for
SARS-CoV) that includes an RdRp domain, conserved in all
RNAviruses. The SARS-CoV uniquely encodes a second RdRp
residing in nsp8, responsible for initiation of the synthesis of
complementary oligonucleotides smaller than 6 residues long,
at relatively low fidelity. These nsp8 RdRp produced primers
are postulated to be utilized by the primer-dependent nsp12
RdRp for replication (Imbert et al., 2006).
The remaining 12 ORFs encode the four structural proteins,
spike (S), membrane (M), nucleocapsid (N) and envelope (E),
and eight accessory proteins (3a, 3b, 6, 7a, 7b, 8a, 8b and 9b).
These accessory proteins are postulated to be non-essential in
tissue culture but may provide a selective advantage in the
infected host. The ORF3a protein has been studied to some
details (Tan et al., 2006) and has been shown to be expressed in
infected cells (Tan et al., 2004c; Yu et al., 2004; Zeng et al.,
2004). ORF3a protein has been shown to bind the spike protein
(Zeng et al., 2004; Tan et al., 2004c) and recent work
demonstrated that it is a novel structural protein (Ito et al.,
2005). The ORF7a protein was also detected in infected cells
and has been found to localize in the ER-Golgi intermediate
compartments where coronaviruses are known to assemble
(Fielding et al., 2004; Nelson et al., 2005). In addition, ORF3a,
ORF3b and ORF7a proteins have been shown to induce
apoptosis (Tan et al., 2004a; Law et al., 2005; Yuan et al., 2005).
Two recent papers on the ORF6 accessory protein also
demonstrated its expression during infection and have showed
that it may be important for viral pathogenesis (Geng et al.,
2005; Pewe et al., 2005). Most recently the ORF6 protein has
been shown to accelerate replication of a related mouse virus, a
property that may contribute towards its increased in vivo
virulence (Tangudu et al., 2007).
In this study, the nsp8 and ORF6 proteins were tested for
interaction in a yeast cellular environment using the yeast two-
hybrid system. These interactions were further verified by in-
vitro coimmunoprecipitation experiments using proteins
expressed by a coupled-transcription/translation system or in
mammalian cells by lipid-mediated transfection of DNA.
Finally, the nsp8–ORF6 interaction was confirmed by coloca-
lization of the two proteins in SARS-CoV infected mammalian
cells (Vero E6). This unique SARS-CoV accessory protein 6
interacting with a non-structural protein, nsp8, suggests that
ORF6 may have a role in SARS virus replication.
Results and discussion
The nsp8 protein of the SARS coronavirus was cloned from
the Tor2 Singapore isolate and expressed using the yeast two-
hybrid vectors resulting in an N-terminal in-frame fusion
protein with the GAL4 activation domain (AD). Similarly the
ORF6 protein was PCR cloned and expressed in yeast two-
hybrid vectors resulting in an N-terminal in-frame fusion
protein with the GAL4 DNA binding domain (BD). In order to
check for correct reading-frame constructs, the final plasmids
were sequenced and checked for in-vitro protein expression.
Saccharomyces cerevisiae AH109 cells were transformed with
single plasmids, or co-transformed with the GAL4 BD- and
AD-vectors containing SARS Co-V ORF6 and/or nsp8,
respectively. The AH109 host strain containing pAS2-N and
pACT2-N were used as positive controls (Surjit et al., 2004).
Fig. 1. Cloning of the putative nsp8 and ORF6 genes from the SARS CoV genome. The full-length nsp8 (198 amino acids) and ORF6 (66 amino acids) genes of the
SARS coronavirus (Tor2 isolate) were PCR-amplified from a genomic construct of clone NC_004718 and cloned into the pCR-XL-TOPO vector (Invitrogen) as
described in Table 1. The scale on top shows genomic region.
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AH109 contains integrated copies of both HIS3 and lacZ
reporter genes under the control of GAL4 binding sites. The
results of the two-hybrid assay are shown in Fig. 2A. Single
transformants used in this assay were yeast (AH109) cells
containing BD-ORF6, and host cells containing AD-nsp8, also
yeast cells containing only the BD- and only the AD-vectors,
were also used as negative controls. All these transformants and
co-transformants grew well on the unrestricted YPD plate (non-
Fig. 2. Yeast two-hybrid results showing that nsp8 and ORF6 proteins interact with each other. (A) AD-nsp8 fusion protein and BD-ORF6 fusion protein tested as
single and co-transformants on various synthetic growth media lacking specific amino-acids. YPD media shows uninhibited growth of all transformants and host
strain. SDTrp− and SD-Leu− selective media have Tryptophan and Leucine missing, respectively. SD Trp−Leu−His− media are triple dropout plates lacking
Tryptophan, Leucine and Histidine. Growth on the SD Trp−Leu−His− plate and blue color (shown here in shades of grey) on the β-gal filter assay represents a positive
interaction. BD-N:AD-N combination was used as a positive control in these yeast two-hybrid experiments (Surjit et al., 2004). (B) Liquid β-galactosidase assay
results of the nsp8–ORF6 protein–protein interactions. Single transformants and co-transformants were analyzed in a liquid β-galactosidase assay and compared with
each other. Values given are in arbitrary units. The numbers above each bar represent the mean from five independent transformants. Y187 corresponds to the
untransformed host strain. Transformants with more than one plasmid are separated by a slash. Positive controls used in this assay are denoted by BD-SNF1/AD-SNF4
(Harper et al., 1993). (C) Measurement of strength of the nsp8–ORF6 interactions on an increasing 3-AT gradient. Activation of the HIS3 reporter was determined for
the host AH109 strain, single transformants (BD, AD, BD-ORF6 and AD-nsp8), and co-transformants (BD-ORF6/AD-nsp8 and BD-N/AD-N). Hundred-fold serial
dilutions of all of the above-mentioned log-phase cultures were plated on YPD (left) followed by SD-His-plus 50 mM 3-AT in increasing concentrations (0 mM to
5 mM 3-AT).
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selective media). Also, the untransformed host cells were plated
as a negative control. Single transformants containing the BD-by
itself or as a fusion with the ORF6 protein, showed growth on the
synthetic dextrose Trp− plate (SDTrp−). Correspondingly, single
transformants containing the AD- by itself or as a fusion with
nsp8 showed growth on the synthetic dextrose Leu− plate
(SDLeu−). The co-transformants were similarly plated on YPD
and synthetic dextrose medium lacking Trp or Leu or Trp, Leu
and upon positive growth on these was subsequently plated on
His− medium (SD Trp−Leu−His−) to test for His prototrophy.
Growth of the co-transformants, containing the BD-ORF6 and
AD-nsp8 constructs, in both SDTrp− and SDLeu− plates simply
showed that both plasmids were present in the transformed cells.
Growth of these clones on the SD Trp−Leu−His− media showed
that the transcription of the HIS3 gene was turned on by the
reconstitution of the GAL4 transactivator due to a specific
ORF6–nsp8 interaction. Colonies were transferred on to
nitrocellulose filters and a β-galactosidase filter assay was per-
formed as described in methods. The co-transformants contain-
ing both the BD-ORF6 and AD-nsp8 constructs along with all
positive and negative controls were used in this assay. Results
obtained from the β-galactosidase filter assay were in
agreement with the results obtained from the SDHis− growth
experiments.
The liquid β-galactosidase assay was conducted and the
activity determined using the substrate chlorophenol red-β-D-
galactopyranoside (CPRG) as described in methods. The host
strain alone, along with single transformants containing either
AD-nsp8 or BD-ORF6 and co-transformants containing AD-/
BD- without a fusion protein was tested. Negative controls (host
untransformed cells) showed almost no liquid β-galactosidase
activity. BD-SNF1/AD-SNF4 was the positive control whereas
the clones containing BD-ORF6/AD-nsp8 were the test samples
in this experiment (Fig. 2B). Relative enzymatic activity was
determined in five independent transformants from each group.
Our results from this assay indicate a moderate strength
protein–protein interaction between the AD-nsp8 and BD-
ORF6 proteins. This observation was further confirmed by the
use of a 3-AT gradient on which the His+ phenotype was tested
(Fig. 2C). 3-AT is known to be a competitive inhibitor of HIS3
protein, thus enhancing the stringency of selection, it reduces
the background signal by inhibiting the product of the HIS3
reporter. This result clearly showed that the interaction of nsp8
with ORF6 was not as strong as the N–N dimerization positive
control interaction. On plates with increasing concentrations of
3-AT, the growth ability of the His+ colonies diminished and
was almost undetectable at 5 mM 3-AT concentrations.
To further confirm these interactions we performed a
coimmunoprecipitation assay using proteins expressed by a
cell-free coupled transcription–translation system. The rabbit
reticulocyte lysates expressing His6-nsp8 and myc-ORF6
proteins separately were tested for expression (Fig. 3A). For
detection of the expressed proteins, the lysates were immuno-
precipitated using the respective antibodies i.e. anti-His
antibody was used for detection of the nsp8 protein and anti-
myc antibody was used for the detection of the ORF6 protein.
When the two cell lysates were mixed in equal proportions, one
of the two antibodies was added and subsequently pulled out
using Protein A Sepharose beads, we observed the interacting
protein to be present in the gel as well. This procedure was
repeated conversely to show the other corresponding antibody
pull out the interacting protein partner as well (Fig. 3B). When
Fig. 3. Confirmation of the nsp8–ORF6 interaction using an in-vitro cell-free coupled transcription/translation coimmunoprecipitation assay. (A) The His6-tagged nsp8
and myc-tagged ORF6 proteins were produced by coupled transcription–translation in the presence of 35S-Met and detected using their corresponding antibodies
(Anti-His and anti-myc, respectively). Both nsp8 and ORF6 proteins were visible and corresponded to their correct molecular sizes on 12% and 20% SDS-PAGE,
respectively. (B) The 35S-Met-His-nsp8 and 35S-Met-myc-ORF6 proteins were detected by autoradiography. The nsp8–ORF6 complex was detected by both anti-His
and anti-myc antibodies on 16% SDS-PAGE. When nsp8 was probed for using anti-His antibody, the ORF6 protein was visible and when ORF6 protein was probed
using myc antibody, the nsp8 protein was visible. (C) In a control reaction, the 35S-Met-His6-nsp8 and
35S-Met-myc-ORF6 proteins showed no cross-reactivity with
the other antibody used in the pull-down experiments. Also this control experiment shows that the proteins do not non-specifically bind to the beads used in the results
shown in panel B. Lane 1 shows the nsp8 protein immunoprecipitated by anti-His, lane 2 does not show nsp8 protein band when immunoprecipitated by anti-myc.
Similarly, lane 3 shows myc-tagged ORF6 protein immunoprecipitated by anti-myc and lane 4 does not show ORF6 protein where it was immunoprecipitated using
anti-His.
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anti-His antibody was used to pull out the nsp8 protein from the
mixture of proteins, it also pulled out the ORF6 protein.
Similarly, when anti-myc antibody was used to pull out the
ORF6 protein, the nsp8 protein was also observed to be pulled
out as an interaction partner of ORF6. In a control experiment
we observed no ORF6 protein binding directly to the anti-His
antibody Sepharose-A complex and similarly observed no
binding of the nsp8 protein to the anti-myc antibody Separose-A
complex (Fig. 3C). These results clearly showed that the two
proteins nsp8 and ORF6 interacted with each other.
In order to verify the interaction between nsp8 and ORF6
in mammalian cells, co-immunoprecipitation experiments
were performed using lysates obtained from Vero E6 cells
expressing transiently transfected myc-tagged nsp8 and
untagged ORF6 proteins carried by a replicative recombinant
vaccinia virus. Myc-polyclonal antibody conjugated to protein
A Sepharose beads was used to pull-down myc-nsp8 or myc-
GST (negative control), and any ORF6 protein that co-
immunoprecipitated was detected using a rabbit polyclonal
antibody raised against a peptide of ORF6 (Abgent). This anti-
body specifically detected the ORF6 protein (∼7 kDa) in cells
that were infected with ORF6 recombinant vaccinia virus (Fig.
4, lanes 1 and 2). As shown in Fig. 4, ORF6 was co-immuno-
precipitated by myc-nsp8 (lane 3) but not by myc-GST (lane 4),
showing that the ORF6 and nsp8 proteins can interact in Vero
E6 cells.
In order to confirm that the interaction between nsp8 and
ORF6 occurs during SARS-CoV infection, co-immunoprecipi-
tation experiments were performed with lysates obtained from
SARS-CoV infected cells. Infection of Vero E6 cells with an
isolate of SARS-CoV (strain HKU 39849) was carried out in a
physical containment level 4 (PC4) laboratory as previously
described (Kaye et al., 2006). The cells were harvested at 0 or
24 h post-infection (h.p.i.) and the lysates were subjected to
Western blot analysis to determine the expression of nsp8 and
ORF6 proteins (Fig. 5). Two specific proteins in the cells at 24 h.
p.i. were detected with purified supernatant from hybridomas
producing monoclonal antibodies against the nsp8 protein (see
Materials and methods) and these were not found in the cells
harvested at 0 h.p.i. (upper panel, lanes 1 and 2). The protein that
Fig. 4. (A) Cell lysates were obtained from Vero E6 cells expressing ORF6 and
myc-nsp8 or ORF6 and myc-GST (negative control) and subjected to Western
blot analysis with either anti-ORF6 polyclonal (upper panel, lanes 1 and 2) or
anti-myc monoclonal antibodies (lower panel, lanes 1 and 2). Equal amounts of
lysates were subjected to immunoprecipitation using anti-myc polyclonal
antibodies and protein A beads. The immuno-complexes were subjected to
Western blot with either anti-ORF6 polyclonal (upper panel, lanes 3 and 4) or
anti-myc monoclonal antibodies (lower panel, lanes 3 and 4). (B) Equal amounts
of total cellular protein from Vero E6 cells either uninfected (lane 1) or infected
with wildtype Dryvax (lane 2), a recombinant vaccinia virus expressing the
SARS-CoV S protein (lane 3), or the recombinant vaccinia virus expressing the
ORF6 protein used in this study (lane 4) were subjected to Western blot and
probed with anti-ORF6 rabbit polyclonal antibody. This demonstrates that the
∼37 kDa band seen in lanes 1 and 2 of panel A is a cross-reacting protein that is
probably a vaccinia virus protein or an up-regulated cellular protein which is
detected by the rabbit anti-ORF6 antibody used in this study.
Fig. 5. Lysates were obtained from SARS-CoV infected Vero E6 cells harvested
at 0 or 24 h post infection (h.p.i.) and Western blot analyses were performed to
determine the expression of SARS-CoV proteins using mouse anti-nsp8 mono-
clonal antibody (upper panel, lanes 1 and 2) and rabbit anti-ORF6 polyclonal
antibody (lower panel, lanes 1 and 2). Cell lysates obtained at 24 h.p.i. were then
subjected to immunoprecipitation using anti-Flag (irrelevant antibody as nega-
tive control) or anti-ORF6 rabbit polyclonal antibodies and protein A beads. The
immuno-complexes were subjected to Western blot analysis with mouse anti-
nsp8 monoclonal antibody (upper panel, lanes 3 and 4).
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migrated at ∼24 kDa matched the predicted molecular mass of
nsp8 while the slower migrating protein (∼65 kDa) may be an
aggregated form of nsp8. As expected, the ORF6 protein was
also detected at 24 h.p.i. and not at 0 h.p.i. (lower panel, lanes 1
and 2). Cell lysates obtained at 24 h.p.i. were then subjected to
immunoprecipitation with either an irrelevant antibody (rabbit
anti-Flag polyclonal antibody, lane 3) or rabbit anti-ORF6
polyclonal antibody (lane 4) and protein-A agarose beads.
Western blot analyses showed that nsp8 protein (∼24 kDa) was
co-immunoprecipitated when anti-ORF6 antibody was used but
not when an irrelevant antibody was used, indicating that the
nsp8 interacts specifically with ORF6 in SARS-CoV infected
cells (upper panel, lanes 3 and 4).
Indirect immunofluorescence analysis of ORF6 expression
in SARS-CoV-infected cells (Fig. 6, middle panel) showed
that, consistent with previous publications (Geng et al., 2005;
Pewe et al., 2005), ORF6 was found in the cytoplasm. Most of
the ORF6 protein seen in infected cells were observed in a
punctate staining pattern consistent with a vesicle-associated
intracellular distribution. Using the rabbit polyclonal antibody
against ORF6 (Abgent) and purified supernatant from hy-
bridomas producing monoclonal antibodies against the nsp8
protein (see Materials and methods), cells infected with an
isolate of SARS-CoV (strain HKU39849) were examined by
indirect immunofluorescence to determine if the two proteins
colocalized, as their interaction would suggest. The extent of
colocalization seen between the two proteins was significant,
both localizing to the same set of punctate structures (Fig. 6,
middle panel, D). The punctate distribution of nsp8 has been
previously described (Prentice et al., 2004a) and the
colocalization of ORF6 protein with nsp8 suggests that
ORF6 could be associated with the SARS-CoV replicase
complex, localized to a subset of the vesicular trafficking
complex in mammalian cells. These ORF6-containing vesi-
cular structures did not colocalize with AP-1 and LAMP-2
(data not shown), which are present in early and late
endosomes respectively. However, the ORF6 protein does
colocalize with LAMP-1 (Fig. 7), which is a lysosomal
marker. LAMP-1 has been used as a marker for characteristic
double-membrane vesicles seen in infections by other viruses
(Jackson et al., 2005) and it has been shown that at least one
other coronavirus induces these double-membrane vesicles,
presumably as a site for the assembly of virus replication
complexes (Prentice et al., 2004b). Given this, the ORF6
protein might localize to these vesicles which have been
suggested to be derived from the cellular autophagosomal
machinery, but further study will be required. A recent struc-
tural study of the nsp8 protein has suggested a role for the
Fig. 6. Indirect immunofluorescence used to study cellular localization of nsp8 and ORF6 in SARS-CoV infected Vero E6 cells. (Upper panel) Mouse anti-nsp8 (A)
and rabbit anti-ORF6 (B) antibodies were used against uninfected cells to determine if the antibodies showed any unspecific staining. Nuclei are represented by means
of a DAPI stain (C). (Middle panel) Vero E6 cells infected with SARS-CoVwere examined by indirect immunofluorescence using the same antibodies. The expression
of nsp8 is represented by FITC staining (E), while the expression of ORF6 is represented by Rhodamine staining (F). Nuclei are represented by means of a DAPI stain
(G). The merged image showed that the nsp8 and ORF6 proteins colocalize to punctuate structures in the cytoplasm (H). (Lower panel) Irrelevant antibodies (mouse
anti-GAL4TA (I) and rabbit anti-flag (J)) were used to probe SARS-CoV infected cells at the same final concentrations as their counterparts in the middle panel to show
the specificity of the antibodies used in detecting the ORF6 and nsp8 proteins.
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nsp8–nsp7 hexadecamer in binding dsRNA intermediates in
the viral replication cycle (Zhai et al., 2005), further lending
impetus to such a study.
This is the first report describing the interaction between
the ORF6 accessory protein and the nsp8 protein. We
demonstrated the strength and specificity of this interaction
by three independent methods, i.e. by yeast-2-hybrid, co-
immunoprecipitation using in-vitro translated proteins in a
cell-free system and co-immunoprecipitation using lysates
from Vero E6 cells. Interestingly, two previous publications
on ORF6 have shed some light on its possible function in
viral pathogenesis. Geng and co-workers detected ORF6
protein in lung and intestine of SARS patients and showed
that it could stimulate cellular DNA synthesis when over-
expressed (Geng et al., 2005). Pewe et al. (2005) showed that
when SARS-CoV ORF gene was introduced into an
attenuated murine coronavirus, the recombinant virus grew
faster in cell culture and also exhibited enhanced lethality of
infection in mice. In contrast, Yount and co-workers reported
that the SARS-CoV virus with ORF6 deleted has the same
viral replication kinetics as the wild-type virus in cell-culture
and mice (Yount et al., 2005). Hence, ORF6 is non-essential
for viral replication in these models although it cannot rule
out that ORF6 (and/or the other accessory proteins of SARS-
CoV) contributes to the virulence and pathogenesis of SARS
coronavirus infection in its natural host. Further experiments
in more robust animal models, like non-human primates that
demonstrate clinical disease upon SARS-CoV infection, will
be needed to determine the actual function of ORF6 during
SARS infection in vivo. Since our data shows that ORF6
interacts with nsp8 which is part of the replicase complex
(Prentice et al., 2004a, 2004b), it will be important in future
studies to determine if the interaction between ORF6 and
nsp8 can modulate the viral synthesis process and to
determine how ORF6 modulates viral pathogenesis in these
animal models.
Materials and methods
Growth media, yeast strains and plasmid constructs
All strains, plasmids and plasmid constructs used in this
study are described in Table 1. The full-length nsp8 and ORF6
genes of the SARS coronavirus (Tor2 isolate) were PCR-
amplified from a genomic construct of clone NC_004718
(Fig. 1), and cloned into the pCR-XL-TOPO vector
(Invitrogen). The full-length nsp8 and ORF6 genes were
subjected to DNA sequencing and the inserts were verified
against the corresponding region of the SARS coronavirus
complete genome NC_004718. The nsp8 gene was excised
from the pCR-XL-TOPO-nsp8 construct using the restriction
enzymes NcoI and EcoRI, and ligated into the yeast two-
Table 1
Yeast strains, plasmids and recombinant plasmid constructs used in this study
Strain/plasmid/
construct
Genotype/description/reference
Strains
AH109 MATa trp1-901 his3 leu2-3, 112 ura3-52 ade2 gal4
gal80URA3∷GAL-lacZ LYS2∷GAL-HIS3
Y187 MATα, ura3-52, his3-200, ade2-101, trp1-901, leu2-3, 112,
gal4Δ, met-, gal80Δ, URA3∷GAL1UAS- GAL1TATA-lacZ
Plasmids
pGADT7/pACT2 GAL4 AD vector [GAL4(768–881)]; LEU2, 2 μm, Ampr
pGBKT7/pAS2 GAL4 DNA-BD vector [GAL4(1–147)]; TRP1, 2 μm, Ampr
Constructs
pACT2-nsp8 pCR-XL-TOPO-nsp8-easy-nsp8 digested with NcoI and
EcoRI, fragment ligated into pACT2
pGBKT7-ORF6 pCR-XL-TOPO-ORF6 digested with NcoI and EcoRI,
fragment ligated into pGBKT7
pRSET-nsp8 pGEMT-nsp8 digested with NcoI and EcoRI,
fragment ligated into pRSET
Fig. 7. Indirect immunofluorescence was used to probe for LAMP-1 (A, E) and ORF6 (B, F) staining in SARS-CoV infected cells (upper panel) and uninfected Vero E6
cells (lower panel). Nuclei are represented by means of a DAPI stain (C, G). The merged image showed that there is colocalization between the LAMP-1 protein and
ORF6 proteins in SARS-CoV infected cells (D, upper panel).
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hybrid Activation Domain vector, pACT2 to generate an N-
terminal in-frame fusion with the GAL4 activation domain
(AD). The ORF6 gene was excised from the pCR-XL-
TOPO-ORF6 construct using the restriction enzymes EcoRI
and PstI, and cloned into the yeast two-hybrid DNA Binding
Domain (BD) vector pGBKT7 in fusion with the GAL4
DNA-binding domain to express an N-terminal fusion
protein. Similarly the NcoI and EcoRI sites were used to
clone the nsp8 gene into the pRSET vector to give the
construct pRSET-nsp8. All DNA manipulations were per-
formed as described by Sambrook et al. (1989). All
constructs were verified by restriction digestion and DNA
sequencing.
Yeast two-hybrid techniques
The GAL4-based two-hybrid system, kindly provided by
Dr. Stephen Elledge (Harper et al., 1993), containing pGBKT7
(DNA-binding domain vector) and pACT2 (activation domain
vector), together with the yeast reporter strain S. cerevisiae
AH109 (trp1-901 his3 leu2-3, 112 ura3-52 ade2 gal4
gal80URA3∷GAL-lacZ LYS2∷GAL-HIS3) were employed.
The host strain containing the Nucleocapsid protein (N) of
SARS virus fusion constructs pACT2-N and pAS2-N, shown
previously to form a homodimer (Surjit et al., 2004) was used
as a positive control. The AH109 host contains integrated
copies of both HIS3 and lacZ reporter genes under the control
of GAL4 binding sites. The AH109 yeast strain was
transformed with the appropriate plasmids, using the lithium
acetate procedure and grown on SD plates in the absence of
Trptophane (Trp) and Leucine (Leu); (SDTrp− and SDLeu−).
Protein interaction was tested on SD plates without Leu, Trp
and Histidine (SDLeu− Trp− His−). After 3 days at 30 °C,
individual colonies were streaked out and tested for liquid and
filter-lift β-galactosidase activity, 5 mM 3-amino-1,2,3-trizole
assay (3AT) and the liquid β-galactosidase assay (Ober et al.,
2002; Peiris et al., 2003; Pewe et al., 2005). The filter β-
galactosidase assay, a parameter directly reflecting the strength
of protein–protein interactions, was performed by streaking
doubly transformed yeast colonies onto filter paper and
allowing them to grow for 2 days on selection medium.
Yeast was permeabilized by freezing yeast-impregnated filters
in liquid nitrogen, and thawing at room temperature. This filter
was placed over a second filter that was pre-soaked in Z buffer
(pH 7.0) containing 10 mg/ml 5-bromo-4-chloro-3-indolyl-β-
D-galactopyranoside (X-gal) and 0.27% β-mercaptoethanol.
Filters were left for 18 h to develop a blue color, which
indicated a positive protein–protein interaction. The liquid β-
galactosidase activity was determined using the substrate
CPRG as described previously (Tyagi et al., 2001, 2002).
Relative enzymatic activity was determined in five indepen-
dent transformants. Data for quantitative assays were collected
for yeast cell number and are the mean±S.E.M. of triplicate
assays. Appropriate positive/negative controls and buffer
blanks were used. The yeast Y187 host strain containing
BD-1111 and AD-1112 were used as positive controls for
these assays.
In-vitro cell-free coupled transcription/translation binding
analysis
The 35[S]-methionine labeled full-length pRSET-His6-nsp8
protein (198 amino acids nsp8 with N-terminal His6-tag) and
radiolabelled 35[S]-methionine full-length ORF6 accessory
protein (66 amino acids with an N-terminal myc tag), were
expressed in separate reactions using a coupled in-vitro
transcription–translation system (TNT coupled reticulocyte
lysate system; Promega) as per manufacturer's instructions.
10 μl of the His6-nsp8 labeled protein lysate was mixed with
10 μl of myc-ORF6 protein lysate. This mixture was incubated
on ice for 2 h and the primary antibody (either anti-His or anti-
myc) was added to the mixture. Subsequently the mixture was
incubated at 4 °C for 1 overnight. Sepharose-A beads were
added to the mixture and incubated at 4 °C with gentle shaking
for 1 h. The beads were washed three times with PBS,
resuspended in 10 μl of SDS-PAGE loading buffer and boiled
for 5 min to dissociate the bound proteins and detected by
autoradiography. Appropriate control reactions were performed
to validate the data.
Mammalian cell cultures
The CV-1 (African Green monkey kidney) cell-line was a
kind gift from Baxter Vaccines, Orth/Donau, Austria. The Vero
E6 cell-line was purchased from the American Type Culture
Collection (Manassas, VA, USA). All cells were cultured at
37 °C in 5% CO2 in DMEM containing 1 g/l glucose, 2 mM L-
glutamine, 1.5 g/l sodium bicarbonate, 0.1 mM non-essential
amino acids, 0.1 mg/ml streptomycin and 100 U penicillin, and
10% FBS (HyClone, Utah, USA).
Generation of ORF6 recombinant replicating vaccinia virus
ORF6 recombinant replicating vaccinia virus was generated
using the system developed by Baxter Vaccine (Orth/Donau,
Austria). The vector, cell-lines and viruses used here were kind
gifts from Baxter Vaccine. ORF6 was amplified from cDNA
prepared from SARS-CoV infected cells as previously
described (Tan et al., 2004b) and the pair of primers used is
ORF6_forward (5′-GCAAGCTTATGTTTCATCTTGTTGA-3′)
and ORF6_reverse (5′-CCGGCGGCCGCTTATGGATAATC-
TAACACC-3′). The amplicon was digested with HindIII and
NotI and cloned into the compatible sites of the pDD4-mh5
vector to create plasmid pDD4-mh5/ORF6. The pDD4-mh5
vector can be used to generate growth-competent recombinants
expressing foreign genes in the D4 locus via a rescue method as
previously described (Holzer and Falkner, 1997). Essentially,
the parental virus lacking the D4 gene is replication negative in
the usual permissive host lines and only the reintegration of D4
into the virus genome allows for growth in these lines. This is in
contrast to classical drug-based screening approaches which
have previously been well established in the generation of
vaccinia recombinants.
CV-1 cells were grown to 70–80% confluence in 60 mm
dishes. Confluent monolayers were washed once with PBS,
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followed by a two washes with 1 ml DME containing no FBS or
antibiotics. The culture medium was removed and overlaid with
0.2 ml defective vaccinia virus (dVVL) (∼multiplicity of
infection is 1 pfu/cell) diluted in 0.6 ml DMEM for 1 h at 37 °C
in CO2, with shaking every 15 min. dVVL is derived from the
vaccinia virus Lister strain (ATCC VR-862; Ober et al., 2002,
and was titered in the complementing cell line RK44.20; Holzer
and Falkner, 1997). The supernatant was removed, replaced
with 2 ml DMEM containing no FBS or antibiotics and cells
were transfected with 5 μg pDD4-mh5/ORF6 using lipofecta-
mine reagent (Invitrogen, Carlsbad, CA, USA), according to the
manufacturer's protocol. After 3 days, advanced cytopathic
effect was evident and the cells were harvested and subjected to
Western blot analysis (see below) for determining ORF6
expression. Alternatively, the cells and culture supernatant
were harvested together and then subjected to three rounds of
freeze-thawing and clarified by centrifugation at 1500 rpm for
5 min. The supernatant, which constitute the P1 viral stock, was
used to infect fresh CV-1 cells after which the P2 viral stock was
harvested in the same manner and stored at −80 °C before use.
The P2 viral stock was titered in CV-1 cells. This approach of
dominant host range selection provides a stringent and time-
saving method for obtaining vaccinia recombinants carrying
foreign genes and has been described previously (Holzer et al.,
1998). The recombinant vaccinia virus expressing the SARS-
CoV S protein was previously generated using the same
methods (Lip et al., 2006).
Expression of viral proteins in mammalian cells and
co-immuoprecipitation experiments
The nsp8 gene was PCR amplified from the pRSET-nsp8
plasmid with the following pair of primers: nsp8_forward
(5′-CGGGATCCGGCACCATGGCTATTGCTTCAG-3′) and
nsp8_reverse (5′-CCGCTCGAGTCACTGTAGTTTAA-
CAGCTG-3′). The amplicon was digested with BamHI and
XhoI and cloned into compatible sites in the mammalian
expression pXJ40myc vector which contains a myc-tag at the
N-terminus for ease of detection. Typically, ∼1×10 6 cells Vero
E6 were plated on 6 cm dish and allowed to attach overnight and
then infected with ORF6 recombinant vaccinia virus at a
multiplicity of infection of 1. Infection media was replaced 1 h
post-infection and the cells were transfected with 1 ug of
pXJ40myc-nsp8 using lipofectamine reagent as described
above. The cells were harvested ∼16 h later and lysed in IP
buffer (50 mM Tris (pH 8.0), 150 mM NaCl, 0.5% NP40, 0.5%
deoxycholic acid, 0.005% SDS) and used in co-immunopreci-
pitation experiments as previously described (Tan et al., 2004c).
Briefly, the lysate was incubated with an anti-myc polyclonal
antibody (A14, Santa Cruz Biotechnology, Santa Cruz, CA,
USA) overnight at 4 °C, followed by adsorption onto a 50 μl
suspension of protein A-sepharose beads (Roche Molecular
Biochemicals). Beads were then washed 3 times with cold IP
buffer and subjected to Western blot analysis as previously
described. Primary antibodies used here were anti-myc mono-
clonal (9E10, Santa Cruz Biotechnology) and rabbit anti-ORF6
(PUP3, Abgent, San Diego, CA, USA).
For co-immunoprecipitation experiments performed with
SARS-CoV infected Vero E6 cells, Vero E6 cells were plated in
25 cm2 flasks and infected with an isolate of SARS-CoV (strain
HKU39849) as previously described (Kaye et al., 2006). The
cells were harvest at 0 or 24 h.p.i. and the lysates were then
subjected to Western blot analysis and co-immunoprecipitation
experiments as described above. Anti-nsp8 monoclonal
(described below) and rabbit anti-ORF6 antibodies were used
for Western blot while rabbit anti-flag polyclonal (Sigma) or
rabbit anti-ORF6 antibodies were used for immunoprecipitation.
Immunofluorescence analysis
Indirect immunofluorescence was performed using SARS-
CoV infected Vero E6 cells as previously described (Tan et al.,
2004c). Briefly, Vero E6 cells were plated onto 4-well chamber
slides (Lab-Tek) and infected with an isolate of SARS-CoV
(strain HKU39849) as previously described (Kaye et al., 2006).
42 h post-infection, chamber slides were washed twice in
phosphate-buffered saline (PBS); cells were then fixed and
permeabilized with methanol for 5 min and subsequently
subjected to gamma-irradiation to neutralize infectivity of the
virus. Cells were then refixed with 4% paraformaldehyde and
permeabilized with 0.2% Triton X100. Blocking was done
using PBS with 1% bovine serum albumin (Sigma) and each
chamber was incubated with relevant and irrelevant control
antibodies before being washed with PBS+1% BSA several
times. Chamber slides were then incubated using FITC-
conjugated goat anti-mouse and rhodamine-conjugated goat
anti-rabbit secondary antibodies (1:200; Santa Cruz) before
being washed again and mounted using glass coverslips and a
mixture of Fluorsave mounting medium (Calbiochem) and
Vectashield mounting medium with DAPI (Vector Labora-
tories). Imaging was done with an Olympus Fluoview upright
confocal microscope (Olympus).
Antibodies for detecting endogenous AP-1 and the FLAG
epitope were purchased from Sigma and antibodies against
LAMP-1 and LAMP-2 were purchased from Abcam plc. The
anti-GAL4TA antibody was purchased from Santa Cruz.
Monoclonal antibody against the nsp8 protein was prepared
as follows: bacterially expressed glutathione S-transferase
(GST)-nsp8 fusion protein was used to immunize BALB/c
mice as previously described (Fielding et al., 2004). The
spleen was excised from a mouse that showed strong antibody
response and hybridoma fusion was performed to generate
hybridomas producing monoclonal anti-nsp8 antibodies as
previously described (Lip et al., 2006). All procedures on the
use of laboratory animals were performed by trained personnel
in accordance with the regulations and guidelines of the
National Advisory Committee for Laboratory Animal
Research (NACLAR), Singapore. The culture supernatants
from several of these hybridoma clones were pooled and
purified using a HiTrap protein G HP column (Amersham)
and verified by immunofluoresence assay to be specific to the
nsp8 protein.
The mouse monoclonal primary antibodies (mouse anti-nsp8
and anti-GAL4TA) were used at concentrations of 0.2 mg/ml
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and the rabbit polyclonal antibodies (anti-ORF6 and anti-flag)
were used at concentrations of 0.0025 mg/ml. Identical dilutions
of secondary antibodies were used for all samples.
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Nitric oxide is an important molecule playing a key role in a broad range of biological process such as
neurotransmission, vasodilatation and immune responses. While the anti-microbiological properties of nitric
oxide-derived reactive nitrogen intermediates (RNI) such as peroxynitrite, are known, the mechanism of
these effects are as yet poorly studied. Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) belongs
to the family Coronaviridae, was ﬁrst identiﬁed during 2002-2003. Mortality in SARS patients ranges from
between 6 to 55%. We have previously shown that nitric oxide inhibits the replication cycle of SARS-CoV in
vitro by an unknown mechanism. In this study, we have further investigated the mechanism of the inhibition
process of nitric oxide against SARS-CoV. We found that peroxynitrite, an intermediate product of nitric
oxide in solution formed by the reaction of NO with superoxide, has no effect on the replication cycle of
SARS-CoV, suggesting that the inhibition is either directly effected by NO or a derivative other than
peroxynitrite. Most interestingly, we found that NO inhibits the replication of SARS-CoV by two distinct
mechanisms. Firstly, NO or its derivatives cause a reduction in the palmitoylation of nascently expressed
spike (S) protein which affects the fusion between the S protein and its cognate receptor, angiotensin
converting enzyme 2. Secondly, NO or its derivatives cause a reduction in viral RNA production in the early
steps of viral replication, and this could possibly be due to an effect on one or both of the cysteine proteases
encoded in Orf1a of SARS-CoV.
© 2009 Elsevier Inc. All rights reserved.
Introduction
Severe acute respiratory syndrome coronavirus (SARS-CoV)
belongs to the family Coronaviridae and was ﬁrst identiﬁed as a
novel coronavirus after the ﬁrst known outbreak in the fall of 2002 in
southern part of China (Resh, 2006; Tan et al., 2006). SARS-CoV is a
positive-sense RNA virus with a genome of ∼30 kb in length that
forms a distinct group within the Coronaviridae family. Common to all
known coronaviruses are the four structural proteins: spike (S),
membrane (M), envelope (E) and nucleocapsid (N) protein (Marra et
al., 2003; Rota et al., 2003). The S protein protrudes from the envelope
of the virus, which results in its characteristic crown-like appearance.
The S protein binds to speciﬁc receptors on the cell surface; in the case
of SARS-CoV, it is the angiotensin-converting enzyme 2 (ACE2). The S
protein has two regions, S1 and S2, where S1 is involved in receptor
binding and S2 in membrane fusion (Li et al., 2005, 2006).
In order to achieve its functionality, the S protein has to undergo
numerous post-translational modiﬁcations like glycosylation (Keng et
al., 2005). In addition, Petit et al. (2007) recently showed the importance
of S-palmitoylation of the endodomain of the spike protein for the
mediation of cell fusion. Palmitoylation involves the addition of
palmitate, which is a 16-carbon saturated fatty acid, and a wide range
of proteins have been shown to carry this speciﬁc modiﬁcation (Resh,
2006). The addition of palmitate can inﬂuence the interaction between
protein and membrane, protein trafﬁcking, and protein–protein inter-
actions (Resh, 2006; Smotrys and Linder, 2004; Thorp et al., 2006). In S-
palmitoylation, the fatty acids are linked through thioester linkages to
thiol groups on cysteine residues (Greaves and Chamberlain, 2007;
Resh, 2006; Smotrys and Linder, 2004).
Nitric oxide (NO) is involved in a broad range of processes and act as
an important signalingmolecule between cells (Adler et al., 1997; Zhang
et al., 2003). NO is produced in mammalian cells by three enzymes,
neuronal (nNOS), endothelial (eNOS) and inducible nitric oxide
synthase (iNOS) and these catalyze the oxidation of L-arginine to NO
and L-citrulline (Boucher et al., 1999). Inducible nitric oxide in the host
cells is commonly elevated during infection by viruses and this can lead
to either inhibition or stimulation of viral replication (Adler et al., 1997;
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Akarid et al., 1995; Akerstrom et al., 2005; Fang, 2004; Klingstrom et al.,
2006; Pope et al., 1998; Saxena et al., 2001; Thorp et al., 2006).
In our previous study, we showed that NO inhibits the replication
cycle of SARS-CoV (Akerstrom et al., 2005). We clearly showed that the
progeny viruses were inhibited in a concentration-dependent manner,
using the exogenous NO donor S-nitroso-N-acetyl-penicillamine
(SNAP). We also demonstrated that endogenously generated NO can
inhibit the replication cycle of SARS-CoV. Another host defence against
microbes is superoxide (O2−) which can be induced when cells are
stressed, for example during an infection (Akaike and Maeda, 2000). If
NO and O2− are elevated at the same time, theywill react rapidly to form
peroxynitrite (ONOO−), which has also been shown to have an
inhibitory effect on viruses (Akaike, 2001). Hantaviruses are one group
of viruses known to be adversely affected by peroxynitrite (Klingstrom
et al., 2006). Hence, it is unclear if the effect of NO on SARS-CoV
replication is caused by peroxynitrite or another derivative of nitric
oxide. In this studywe showthat peroxynitrite doesnot playa signiﬁcant
role in the NO-mediated inhibition of the SARS-CoV replication cycle.
Most interestingly, our data suggest that the effect of NO or its
derivatives on the replication cycle of SARS-CoV is twofold: Firstly, NO
or its derivatives causes a reduction in the palmitoylation of the S protein
which results in the inhibition of membrane fusion mediated by the
interaction between S protein and the ACE2 receptor. Secondly, NO or its
derivatives have an inhibitory effect on the production of viral RNA,
which can be observed as early as 3 h post-infection.
Results
Peroxynitrite has no effect on SARS-CoV
SIN-1, which produces peroxynitrite, was used in conjunction with
a superoxide scavenger, MnTBAP, to determine if peroxynitrite was
Fig. 1. SIN-1 treatment has no antiviral effect on SARS-CoV infected Vero E6 cells. Vero
E6 cells were infected with SARS-CoV at an MOI of 1.0, at 1 hpi cells were treated with
different concentrations of SIN-1 and/or MnTBAP. (A) Cells treated with different
concentrations of SIN-1. 24 hpi, virus was harvested and titers determined. (B) Cells
treated with 400 μM SIN-1 and different concentrations of MnTBAP. Virus was
harvested 24 hpi and titers determined. (C) Cells treated with different concentrations
of MnTBAP, virus was harvested 24 hpi and titers determined.
Fig. 2. Effect of SNAP on nitration and palmitoylation of S protein. Vero E6 cells were
infected with rVV-L-S at an MOI of 0.1. At 1 hpi cells were treated with 400 μM SNAP or
NAP. (A) At 24 h post-infection, the cells were lysed and immunoprecipitation was
performed with nitrotyrosine afﬁnity sorbent. Western blot was then performed using
rabbit anti-S polyclonal antibody. (B, C) At 24 h post-infection, cells were labelled with
400 μCi of [3H]-palmitic acid for 2 h, or starved with methionine-cysteine (Met-Cys)-
free medium for 30 min before being labelled with 22 μCi of [35S]-methionine-cysteine
for 2 h. The cells were then lysed and imunoprecipitation was performed with rabbit S
polyclonal antibody to detect the amount of radiolabelled S protein.
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involved in the inhibition of SARS-CoV replication. SARS-CoV infected
Vero E6 cells were treated with different concentrations of SIN-1, and
it was observed that no signiﬁcant inhibition of viral replication
occurred. This suggested that SIN-1 administration had no effect on
the replication cycle of SARS-CoV.
Next, we treated the SARS-CoV infected Vero E6 cells with different
concentrations of MnTBAP together with SIN-1. MnTBAP removes the
superoxide, resulting in a reduction in the amount of peroxynitrite and
an increase in the amount of free NO. The results in Fig. 1B clearly
demonstrate that with increasing amount of MnTBAP in presence of
SIN-1 (400 μM), there is an inhibition in the production of progeny virus
in a concentration-dependent manner. Although a slight reduction on
the production of progeny virus was observed when the cells were
treated with the highest concentration of MnTBAP used in this study
(800 μM, Fig. 1C), the reduction of virus replication in cells treated with
both SIN-1 and MnTBAP is signiﬁcantly higher than those treated with
MnTBAP alone. This slight reduction might be explained by the
possibility that the use of the superoxide scavengerwould have resulted
in an increase in intracellular free NO, which could then, directly or
through an intermediary compound, exert an inhibitory effect.
Treatment with NO donor leads to the nitration of the S protein of SARS-
CoV and a reduction in its palmitoylation
In order to determine whether nitric oxide or its derivatives were
reactingwith the SARS-CoV S protein, Vero E6 cells were infectedwith
recombinant vaccinia virus carrying the S gene (rVV-L-S) and treated
with 400 μM of SNAP or NAP. Following immunoprecipitation with
nitrotyrosine afﬁnity sorbent (Cayman), which speciﬁcally binds
nitrated proteins, and detection of S by Western blotting, it was
clearly demonstrated that S had been nitrated after stimulation with
SNAP but not with NAP (Fig. 2A).
To determine whether the palmitoylation of S was affected by
nitric oxide, cells infected with rVV-L-S were treated with either
SNAP, NAP, SIN-1 or SIN-1 and MnTBAP and then labelled with [3H]-
palmitic acid. After immunoprecipitation of the S protein with an
anti-S rabbit polyclonal antibody, the amount of palmitoylated S
protein detected in the SNAP-treated cells was found to be
noticeably reduced when compared to the mock-treated or NAP-
treated ones (Fig. 2B). Treatment with the peroxynitrite donor SIN-1
did not cause a reduction in the palmitoylation of S (Fig. 2C),
conﬁrming other results that showed a lack of effect by peroxynitrite
treatment on SARS-CoV titer. On the other hand, if [35S]-methionine-
cysteine labelling was used, there was no difference in the amount
of total S protein immunoprecipitated for all treatments, indicating
that the SNAP and SIN-1 treatments did not affect the expression of
S (Figs. 2B, C).
Nitric oxide reduces the cell–cell fusion activity of the S protein
An in vitro assay was used to examine the effect of nitric oxide on
the cell–cell fusion activity of the S protein (Lip et al., 2006). In this
case, the S-expressing cells were treated with SNAP or NAP before
they were mixed with CHO-ACE2 cells stably expressing the ACE2
receptor. The formation of syncytia was observed 6 h later. Cells
treated with SNAP showed no fusion (Fig. 3B), whereas cell–cell
fusion was clearly visible in the NAP (Fig. 3C) or mock-treated cells
(Fig. 3A). As expected, the mock-infected cells showed no fusion as
the S protein was not expressed (Fig. 3D).
SARS-CoV S pseudotyped virus produced in the presence of nitric oxide is
less efﬁcient in viral entry
In order to investigate the effect of SNAP on the S-mediated entry
of SARS CoV into cells, we used the HIV pseudotyped virus system to
produce pseudotyped viruses with S on the surface. Pseudotyped
viruses were produced from untreated cells or cells treated with SNAP
(200 μM or 400 μM) or NAP (200 μM or 400 μM). SNAP and NAP
Fig. 3. SNAP interferes with cell–cell membrane fusion. A 293T-GFP stable cell line was infected with rVV-L-S and treated with SNAP or NAP 1 h post-infection. At 24 hpi cells were
trypsinized and mixed with pre-plated CHO-ACE2 cells. 6 h after mixing the cell lines, syncytium formation was observed. (A) Infected cells, mock-treated (B) Infected cells, treated
with 400 μM SNAP (C) Infected cells, treated with 400 μM NAP (D) Mock-infected cells.
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treatments did not affect the assembly of S on the pseudotyped
viruses as Western blot analysis showed that similar amounts of S
were incorporated into the pseudotyped viruses (Fig. 4A). Similar to
our previous observation (Keng et al., 2005), two forms of S were
detected and these correspond to the unglycosylated and glycosylated
forms of the protein.
Fig. 4. SARS-CoV S pseudotyped virus produced in the presence of SNAP is less efﬁcient in viral entry. Pseudotyped viruses produced under different conditions were puriﬁed and
concentrated using ultra-centrifugation through a 20% sucrose bed. (A) The presence of S and HIV-1 p24 proteins in the puriﬁed viruses were determined by Western blot analysis.
(B) Puriﬁed viruses were used for the transduction of CHO-ACE2 cells and the degrees of viral entry were determined by measuring the luciferase activities. Percentages of infectivity
were computed by normalizing the entry of untreated S-bearing pseudotyped viruses to 100%. Means and standard deviation from duplicate readings were shown. (C) Nitric oxide or
its derivatives do not exert a noticeable effect on the binding of the SARS S protein to ACE2. Cells were infected with pseudotyped virus bearing the S protein, produced under SNAP or
NAP treatment. A p24 ELISA kit was used to measure p24 concentration and concentration of bound virus was derived from a standard graph.
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The entry of the pseudotyped virus into CHO-ACE2, which is stably
expressing the S receptor ACE2 on the surface of the cells, was
reﬂected by the luciferase activity in the CHO-ACE2 cells at 72 h after
infection. As shown in Fig. 4B, the luciferase activity in the cells
infected with pseudotyped virus bearing S was signiﬁcantly higher
than those without S as the latter contained no viral envelope protein
and could not enter the CHO-ACE2 cells. The reading from the cells
infected with pseudotyped virus bearing S was normalized to 100% to
calculate percentage of infectivity. Treatment with 200 μM and
400 μM of NAP caused appropriately 15% and 25% reduction in
infectivity, respectively. However, treatment with 200 μM and 400 μM
of SNAP resulted in a signiﬁcantly higher reduction, appropriately
70%, in infectivity. In order to exclude any effect on the binding of the
S protein to the ACE2 receptor, a p24 ELISA kit (Perkin Elmer) was
used to determine the concentration of virus bound to cells infected
with the HIV pseudotyped virus which had been produced in cells
either treated with 400 μM SNAP or 400 μMNAP. As shown in Fig. 4C,
SNAP and NAP treatment had no signiﬁcant effect on the concentra-
tion of bound virus, indicating that the primary effect of SNAP
treatment on the S protein occurs post-binding, possibly during entry.
SNAP treatment reduces the production of positive-stranded viral RNA
In order to determine if the effect of nitric oxide on SARS-CoV was
limited to the post-translational modiﬁcation of the S protein, we
examined the production of viral RNA by realtime PCR analysis. RNA
isolated from SARS-CoV infected Vero E6 cells at different time points
post-infection in the presence of SNAP, NAP or mock treatment was
reverse transcribed and quantitated using primers speciﬁc for the N
gene of SARS-CoV. An identical amount of each RNA sample was also
reverse transcribed and quantitated using primers speciﬁc for GAPDH,
which served as a housekeeping control. The results showed that
SNAP treatment of Vero E6 cells resulted in a reduction in the amount
of total positive-stranded viral RNA produced. This effect was
observed as early as 3 h post-infection and viral RNA levels remained
low at 24 h post-infection (Fig. 5). In order to determine if this
observed effect could be exaggerated by pretreating Vero E6 cells with
nitric oxide, another experiment was run in parallel which included
an additional SNAP treatment step an hour before infection. The effect
observed was approximately the same as in cells treated post-
infection, suggesting that the pretreatment of Vero E6 cells with nitric
oxide did not signiﬁcantly increase the effects of nitric oxide on the
production of viral RNA (Fig. 5). The possibility that the pretreatment
had an effect on SARS-CoV particles before infection was excluded by
titrating SARS-CoV that had been incubated in SNAP-containing
media, which showed that the TCID50 of the virus was unchanged
(data not shown). It has been previously shown by others that nitric
oxide or its derivatives can exert an effect on the activity of cysteine
proteases (Cao et al., 2003; Saura et al., 1999). As SARS-CoV encodes
two different cysteine proteases, PLpro and 3Cpro, we tried to
determine if the effect seen on production of positive/stranded viral
RNAmight involve a loss or reduction of the function of one or both of
these proteases, which serve to cleave the different replicase proteins
from the pp1ab polyprotein expressed from Orfs 1a and 1b of the viral
genome (Thiel et al., 2003). One simple way to study this effect would
be to look at the cleavage of replicase proteins by Western blotting. A
previously described monoclonal antibody (Kumar et al., 2007)
targeting the nsp8 protein was used against SDS-PAGE-separated
lysates from SARS-CoV infected Vero E6 cells which had been treated
with either SNAP, NAP or untreated. Surprisingly, there was no
signiﬁcant difference in nsp8 levels at 24 h post-infection (Fig. 6).
Interestingly though, two other peptide species, detected by the nsp8
antibody in infected cells, showed differences in their respective
expression levels in SNAP-treated lysates. These high molecular
weight species could possibly represent cleavage intermediates of the
ORF1a replicase polyprotein from which nsp8 is cleaved. In order to
ascertain that NO was acting in these cells, the same lysates were
probed for the SARS N protein using a monoclonal antibody against N
(Zymed Laboratories). It was observed that N expression was
signiﬁcantly reduced in the same lysates. This was consistent with
earlier work (Akerstrom et al., 2005) and showed that the SNAP
treatment was working within the Vero E6 cells.
Discussion
NOcaneither inhibit or stimulateviral replicationduringan infection
(Adler et al., 1997; Fang, 2004;Akarid et al., 1995;Akerstromet al., 2005;
Greaves and Chamberlain, 2007; Klingstrom et al., 2006; Pope et al.,
1998; Saxena et al., 2001; Thorp et al., 2006). However, there are only a
few reports demonstrating the inhibition mechanism of NO. NO has
been shown to affect Epstein–Barr virus (EBV) by downregulation of the
Zta protein, an immediate early transactivator. The downregulation of
Zta helps to maintain latency of the virus. In the same study, it was also
shown that apoptosis in B cell lines were L-arginine dependent and that
NO can inhibit apoptosis in B cells (Mannick et al., 1994). In a previous
studywehave shown that NO inhibits the replication cycle of SARS-CoV.
The administration of the exogenous NO donor, SNAP, and endogenous
cytokine inducers of NO reduced the amount of progeny virus in a
concentration-dependent manner. In tissues that are stressed or
inﬂamed, both NO and O2− are elevated. Although SNAP predominantly
increases the NO level in the cell, peroxynitrite may also become
elevated after SNAP treatment as NO can react with endogenous O2− to
form peroxynitrite. However, if SIN-1 is used instead, both NO and O2−
are produced simultaneously and peroxynitrite is rapidly formed. Our
results show that unlike SNAP, treatment of SARS-CoV infected Vero E6
cells with SIN-1 has no signiﬁcant effect on the production of progeny
virus (Fig. 1A), suggesting that peroxynitrite does not inhibit SARS-CoV
replication. Moreover, if a superoxide scavenger (MnTBAP) is used to
remove the O2− and allow more NO to accumulate inside the SIN-1-
treated cells, a signiﬁcant inhibition of the virus replication was
observed (Fig. 1B). These results clearly demonstrate that peroxynitrite
has no effect on the replication of SARS-CoV and that it is NO, or a
derivative of NO, that inhibits the virus.
Palmitoylation is an important post-translational modiﬁcation of
proteins. Petit et al. (2007) have demonstrated that palmitoylation of
the SARS-CoV S protein plays a role in S-mediated cell–cell fusion. By
Fig. 5. SNAP treatment causes a reduction in the production of positive-stranded viral
RNA. Vero E6 cells were either treated with 400 μM SNAP, NAP or mock-treated and
infected with SARS-CoV at an MOI of 1. A parallel set of cells were additionally treated
an hour before infection. Cells were harvested from all sets of treatments at 3 h and 24 h
post infection and subjected to reverse transcription and realtime PCR using primers
and probes speciﬁc for the N gene of SARS-CoV and GAPDH. Ct values obtained for N in
each sample was normalized against GAPDH control values and plotted for each time
point and treatment.
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substituting select cysteine clusters at the carboxyl terminus of the S
protein for alanines, it was shown that palmitoylation of at least two
cysteine clusters at the C-terminus was important in membrane
fusion that occurred after binding of the S protein to its cognate ACE2
receptor, critical to the infectivity of SARS-CoV. It has also been
previously shown that NO or its derivatives have an effect on the
palmitoylation of the rat myelin protein (Bizzozero et al., 2001). In
agreement with both of these ﬁndings, our results in this work
indicate that NO or its derivatives reduce the palmitoylation of the S
protein and consequently exerts an effect downstream of the S
protein binding to ACE2, which is shown by the cell–cell fusion assay.
While cell–cell fusion remains an unobserved phenomenon in SARS-
CoV infection, in this paper the cell–cell fusion assay has proved useful
in examining the interaction of the S protein and its cognate ACE2
receptor. However, the cell–cell fusion assay does not address the
question of whether the underpalmitoylation of the S protein affects
its expression, folding or incorporation into the mature virus particle.
To this end we have created a pseudotyped virus based on HIV which
incorporates the S protein and shown that SNAP treatment of cells
does not affect the expression or incorporation of the S protein and it
is only the infectivity of the pseudovirus, as shown by the luciferase
assay, that is affected. It is known that treatment of mammalian cells
with NO donors results in at least two different types of post-
translational modiﬁcations—nitration of tyrosine residues (Ischiro-
poulos et al., 1992) and S-nitrosylation of cysteine residues (Stamler
et al., 1992). We demonstrate that nitric oxide or a derivative
compound is interacting with the S protein by means of the tyrosine
nitration assay. However, as tyrosine nitration depends on the
presence of peroxynitrite (Ischiropoulos et al., 1992), which has
been excluded from having an effect on the replication cycle of SARS-
CoV in this work, this indicates that either (a) the tyrosine residues
which have been nitrated have little or no role to play in the binding
between the S protein and ACE2, or (b) that the nitration of these
tyrosine residues do not impair their role in the S-protein. The true
effect of NO on the binding process might then manifest itself at the
cysteine residues on the S proteinwhichmayhave beenpalmitoylated,
in particular the clusters at the carboxy terminal that have been
demonstrated to play a role in cell–cell fusion. But what needs to be
determined is whether these residues have simply been under-
palmitoylated as a result of an effect on palmitoyl-acyl transferases in
the host cell or whether, given that these are cysteine residues,
competitively nitrosylated. S-nitrosylation motifs have been previ-
ously described as an acid–base motif ﬂanking cysteine residues
(Ascenzi et al., 2000, Stamler et al., 1997), and a search of the S-protein
amino acid sequence for previously described motifs yielded no
results. Further studieswill have to be done to answer these questions.
While the palmitoylation of the S protein has been shown to be
affected by the administration of SNAP as an NO donor, this is an effect
that is seen in the later steps of infection, after the expression of viral
proteins. However, nitric oxide and its derivatives have been shown in
the case of several micro-organisms to have an effect on the early
steps of replication, in both bacterial and viral infections. The work
done by several groups has demonstrated that cysteine proteases are
particularly susceptible to nitric oxide, as has been described for
coxsackieviruses (Saura et al., 1999) and adenoviruses (Cao et al.,
2003). The use of realtime PCR directed against positive-stranded RNA
species encoded by SARS-CoV showed that SNAP treatment of Vero E6
cells caused a signiﬁcant decrease in viral RNA production which
could be observed as early as 3 h post-infection compared to NAP-
treated and mock-treated controls. This observation is interesting as
SARS-CoV encodes 2 cysteine proteases, the papain-like protease
(PL2pro) and the 3C-like protease(3CLpro) (Thiel et al., 2003). These
cleave the pp1ab replicase polyprotein at non-overlapping sites to
yield 15 replicase proteins, termed nsp1 to nsp15. PL2pro is predicted
to cleave the polyprotein at 3 sites, and the rest of the non-structural
proteins have been predicted to be cleaved by 3CLpro. Hence, in order
to examine a possible effect of NO on the activity of these proteases, a
monoclonal antibody directed against the nsp8 protein was used to
look at the relative amounts of cleavage products being formed in
SARS-CoV infected Vero E6 cells treated with either SNAP, NAP or in
mock-treated cells. If NO or its derivatives exerted a discrete effect on
the activity of 3CLpro, one might expect to see a reduction in the
amount of nsp8 protein as determined by Western blotting.
Surprisingly, no difference was seen in the levels of cleaved nsp8
amongst the different treatments. However, 2 bands of higher
molecular weight (of around 60 kDa and 130 kDa) was seen to
exhibit altered intensities in SARS-CoV infected cells treated with
SNAP. As these bands are speciﬁc to infection and are detected by the
nsp8 antibody, they might represent cleavage intermediates of the
replicase polyprotein. In a 2004 study, Fan and coworkers expressed
and puriﬁed the SARS-CoV 3CLpro in order to study its activity. Using
an HPLC-based peptide cleavage assay, they found that the 11 unique
3CLpro cleavage sites on the pp1ab replicase polyprotein were cleaved
with different efﬁciencies (Fan et al., 2005). In light of this
information, the differences seen in the amounts of cleavage products
might make more sense to the observer. It could be possible that the
effect of NO or its derivatives on 3CLpro might have altered its
substrate speciﬁcities, resulting in a different pattern of cleavage
efﬁciencies from that previously observed. This might account, then,
for the lack of a difference in nsp8 levels while an accumulation is
observed for a different intermediate cleavage product which might
have had its cleavage efﬁciency altered more detrimentally. In order
to conﬁrm that NO was actually working in these samples, we
performed aWestern blot using a monoclonal antibody speciﬁc to the
N protein of SARS-CoV (Fig. 6). It was observed that the expression of
the N protein was reduced, in agreement with previous ﬁndings
(Akerstrom et al., 2005). This showed the intended effect of SNAP
treatment and therefore that the observed differences in cleavage
product intensities was being observed in cells which were being
affected by SNAP treatment.
Fig. 6. SNAP treatment causes a difference in observed levels of replicase polyprotein
cleavage products. Lysates from either uninfected or SARS-CoV infected Vero E6 cells
which had either been treated with SNAP, NAP or mock-treated harvested 24 h post-
infection were subjected to Western blot analysis using a monoclonal antibody
targeting the nsp8 protein.
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From the results presented here, we suggest that the effect of nitric
oxide on the replication of SARS-CoV is at least twofold: an effect on
the production of viral RNA in the early steps of replication and a
reduction in the palmitoylation of the S protein later in the replication
cycle. What remains to be elucidated is whether both of these effects
arise strictly from a direct effect of nitric oxide or its derivatives on
viral proteins, or strictly from an effect on host factors which are
subverted in the course of infection, or a combination of both.
Materials and methods
Peroxynitrite and superoxide dismutase treatment
Vero E6 cells grown in 24-well plates were infectedwith SARS-CoV
Frankfurt strain 1 at an MOI of 1. At 1 hpi, cells were washed twice
with PBS, and medium with or without 3-morpholinosydnonimine
hydrochloride (SIN-1; Sigma-Aldrich) was added. 50, 100, 200 or
400 μM of SIN-1 were added 3 times with 4-h intervals. After 24 h, the
virus was harvested and titration of progeny virus was titrated out on
a 96-well plate containing Vero E6 cells as described previously
(Akerstrom et al., 2005). At 48 hpi, the amount of virus (TCID50) was
calculated from the cytopathic effect (CPE) induced in cell culture by
serial tenfold dilutions of the harvested virus.
Similarly, SARS-CoV infected Vero E6 cells were treated with a
superoxide scavenger, Mn(III)tetrakis(4-Benzoic acid)porphyrin
chloride (MnTBAP; Calbiochem), in the absence or presence of
400 μM SIN-1. 100, 400 or 800 μM of MnTBAP with or without
400 μM SIN-1 were added 3 times with 4-h intervals. The amount of
progeny virus was measured as described above. All SARS-CoV
infection work (described here and elsewhere in the manuscript)
was carried out at the BSL4 facility at the Swedish Institute for
Infectious Disease Control in Solna, Sweden.
Radiolabelled immunoprecipitation
Vero E6 cells grown in 60 mm dishes were infected with
recombinant vaccinia virus carrying the S gene (rVV-L-S), at a MOI
of 0.1. For mock-infected cells, a recombinant vaccinia virus carrying
the N gene (rVV-L-N) was used. Both rVV-L-S and rVV-L-N are kind
gifts from Baxter Vaccine (Orth/Donau, Austria) and have been
previously described (Lip et al., 2006). At 1 h post-infection, the cells
were treated with 400 μM of SNAP (Sigma, St. Louis, Mo.), 400 μM N-
acetylpenicillamine (NAP; Sigma), 400 μM of SIN-1 (Sigma, St. Louis,
Mo) or 400 μM of SIN-1 and 400 μM of MnTBAP (Calbiochem).
Treatments were repeated 4 times with 2-h intervals. At 24 h post-
infection, cells were labelledwith 400 μCi of [3H]-palmitic acid (Perkin
Elmer, USA) for 2 h or starved with methionine-cysteine (Met-Cys)-
free medium for 30 min before being labelled with 22 μCi of [35S]-
methionine-cysteine for 2 h. The labelled cells were washed 3 times
with cold PBS and lysed in 1 ml TES lysis buffer (20 mM Tris–HCl [pH
7.5], 100mMNaCl, 1mMEDTA, 1% Triton X-100 and 2mMPMSF). Cell
debris was removed from the lysates by centrifugation at 13,000 rpm
for 10 min. Immunoprecipitation was carried out by adding rabbit
anti-SΔ10 antibody (Keng et al., 2005) to the lysates and rotating at
4 °C for 1 h, followed by overnight incubation with protein A-
Sepharose beads (Roche Diagnostics). The beads were washed 3 times
with lysis buffer and boiled in 20 μl of 2× Laemmli's SDS loading
buffer. Samples were separated in a 7.5% SDS-PAGE gel, ﬁxed for
30 min using ﬁxing solution (10% acetic acid, 45% methanol), and
treated with Amplify Fluorographic Reagent (Amersham Biosciences)
according to protocol. Visualization was done by autoradiography.
Cell–cell membrane fusion assay
An in vitro cell fusion assay that can be used to study S-mediated
membrane fusion has been previously developed (Lip et al., 2006).
Brieﬂy a 293T cell-line stably expressing GFPwas infected with rVV-L-
S in order to express the S protein and then treated with SNAP or NAP
as described above. Another stable cell line stably expressing ACE2,
CHO-ACE2, was plated in a 12-well plate in DMEM containing 1 mg/
ml porcine trypsin (JRH Biosciences Inc.). Infected 293T-GFP cells
were mixed with the CHO-ACE2 cells in a 1:1 ratio per well and
syncytium formation was observed 6 h later.
Pseudotyped virus entry assay
To produce HIV pseudotyped virus bearing the SARS-CoV S
protein, 9 μg of HIV-1 luciferase reporter vector pNL4.3.Luc.R-E-
(HIV-luc) and 4.5 μg of SARS-CoV S protein expression plasmid
(pXJ3′-S-HA) were co-transfected into 293T cells in a 100-mm dish
using Lipofectamine2000 reagent (Invitrogen) following manufac-
turer's instructions. For the negative control, the cells were trans-
fected with pNL4-3.Luc.R-E-alone. The construction of the plasmids
has been described previously (Connor et al., 1995; He et al., 1995;
Tan et al., 2004). The virus-containing medium was harvested after
72 h of incubation and centrifuged at 2000 rpm for 5 min to remove
any cell debris. Virus in the supernatant was subsequently concen-
trated through a 20% sucrose cushion for 3 h at 30,000 rpm and 4 °C by
using an SW41 rotor, and subsequently resuspended in DMEM. In
order to normalize the amount of pseudotyped virus used, 10 μl of
each sample was used to measure p24 content using a p24 ELISA kit
(Perkin Elmer), according to the manufacturer's protocol. Absorbance
readings were made at 492 nm in a plate reader (Tecan) and sample
concentrations were determined from a standard graph. Appropriate
volumes corresponding to 16 ng of pseudotyped virus were then used
to infect CHO-ACE2 cells (Chou et al., 2005). At 72 hpi, supernatant
was removed and the cells were washed and harvested in trypsin and
washed again in PBS. Cell pellet was lysed using the Promega lysis
buffer and luciferase activity was determined using a luciferase assay
kit, following manufacturer's instructions (Promega). Luciferase
readings were measured using a Veritus microplate luminometer
(Turner Biosystems).
Pseudotyped virus binding assay
HIV pseudotyped virus bearing the SARS-S protein was produced
as described in the pseudotyped virus entry assay (see above). Virus-
containing medium was harvested after 24 h of incubation and
centrifuged at 3000 rpm for 5 min to remove any cell debris. 10 μl of
themediumwere diluted 20× using DMEMand used tomeasure virus
concentration using a P24 ELISA kit (Perkin Elmer), according to the
manufacturer's protocol. Virus concentration was determined from a
standard graph, and 80 ng of virus was used for infection of CHO-ACE2
cells. CHO-ACE2 cells were pre-incubated in DMEM with 1% BSA at
4 °C for 1 h prior to infection at 4 °C for 2 h. After infection, the cells
were washed 4× using 1× PBS with 1% BSA and harvested in DMEM,
freeze–thawed six times and sonicated for 2 min with 20-s intervals.
Sampleswere centrifuged at 13,000 rpm to remove any cell debris and
200 μl of supernatant was used to determine P24 content using the
P24 ELISA kit. The concentration of bound virus was then determined
using the standard graph.
Western blot and detection of nitrated SARS-CoV S protein
Vero E6 cells grown in 60 mm dishes were infected with rVV-L-S
and rVV-L-N and treated with 400 μM SNAP or NAP as described
above. After 24 h, the cells were lysed (50 mM Tris [pH 8], 150 mM
NaCl, 0.5% NP40, 0.5% deoxycholic acid, 0.005% SDS, 1 mM PMSF) and
the concentration of total protein in the cell lysates was determined
using Coomassie Plus reagent (Pierce). Appropriate volumes yielding
500 μg of total protein from each sample were added to 20 μl of
Nitrotyrosine Afﬁnity Sorbent (Cayman Chemical) after washing the
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beads three times in PBS. The samples were left for rotation at 4 °C
over night. Next day, the beads were washed 3 times with lysis buffer,
resuspended in 20 μl of Laemmli's SDS loading buffer and boiled for
10 min at 100 °C. Samples were separated on a 7.5% SDS-PAGE gel,
transferred to a nitrocellulose membrane, and blocked for 1 h in room
temperature in 5% non fat dry milk in PBS with 0.1% Tween 20.
Membrane was incubated overnight in 5% non-fat dry milk with
rabbit anti-SΔ10 antibody (diluted 1:6000) at 4 °C. The next day, the
membrane was incubated with HRP-conjugated secondary antibody
(goat anti-rabbit antibody diluted 1:2000) for 1 h at room temper-
ature and washed in PBS-Tween. Detection was performed with
SuperSignal West Pico Chemiluminescent Substrate (Pierce).
Quantiﬁcation of viral RNA
Vero E6 cells were grown in 24-well plates and infected with
SARS-CoV at an MOI of 1. Cells were treated with SNAP, NAP or mock-
treated either 1 h before infection and 1 h, 3 h or 6 h post-infection or
only 1 h, 3 h, 6 h post-infection without pretreatment. At 24 h post-
infection, cells were harvested in Trizol reagent (Invitrogen) and total
RNA was extracted using an RNeasy mini kit (Qiagen). Viral RNA was
quantitated using a Nanodrop spectrophotometer and equal amounts
of total RNA were added to a reverse transcription reaction using
either of the following gene-speciﬁc primers: SARSNRTREV-5′
TTATGCCTGAGTTGAATCAGCAGAA 3′; GAPDHRTREV-5′ AGCCTTCTC-
CATGCTGGTGAAGAC 3′. Equal amounts of each reverse transcription
reaction were then added to a portion of LightCycler Taqman Master
reaction mix (Roche) along with either of the following primer pairs:
SARSNCCORFP-5′ TGCCTCTGCATTCTTTGGA 3′, SARSNCCORRP-5′-
TAAGTCAGCCATGTTCCCG 3′, GAPDHF-5′ GAAGATGGTGATGGGATTTC
3′, GAPDHR-5′ GAAGGTGAAGGTCGGAGT 3′ and the following probes:
SARSNCCORP1-5′ FAM (6-carboxy-ﬂourescein)-, TGTGACTTCCATGC-
CAATGCGTG-TAMRA (6-carboxy-tetrylrhodamine quencher) 3′ or
GAPDHP-5′FAM-,CAAGCTTCCCGTTCTCAGCC-TAMRA 3′. Cycle thresh-
old values obtained for the SARS N gene were normalized against
those for GAPDH to obtain relative quotients (2ΔΔCt) which were then
plotted for SNAP, NAP and mock treatments.
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Abstract 
Background 
The ORF6 protein is one of the eight accessory proteins of the severe acute 
respiratory syndrome coronavirus (SARS-CoV).  Numerous properties of ORF6 have 
been documented and this study focuses on two of these, namely, its ability to 
suppress the expression of co-transfected expression constructs and its subcellular 
localization to vesicular structures. 
Findings 
Using a transient transfection system, ORF6’s ability to suppress the expression of co-
transfected expression constructs was measured in a quantitative manner.  While 
ORF6 does not have a global effect on protein synthesis, quantitative real-time PCR 
revealed that it down-regulated the mRNA level of the co-transfected myc-nsp8 gene.  
Furthermore, alanine substitution of a diacidic cluster motif (aa53-56) in the ORF6 
gene caused a reduction in the suppression of expression of co-transfected myc-nsp8 
gene.  Our previous study revealed that ORF6 localized to vesicular structures in 
SARS-CoV infected Vero E6 cells.  Here, ORF6 was observed to be localized to 
similar vesicular structures in Vero E6 cells which have been transiently transfected 
with a mammalian expression plasmid encoding for untagged ORF6.  ORF6 showed 
partial colocalization with cellular proteins CD63 and Lamp1, suggesting that the 
vesicular structures may be a subpopulation of endosomal/lysosomal vesicles. The 
alanine substitution of the diacidic cluster motif also altered the subcellular 
localization of the ORF6 protein, indicating a potential relationship between the 
subcellular localization of the ORF6 protein and its ability to suppress the expression 
of co-transfected expression constructs. 
Conclusion 
By combining quantitative real-time PCR and transient transfection system, a simple 
and safe method is established to measure ORF6’s ability to suppress the expression 
of co-transfected myc-nsp8.  In addition, immunofluorescence analysis revealed that 
the subcellular localization of ORF6 when expressed on its own is similar to that 
observed in SARS-CoV infected cells.  Through the use of these two assays, a 
putative diacidic motif in the SARS-CoV ORF6 protein was found to influence its 
subcellular localization and ability to suppress the expression of co-transfected 
expression constructs. 
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Background 
 
An outbreak of Severe Acute Respiratory syndrome in 2003 which carried 
with it a fatality rate of 8% was traced to a novel coronavirus dubbed the SARS 
Coronavirus (SARS-CoV). This novel coronavirus was eventually classified as a 
Group IIb coronavirus, a subset of the Group II coronaviruses. The subclassification 
was, in part, due to the presence of several accessory genes in the coronavirus which 
have no known homologs within the family Coronaviridae. These accessory genes 
have been the subject of study by many groups (for reviews, see 1 and 2) and have 
been assigned a plethora of physical characteristics and intracellular functions. Most 
importantly, almost all of these accessory genes have been shown to be dispensable 
for viral replication, with the exception of the 3a accessory gene (3). It has been 
suggested these accessory genes have subtle effects on SARS-CoV replication and 
may be more important for viral replication or pathogenesis in vivo. 
One of these accessory genes, ORF6, encodes for a ~7kDa protein with a 
hydrophobic N–terminal and that has been suggested to have a N-endo-C-endo 
conformation (4). Several groups have undertaken to characterize the protein product 
of the ORF6 gene and found that it interacts with the nsp8 protein from the SARS 
replicase complex (5), is able to increase infection titer during early infection at low 
MOI (6), increase the rate of cellular gene synthesis (7), inhibit interferon production 
(8), and inhibit the nuclear translocation of STAT1 by interacting with karyopherin 
c2 (9). Most recently, the ORF6 protein has been suggested to induce intracellular 
membrane rearrangements resulting in a vesicular population in the infected cell 
which could possibly serve some role in increasing replication (10). Such virus-
induced or virus associated vesicles have previously been shown in other viral 
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infections, such as protein trafficking in Herpes simplex virus (11) and Sendai virus 
(12). Members of the coronavirus family have been shown by several groups to also 
utilize vesicular structures within the infected cell; most of these studies suggest that 
vesicles play a role in viral replication (13-16).  
We have previously shown that the ORF6 protein colocalizes with Lamp1-
positive vesicles in SARS-CoV infection (5) and also with the nsp8 protein in the 
same set of infected cells, indicating a possible role for the ORF6 protein in the 
replicative process of SARS-CoV. However, there has been, to date, little work done 
to link the subcellular localization of the ORF6 protein to its known functions. 
Gallagher and co-workers have shown that the ability of ORF6 to impede nuclear 
translocation resulted in the suppression of expression of transgenes from co-
transfected expression constructs if these need transcription in the nucleus (17).  
Using this knowledge, a simple co-transfection system and alanine substitution 
mutants in the ORF6 gene is used here to determine regions of the ORF6 protein that 
modulate its ability to suppress the expression of co-transfected myc-nsp8. The 
subcellular localization of these mutants is then examined by immunofluorescence 
experiments and compared to that of wildtype ORF6. 
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Mater ials and Methods 
Cells, Plasmids and Antibodies 
Vero E6 cells were obtained from ATCC, and cultured in DMEM (Invitrogen) 
supplemented with 10% FBS (Gibco) and penicillin/streptomycin (Sigma). Cells were 
cultured in a 37˚C incubator with 5% CO2. ORF6 was cloned into the pXJ3’HA 
vector (T. Leung, Institute of Molecular and Cell Biology, Singapore, personal 
communication) using the sites BamHI and XhoI with a stop codon to create pXJ3’-
ORF6, expressing an untagged protein. The nsp8 gene from SARS-CoV was cloned 
using BamHI and XhoI sites into pXJ40myc to create pXJ40myc-nsp8, with an N-
terminal myc tag for detection. GST was cloned into pXJ40flag to create pXJ40flag-
GST, which expresses an N-terminal flag tagged GST protein. The ORF6A49-52 and 
ORF6A53-56 mutants were generated by 2 rounds of PCR: the first round of PCR 
was used to generate 5’ and 3’ fragments of ORF6 containing the appropriate alanine 
substitutions; these were then amplified into full-length ORF6 using end primers for 
the ORF6 gene and cloned into pXJ3’HA using BamHI and XhoI sites. The following 
antibodies were used in this study: rabbit anti-ORF6 was purchased from Abgent, 
mouse anti-actin from Sigma, mouse anti-Lamp1 from Abcam, mouse anti-myc from 
Santa Cruz and mouse anti-CD63 was purchased from Biodesign International.  
 
Immunofluorescence 
Vero E6 cells were plated in 60mm dishes containing coverslips and 
subsequently transfected with mammalian expression plasmids relevant to the 
experiment being performed. Trasfection was performed using Lipofectamine 2000 
(Invitrogen) according the manufacturer’s instructions. 16 hours after transfection, 
coverslips were prepared for immunofluorescence as follows: Fixation was carried 
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out in 100% methanol for 5 minutes and coverslips were left to dry before being 
blocked with PBS containing 1% BSA for 30 minutes. Primary antibody incubation 
was carried out in a humidified chamber for 1 hour before coverslips were washed 3 
times in blocking solution. Secondary antibody incubation was then carried out for an 
hour in a humidified chamber before the coverslips were washed 3 times. Coverslips 
were mounted onto glass slides using a mounting mixture of 70% Fluorsave 
(Calbiochem) and 30% Vectashield containing DAPI (Vector Laboratories). Slides 
were imaged using a Zeiss LSM510Meta confocal microscope (Zeiss). 
 
SARS-CoV Infection 
Vero E6 cells grown on coverslips were infected with SARS-CoV Frankfurt 
strain 1.  When the cells showed 75 % cytopathic effects, they were subjected to 
immunofluorescence as described above.  All SARS-CoV infection work was carried 
out at the BSL4 facility at the Swedish Institute for Infectious Disease Control in 
Solna, Sweden. 
 
Western Blotting 
Vero E6 cells were transfected with relevant plasmids for each experiment. 16 
hours after transfection, cells were scraped into media before being spun down in a 
benchtop centrifuge and washed twice with PBS. After washes, the cell pellets were 
resuspended in RIPA buffer (50 mM Tris (pH 8.0), 150 mM NaCl, 0.5% NP40, 0.5% 
deoxycholic acid, 0.005% SDS) and freeze-thawed in liquid nitrogen 3 times before 
being spun down at 13K rpm to remove cellular debris. SDS loading buffer was added 
to clarified lysates before being boiled at 100˚C and loaded onto an SDS-PAGE gel 
for separation. Gels containing separated lysates were transferred onto Hybond-C 
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nitrocellulose membranes (Amersham) before blocking with 5% skimmed milk in 
PBS-Tween. Antibody incubations were carried out at 4˚C overnight or at room 
temperature, with constant rotation. After each incubation, membranes were washed 3 
times for 10 minutes each with PBS-Tween. Following washes after secondary 
antibody incubation, membranes were treated with chemiluminescent substrate 
(Thermo) and exposed to film. 
 
Metabolic labeling 
Vero E6 cells were transfected with 1µg or 2ug of either pXJ3’-ORF6 or 
empty vector. 16 hours post transfection, cells were starved using DMEM without L-
glutamine, cysteine and methionine (Invitrogen) before being incubated with 100µCi 
of 
35
S-labelled cysteine and methionine (Perkin Elmer) diluted in starvation medium 
for 30 minutes. At the end of each incubation period, cells were washed in cold PBS 
and scraped into a centrifuge tube and lysed in RIPA buffer. 20 µg of each lysed 
sample was boiled with SDS loading buffer and PAGE separated before being fixed 
and dried in a Model 583 Gel Dryer (Bio-Rad). Dried gels were exposed to film at -
80˚C to obtain autoradiograph.  Quantification of signals was performed using the gel 
analysis module in Image J. 
 
Quantitative Realtime PCR 
Vero E6 cells were co-transfected with increasing amounts of pXJ3’-ORF6 (0 
- 2 µg) and a fixed amount of pXJ40myc-nsp8 (1 µg). For each sample, the total 
amount of DNA was normalized to 3 µg by addition of the empty vector, pXJ3’HA, 
when necessary.  16 hours post-transfection, cells were scraped into media and spun 
down in a benchtop centrifuge. Cells were washed twice with PBS and cell pellets 
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were resuspended with Trizol reagent (Invitrogen). Trizol samples were mixed with 
chloroform and spun down in a benchtop centrifuge at 4˚C before being processed 
with an RNeasy Mini Kit (Qiagen), according to the manufacturer’s instructions. 
RNA samples were quantified with a Nanodrop ND-1000 spectrophotometer 
(Nanodrop Technologies). Equal amounts of each RNA sample were then reverse 
transcribed using poly d(T)12-18 (Invitrogen) and with Superscript II reverse 
transcriptase (Invitrogen), following manufacturer instructions. Following reverse 
transcription, equal amounts of each cDNA sample were added to a portion of 
reaction mix (Roche) along with either of the following primer pairs: SARS-nsp8-F: 
5’-TGAATGCTAAATCTGAGTTTGA-3’, SARS-nsp8-R: 5’-
CATAGCCTGATCTGCCATCTTTT-3’, GAPDH-F: 5’-
GAAGGTGAAGGTCGGAGTC-3’, GAPDH-R: 5’-
GAAGATGGTGATGGGATTTC-3’ and one of the following probes: SARS-nsp8-P: 
5' 6-FAM-CGTGATGCTGCCATGCAACGC-BHQ 3', GAPDH-P: 5’ 6-FAM-
CAAGCTTCCCGTTCTCAGCC-BHQ 3’. Reaction mixes were subjected to 
quantitative real-time PCR in a Roche Lightcycler 2.0. Cycle threshold values 
obtained for the SARS nsp8 gene were normalized against those for GAPDH to obtain 
relative quotients which were then plotted for increasing amounts of pXJ3’-ORF6 
transfected.   Briefly, the Ct for the GAPDH control was subtracted from the Ct for 
the nsp8 gene (ÄCt).  The fold changes were then calculated from the ÄÄCt, which 
was obtained by subtracting each ÄCt from the ÄCt obtained when 2 µg of pXJ3’HA 
vector was used.  Alternatively, quantitative real-time PCR was carried out using 
SsoFast EvaGreen SYBR Green Master mix (Bio-Rad) using the same primers for 
nsp8 and GAPDH as listed above; probes were omitted from these experiments. These 
reactions were carried out in an ABI 7500Fast Realtime PCR system.  
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Results 
The ORF6 protein exerts an effect on the expression of transgenes from co-
transfected expression constructs.  
To determine amount of ORF6 required to exert an effect on the expression of 
transgenes from co-transfected expression constructs, Vero E6 cells were transfected 
with 1µg of pXJmyc-nsp8 alone or with either 1µg, 2µg or 3µg of pXJ3’-ORF6 
plasmid. Western blotting showed a dose-dependent reduction in the expression of 
nsp8, concomitant with an increase in the expression of ORF6 (Fig. 1A). In order to 
determine the specificity of this effect, Vero E6 cells were cotransfected with another 
mammalian expression construct pXJflag-GST and pXJ3’-ORF6 in the same manner 
as previously done with the construct encoding for nsp8. When titrated against 
increasing amounts of ORF6 protein, the flag-tagged GST protein was also observed 
by Western Blotting to show reduced levels of expression in a dose-dependent 
manner (Fig. 1B). Thus, it seems that ORF6 exerts an effect on the expression of 
transgenes from co-transfected expression constructs regardless of the nature of the 
transgenes.  However, when increasing amounts of GST were titrated against nsp8 in 
the same manner, no significant reduction in nsp8 expression was observed, 
indicating that this effect was specific to the ORF6 protein (Fig. 1C).  
 
ORF6 does not affect total cellular protein synthesis 
The ORF6 protein has been observed to cause a reduction in the expression of 
2 different proteins, with different epitope tags. In order to examine the possibility 
that this downregulation could be a global effect, Vero E6 cells were transfected with 
either empty vector, pXJ3’HA, or pXJ3’-ORF6, and metabolically labeled with 
35
S 
for a period of 30 minutes. Quantification of the signals in each lane of the resulting 
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autoradiograph was performed and the readings were normalized to the reading in the 
lane from the untransfected cells (Fig. 2).  When 1 µg of DNA was used, there is a 
slight decrease in the total cellular protein synthesis in ORF6 expressing cells when 
compared to cells which had been transfected with empty vector.  However, almost 
the same degrees of decrease in the total cellular protein synthesis were observed in 
both pXJ3’HA and pXJ3’-ORF6 transfected cells when 2 µg of DNA was used.  
Hence, the decrease in total cellular protein synthesis observed seems to be related to 
the transfection process rather than the expression of ORF6.  This suggests that the 
cellular effect of ORF6 is not global. 
 
ORF6 exerts its effect at a transcriptional level 
In order to examine the possibility that ORF6 affects the expression of 
transgenes from co-transfected expression constructs via a transcriptional mechanism, 
Vero E6 cells were transfected with 1µg of pXJ40myc-nsp8 and either 1µg, 2µg of 
pXJ3’-ORF6 or no ORF6 plasmid. 16 hours post-transfection, total RNA was 
extracted, reverse transcribed and subjected to quantitative real-time PCR. Taqman 
chemistry was used to assay for nsp8 and GAPDH was used as an endogenous 
control. The ÄÄCt method was used to calculate the nsp8 mRNA level with respect to 
the level in the absence of ORF6. As shown in Fig. 3, ORF6 caused a reduction in the 
level of nsp8 mRNA in a dose-dependent manner, indicating a transcriptional 
reduction caused by ORF6. These results suggest that ORF6 is able to exert some 
form of transcriptional inhibition, which is seen in the reduced expression from co-
transfected plasmids.  
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The ORF6 protein localizes to intracellular vesicles positive for Lamp1 and CD63 
It has been previously reported that the SARS-CoV ORF6 protein localizes to 
intracellular membranous compartments, which have been suggested to be induced by 
ORF6 itself (10). In agreement, it was observed in this study that ORF6 localized to 
vesicular compartments both in SARS-infected Vero E6 cells and Vero E6 cells 
transfected with a plasmid encoding for the ORF6 protein (Fig. 4A). Vero E6 cells 
were infected with SARS-CoV and analyzed by immunofluoresence, using an 
antibody against the ORF6 protein. ORF6 was observed to localize to a distinct 
population of intracellular vesicles in these infected cells (Fig 4A). Following this, a 
mammalian expression plasmid pXJ3’-ORF6 was transfected into Vero E6 cells and 
analyzed in the same manner with the same antibody. Confocal microscopy showed 
that the ORF6 protein localized to a similar population of intracellular vesicles.  
In our previous work studying the interaction between ORF6 and the nsp8 
protein of SARS-CoV (5), we showed a colocalization of ORF6 and Lamp1 in Vero 
E6 cells infected with the HKU39849 strain of SARS-CoV. Similarly, there was a 
significant degree of colocalization between the Lamp1 and ORF6 in transiently 
transfected Vero E6 cells (Fig. 4B), indicating that the ORF6-positive vesicles seen in 
both infected cells and transiently transfected Vero E6 cells were probably an 
identical population of vesicles. This allowed us to then use pXJ3’-ORF6-transfected 
Vero E6 cells to further study the characteristics of this vesicular population. In 
addition to Lamp1, CD63 (a marker for late endosomes) was used to examine the 
compartmental characteristics of the vesicles. As shown in Fig. 4B, ORF6-positive 
vesicles coincide significantly with CD63-positive vesicles in Vero E6 cells. This 
population of vesicles is therefore a subset of the late endosomal and lysosomal 
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populations, and shows that the plasmid system employed here yields similar 
colocalization of ORF6 with cellular markers as seen in previous infection work (5).  
 
Amino Acids 53-56 in ORF6 constitute a putative diacidic motif which affects the 
suppression of the expression of co-transfected myc-nsp8 
Using the CBS Prediction Servers (http://www.cbs.dtu.dk/services/), it was 
determined that the ORF6 protein had several putative motifs of interest. Of these, 
aa49-52 (YSEL) was predicted to be a lysosomal targeting motif YXXL (18), and 
aa53-56 (DDEE) bears similarity to a putative diacidic motif DxE, which governs ER 
export and subsequent localization to different membranous compartments (19). 
These motifs were also predicted by Netland and co-workers (4). In order to 
determine the contribution of these motifs to the function of the ORF6 protein, 
alanine substitutions were introduced by two-step PCR to yield ORF6A49-52, which 
substituted four alanine residues for the YSEL region, and ORF6A53-56, which 
substituted four alanines for the DDEE region (Fig. 5A).  
These alanine substitution mutants were cloned into the same vector as the 
wildtype ORF6 gene and titrated against the nsp8 gene, by co-transfection of Vero E6 
cells with plasmids encoding for myc-nsp8 and either wildtype ORF6, ORF6A49-52 
or ORF6A53-56. It was observed that both mutants showed increased levels of 
expression compared to wildtype ORF6, and this observation was reproducible (data 
not shown). The effect of ORF6A49-52 mutant on the expression of the nsp8 gene 
was similar to wildtype ORF6 (Fig. 5B). On the other hand, the nsp8 expression in the 
presence of ORF6A53-56 was higher than that in the presence of wildtype ORF6 
(Fig. 5B), which suggest that ORF6A53-56 is less efficient in the suppressing the 
expression of co-transfected myc-nsp8. 
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As the difference between wildtype ORF6 and ORF6A53-56 was subtle, a 
more quantitative approach to assay nsp8 expression was deemed necessary. Hence, 
Vero E6 cells were transfected in the same manner and instead RNA was extracted 
and reverse transcribed and subjected to SYBR Green QPCR using primers for nsp8. 
GAPDH was used as a housekeeping gene in order to normalize the expression levels 
seen. When pXJmyc-nsp8 was co-transfected with 1µg of pXJ3’-ORF6, ORF6A49-
52 or ORF6A53-56, the levels of nsp8 mRNA were similar (Fig. 5C).  However, at 
2µg, the levels of nsp8 mRNA for both ORF6 mutants were slightly higher than wild-
type ORF6 (Fig. 5C).  In order to determine if these differences are statistically 
significant, 5 independent experiments were performed, and the results were then 
used to perform a t-test measuring the significance of the difference between nsp8 
expression levels when either 2µg of wildtype ORF6 or 2µg of each mutant were 
used. The difference in nsp8 expression when co-transfected with either wildtype 
ORF6 and ORF6A49-52 is not statistically significant (a two-tailed p-value of 0.08).  
On the other hand, the difference in nsp8 expression when co-transfected with either 
wildtype ORF6 and ORF6A53-56 is statistically significant (a two-tailed p-value of 
0.01). This indicated that the reduction in impedance of nuclear transport by 
ORF6A53-56 was significant, and therefore that the putative diacidic motif defined 
by amino acids 53-56 has a role to play in the ability of the ORF6 protein to suppress 
the expression of co-transfected myc-nsp8. The ORF6A49-52 mutant did not show as 
high a level of significance.  
 
Alanine substitutions at amino acids 53-56 alter the subcellular localization of ORF6 
Next, the subcellular localization of ORF6A49-52 and ORF6A53-56 was 
compared to wildtype ORF6. Vero E6 cells were transiently transfected with either 
 14
pXJ3’-ORF6, pXJ3’-ORF6A49-52 or pXJ3’-ORF6A53-56 and subjected to 
immunofluoresence analysis. It was observed that the localization of ORF6A49-52 
was somewhat similar to wild-type ORF6 with main expression in distinctive vesicles 
(Fig. 6).  However, slightly more ORF6A49-52 than wildtype ORF6 was found to 
spread diffusely throughout the cytoplasm. The ORF6A53-56 also has some 
cytoplasmic staining but it was also observed that this mutant protein localized to 
vesicles that were clustered into groups of 3-5 vesicles to form large aggregates. 
Careful examination of the localization of the wildtype protein did not yield similar 
observations of clusters. This indicated that the putative diacidic motif from amino 
acids 53-56, in addition to being involved in the suppression of the expression of co-
transfected myc-nsp8, is also involved in the subcellular localization of the ORF6 
protein and therefore these 2 phenomena may be linked.   
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Discussion 
 
Work done by several groups have shown that the ORF6 protein interacts with 
the nsp8 primase and localizes to a lysosomal compartment (5), impedes the nuclear 
translocation of STAT1 and other proteins specifically governed by the importin-ß 
superfamily (9), is able to enhance replication of both SARS-CoV (6) and MHV-JHM 
(20), induces membrane rearrangements by means of its C-terminus (10) and induces 
apoptosis via a JNK-dependent mechanism (21). Through the use of alanine 
substitutions, many of these functions have been attributed to specific regions of the 
ORF6 protein.  
In this study, we have employed the use of transiently transfected mammalian 
expression plasmids encoding for ORF6 to study its function. We have shown that 
ORF6 expressed in our system is functionally similar to that shown by others, by 
means of 2 assays. Firstly, the ORF6 expressed in our system is able to suppress the 
expression of a co-transfected CMV promoter-driven plasmid expressing either the 
nsp8 protein or GST. Secondly, the localization of ORF6 expressed via transient 
transfection was compared to the localization of virally expressed ORF6, and both 
display similar subcellular localization as well as colocalization to the Lamp1 marker.  
Using a bioinformatics approach to defining regions of interest in the ORF6 
gene, we have identified 2 regions of interest, a putative lysosomal targeting motif 
YSEL between amino acids 49 to 52 and a putative diacidic motif DDEE between 
amino acids 53 to 56 (Figure 5A). Our results indicate that the putative diacidic motif 
is involved in both the suppression of expression of co-transfected expression 
constructs by ORF6 as well as its subcellular localization. While we were not able to 
completely restore the expression of co-transfected nsp8 in our system, the effect on 
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nsp8 mRNA level between wildtype ORF6 and ORF6A53-56 was nonetheless found 
to be significantly different.  However, the difference is small and suggests that the 
diacidic motif is largely dispensable for this function of ORF6.  In contrast, the 
putative lysosomal targeting motif YSEL does not appear to contribute to these 
properties of ORF6 and this is consistent with a recent report that alanine substitution 
of the region from amino acids 49 to 53 fails to inhibit the ability of the protein to 
impede the nuclear translocation of STAT1 (9). Also, others have shown that the 
ORF6 protein induces membrane rearrangements and that the C-terminus of the 
protein is important to this function. Our results show that the region from amino 
acids 53 to 56 is involved in the subcellular localization of the ORF6 protein, since 
alanine substitution of this region results in a clustered-vesicle phenotype that is not 
observed with wildtype ORF6. The reason for the difference in the subcellular 
localization of wild-type ORF6 and ORF6A53-56 mutant is not clear.  One possibility 
is that the substitutions of four acidic residues with alanine residues might have 
reduced the solubility of ORF6.  Alternatively, the substitutions may have disrupted 
the interaction of ORF6 with certain host proteins. 
 
Conclusions 
Taking these results together, the putative diacidic motif in ORF6 seems to be 
important for two properties of ORF6, namely its ability to suppress the expression of 
co-transfected expression constructs and its subcellular localization to vesicular 
structures. The implication of this is that the 2 functions may be inextricably linked.  
However, a cause-effect relationship has yet to be determined for these functions and 
in light of our findings, their relationship to the membrane rearrangements induced by 
the ORF6 protein should be examined in future studies. In addition, while the ability 
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of ORF6 to suppress the expression of co-transfected expression constructs, was 
previously linked to the blockage of nuclear translocation (17), further experiments 
are needed to ascertain if amino acids 53-56 are involved in regulating the nuclear 
translocation process. 
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Figure Legends 
 
Fig. 1 ORF6 specifically impedes expression of co-transfectants. Vero E6 cells were 
co-transfected with mammalian expression plasmids encoding for ORF6 and nsp8 
(A), ORF6 and GST (B) or GST and nsp8 (C). Cells were lysed 16 hours post 
transfection and subjected to Western Blot analysis using equal amounts of lysate 
from each transfection. Blots were stripped post-detection and re-probed with an anti-
actin antibody as a loading control.  Similar results were obtained in three 
independent experiments, and a representative set of data is presented. 
Fig. 2 ORF6 expression in Vero E6 cells does not cause a reduction in total cellular 
protein. Vero E6 cells were transfected for 16 hours with increasing amounts of 
pXJ3’-ORF6 or an empty vector, pXJ3’HA. Cells were starved of methionine and 
cysteine for 1 hour and labeled with a mixture of 35S-labelled methionine and 
cysteine for 30 minutes, then subjected to PAGE separation and autoradiography 
(lower panel). Quantification of the signals in each lane of the resulting 
autoradiograph was performed and the readings, after normalization to the reading in 
the lane from the untransfected cells, are shown at the bottom of the autoradiography.   
A fraction of lysate was subjected to Western Blotting using an antibody directed 
against the ORF6 protein (upper panel). Similar results were obtained in two 
independent experiments, and a representative set of data is presented. 
Fig. 3 The ORF6 protein exerts a transcriptional effect on nsp8 expression. Vero E6 
cells were co-transfected with 1µg of pXJ40myc-nsp8 and different amount of pXJ3’-
ORF6. For each sample, the total amount of DNA was normalized to 3 µg by addition 
of the empty vector, pXJ3’HA, when necessary.  Total RNA was harvested 16 hours 
later, reverse transcribed and subjected to quantitative real-time Taqman PCR using 
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primers and probes specific to nsp8 and cellular protein, GADPH.  Relative quotients 
between the resulting Ct values for each sample were calculated using the ÄÄCt 
method.  Similar results were obtained in three independent experiments, and a 
representative set of data is presented. 
Fig. 4 ORF6 expressed from a plasmid adopts a similar subcellular localization to 
virally expressed ORF6 and colocalizes partially with CD63 and Lamp1. (A) Vero E6 
cells were either transiently transfected with pXJ3’-ORF6 or infected with SARS-
CoV. At either 16hrs post-transfection or at 75% CPE, cells were fixed and processed 
for immunofluorescence using an antibody directed against the ORF6 protein. (B) 
Vero E6 cells, which have been transiently transfected with ORF6, were fixed and 
stained for antibodies directed against ORF6 and either Lamp1 or CD63.  Similar 
results were obtained in three independent experiments, and a representative set of 
data is presented. 
Fig. 5 Alanine substitutions in the putative diacidic motif in ORF6 exert an effect on 
impedance of nsp8 expression. (A) A schematic of the ORF6 amino acid sequence 
showing the position of two putative motifs, a lysosomal targeting motif and a 
putative diacidic motif. (B) Vero E6 cells were transfected with 1µg of pXJ40myc-
nsp8 and either 0µg, 1µg, 2µg of either pXJ3’-ORF6 (left panel), pXJ3’-ORF6A49-
52 (centre panel) or pXJ3’-ORF6A53-56 (r ight panel). 16 hours post transfection, 
cells were harvested, lysed and subjected to Western Blotting using an antibody 
directed against either ORF6 or myc-nsp8. Actin was used as a loading control. 
Similar results were obtained in three independent experiments, and a representative 
set of data is presented. (C) Vero E6 cells were similarly transfected as in (A) and 
total RNA was harvested 16 hours later, reverse transcribed and subjected to SYBR-
Green QPCR using specific primers for nsp8, with GAPDH as a housekeeping 
 24
control. Relative quotients were calculated and plotted from the Ct values obtained, 
using the ÄÄCt method. The average values with standard deviations are plotted and 
the standard deviations are also shown in parentheses in the x-axis labels.  Students’ 
T-test was performed on selected results and the p-values are indicated. P < 0.05 was 
considered statistically significant.  Similar results were obtained in five independent 
experiments, and a representative set of data is presented. 
Fig. 6 Alanine substitution mutant ORF6A53-56 shows altered subcellular 
localization. Vero E6 cells were transiently transfected with pXJ3’-ORF6, pXJ3’-
ORF6A49-5 or pXJ3’-ORF6A53-56 and immunofluorescence analysis performed 
with an antibody directed against ORF6.  Similar results were obtained in three 
independent experiments, and a representative set of data is presented. 
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Abstract 
 
It has been previously shown that the ORF6 protein of the SARS Coronavirus induces ER 
stress and apoptosis via a JNK-dependent mechanism. In order to further characterize this 
induction of apoptosis by ORF6, we have generated a replication-defective, recombinant 
vaccinia virus based on the Lister strain expressing ORF6, and shown that ORF6 expressed 
using this recombinant system induces apoptosis. Total cDNA from Huh7 cells which were 
infected with either this recombinant virus or an empty similar virus was analyzed using a 
SYBR Green-based quantitative realtime PCR (QPCR) array specific to various genes 
involved in apoptosis. Genes which were observed to be differentially expressed in the array 
were validated using a different set of primers and probes utilizing Taqman chemistry, and 
the validated genes pointed to an upregulation of the extrinsic pathway of apoptosis by the 
ORF6 protein. Further analysis of the validated genes in other human cell lines known to be 
permissive to SARS-CoV infection showed general agreement in the trend of differential 
expression, pointing to the possibility that ORF6-indiced apoptosis employed similar 
mechanisms in different cell lines. Also, microarray analysis was undertaken on the same set 
of samples, which showed a similar trend of differential expression in the same validated 
apoptotic genes. Analysis of the microarray data also showed the downregulation of 3 anti-
apoptotic genes - LPRT1, MAPK8IP2 and PTK2B, and suggested that the induction of 
apoptosis by ORF6 following ER stress is calcium-dependent. 
 
 
 
Introduction 
 
A novel coronavirus was found to have fulfilled Koch’s postulates for being the etiological 
agent for an acute respiratory syndrome originating in southern China in 2002 and was 
dubbed the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) (Peiris et al 2003, 
Ksiazek et al 2003).  In its wake it left a fatality rate of 8% and inflicted heavy economic 
damage on several economies, mostly related to the Chinese diaspora. This virus was 
subsequently sequenced and found to be rather novel to the coronavirus family, sparking a 
great deal of research in addition to that already being done to find a means of intervention 
for its rapid spread. Part of the reason for this was that the SARS-CoV carried in its large 
29kb genome, nestled amongst the usual coronavirus structural genes and replicase genes, a 
few genes dubbed ‘accessory genes’ which had no known homologs in the coronavirus 
family. It was hoped that accessory proteins might explain the significantly higher virulence 
of this novel coronavirus as compared to other circulating coronaviruses (such as HCoV 229E 
and OC43) which have been observed in the same geographic locations and which mostly 
caused nothing more than the common cold. If accessory proteins were important to the 
  
pathology of SARS-CoV, they would be attractive targets for intervention. Research into 
these accessory genes resulted in a flurry of published literature attempting to demonstrate 
either form or function of these genes (for a review see Tan et al 2007).  
 
One of the most studied accessory genes encoded within the SARS-CoV genome is the ORF6 
accessory gene, which encodes for a small protein with a molecular mass of ~7kDa. This 
protein product of the ORF6 gene (which has no known homology amongst the coronavirus 
family) is 63 amino acids long, with a hydrophobic N-terminal and a signal-rich C-terminal, 
leading to suggestions that the protein may be bifunctional. Biochemical studies have shown 
that the ORF6 protein localizes to the ER/Golgi and also to intracellular vesicles which 
stained positive for lysosomal and late endosomal markers (Kumar et al 2007, Gunalan et al 
2011). Indeed, a plethora of functions have been assigned to the ORF6 protein – that it 
functions as an interferon antagonist by impeding the nuclear translocation of STAT1 
(Frieman et al 2007), that it is required for optimal SARS-CoV replication especially at low 
MOIs ((Zhao et al 2009). Also, the ORF6 protein has been shown to cause ER stress and 
thereby induce apoptosis in a JNK-dependent, caspase-3-dependent manner (Ye et al 2010).  
 
Viral apoptosis is an intriguing aspect of the infection process, as viruses can induce 
apoptosis towards different, and opposing ends. Viruses may inhibit apoptosis in order to 
prevent the use of the apoptotic program by infected cells or immune cells to halt the spread 
of infection, and at the same time, apoptosis may be a useful tool used by viruses either to 
neutralize cells of the immune system or to aid viral spread by the breakdown of infected cells 
(Best et al 2008, Galluzzi et al 2008). The pathogenesis observed in several viral infections 
can be traced to the induction of apoptosis either by the virus or by the immune system. 
Evidence of SARS-CoV-induced apoptosis has been observed in hepatocytes (Chau et al 
2004) as well as thyroid glands from SARS patients (Wei et al 2007), suggesting that the the 
pathogenesis of SARS might be due to apoptosis in these tissues. SARS-CoV has been 
observed to induce apoptosis mammalian cell culture (Yan et al 2004, Bordi et al 2004, Ren 
et al 2005), and several viral proteins from this virus have been shown to possess pro-
apoptotic properties (Tan et al 2004, Surjit et al 2004, Yeung et al 2008, Freundt et al 2010). 
The study and characterization of viral apoptosis also has its utility in having the potential to 
shed light on cellular processes which are modulated by viral infection or the expression of a 
particular viral protein. In this study we undertake to characterize the expression of genes in 
the apoptotic pathway by the ORF6 gene of SARS-CoV, using medium to high throughput 
methods. We use a defective recombinant vaccinia virus expressing the ORF6 gene in order 
to create a comprehensive expression background in which the changes in host gene 
expression can be studied.  
 
 
 
Materials and Methods 
 
Cells, plasmids, antibodies 
 
The following cell lines used in this study were purchased from ATCC: CaCo2, Huh7.5, Vero 
E6 and CV-1. RK-D4R-44.20 cells were a gift from Baxter, and Huh7 cells were a gift from 
Prof. Hak Hotta (Kobe, Japan). The pDW2 plasmid was a gift from Baxter. Rabbit anti-ORF6 
(PUP3) was purchased from Abgent.  
 
Generation of defective recombinant vaccinia virus 
 
The ORF6 gene was cloned into the plasmid pDW2-mh5 using BamHI and NotI sites. CV-1 
cells were infected with replicative vaccinia virus (Lister) and subsequently transfected with 
10µg of pDW2-mh5-ORF6 using Lipofectamine 200 reagent (Invitrogen). 72 hours post-
infection, cells were scraped into infection medium and spun down. The pellet was then 
  
resuspended in PBS and freeze-thawed 3 times to yield a recombination crude stock. Crude 
stock was used to infect the complementing cell line RK-D4R-44.20 and blue plaque 
selection was performed 3 times under agarose overlays containing gpt selection reagents 
(Falkner and Moss 1988). White plaque selection was then performed under agarose overlays 
without gpt selection in CV-1 cells and selected plaques were picked and amplified in 
RK44.20 cells and titrated in the same cell line. Titration was performed by infecting 
RK44.20 cells with serial dilutions of virus stock and 72 hours later, staining with 0.1% 
crystal violet in 20% ethanol to visualize virus plaques. Plaques were counted and averaged 
between 2 identically-infected wells at the appropriate dilution of virus stock. 
  
Western Blotting 
 
Huh7 and Vero E6 cells were infected with either dVV-L-ORF6 or dVV-L for the appropriate 
timepoints, after which cells were scraped into media before being spun down in a benchtop 
centrifuge and washed twice with PBS. After washes, the cell pellets were resuspended in 
RIPA buffer (50 mM Tris (pH 8.0), 150 mM NaCl, 0.5% NP40, 0.5% deoxycholic acid, 
0.005% SDS) and freeze-thawed in liquid nitrogen 3 times before being spun down at 13k 
rpm to remove cellular debris. SDS loading buffer was added to clarified lysates before being 
boiled at 100˚C and loaded onto an SDS-PAGE gel for separation. Gels containing separated 
lysates were transferred onto Hybond-C nitrocellulose membranes (Amersham) before 
blocking with 5% skimmed milk in PBS-Tween. Antibody incubations were carried out at 
4˚C overnight or at room temperature, with constant rotation. After each incubation, 
membranes were washed 3 times for 10 minutes each with PBS-Tween. Following washes 
after secondary antibody incubation, membranes were treated with chemiluminescent 
substrate (Thermo) and exposed to film. 
 
Immunofluorescence 
 
Huh7 cells were plated in 60mm dishes containing coverslips and subsequently transfected 
with mammalian expression plasmids relevant to the experiment being performed. 
Trasfection was performed using Lipofectamine 2000 (Invitrogen) according the 
manufacturer’s instructions. 16 hours after transfection, coverslips were prepared for 
immunofluorescence as follows: Fixation was carried out in 100% methanol for 5 minutes 
and coverslips were left to dry before being blocked with PBS containing 1% BSA for 30 
minutes. Primary antibody incubation was carried out in a humidified chamber for 1 hour 
before coverslips were washed 3 times in blocking solution. Secondary antibody incubation 
was then carried out for an hour in a humidified chamber before the coverslips were washed 3 
times. Coverslips were mounted onto glass slides using a mounting mixture of 70% Fluorsave 
(Calbiochem) and 30% Vectashield containing DAPI (Vector Laboratories). Slides were 
imaged using a Zeiss LSM510Meta confocal microscope (Zeiss). 
 
Caspase Assay 
 
Huh7 cells were seeded in triplicates in 96-well plates. After being allowed to attach 
overnight, cells were infected with ether dVV-L-ORF6, dVV-L-7a or dVV-L for either 6, 12 
or 24 hours. After each timepoint, WST-1 cell proliferation reagent (Promega) was added to 
the cells in half the plates and incubated for 1.5hrs, shaken at 500rpm for 1minute and 
absorbance was measured at 440nm in a spectrophotometer (Tecan), using a reference 
wavelength of 600nm. Caspase-Glo reagent (Promega) was added to the remaining plates and 
shaken at 500rpm for 30 seconds to lyse cells in place before incubation at room temperature 
for 30 mins to 3hrs. Luminescence readings were obtained at 30mins, 1hr, 2hrs and 3hrs and 
the peaks readings were recorded. These readings were normalized using the WST-1 
absorbance readings to yield final caspase activity readings.    
 
Quantitative Realtime PCR 
  
 
Both Huh7 and Vero E6 cells were infected with either dVV-L or dVV-L-ORF6 at an MOI of 
5. At 6 and 12 hours post-infection, cells were scraped into a 15ml Falcon tube and spun 
down at 1.5k rpm, washed twice with PBS, and resuspended in Trizol Reagent (Invitrogen). 
Trizol samples were mixed with chloroform and spun down for 15 minutes at 11k rpm, and 
the upper, aqueous phase was purified using an RNeasy Mini Kit (QIAGEN). RNA 
concentrations were determined using a spectrophotometer (Tecan). Equal amounts of RNA 
were then reverse transcribed using poly d(T)12-18, and Superscript II reverse transcriptase 
(Invitrogen). Equal amounts of the resulting cDNA was subjected to realtime PCR using an 
ABI Fast 7500 Realtime PCR System (Life Technologies) using the following primers: 
rpo35fwd: 5’ - GCCAATGAGGGTTCGAGTTC -3’, rpo35rev: 5’ – 
CAACATCCCGTCGTTCATCA - 3’, GAPDHQfwd: 5’ - GAAGGTGAAGGTCGGAGTC - 
3’, GAPDHQrev: 5’ – GAAGATGGTGATGGGATTTC - 3’. All PCR reactions were 
performed using SsoFast EvaGreen SYBR Green Master Mix (Bio-Rad). Resulting Ct values 
for rpo35 were normalized using GAPDH Ct values and fold changes were calculated using 
the ∆∆Ct method, with GAPDH serving as an internal control. 
 
Quantitative Realtime PCR Array 
 
Huh7 cells were infected with either dVV-L or dVV-L-ORF6 at an MOI of 5. At 24 hours 
post-infection, cells were scraped into a 15ml Falcon tube and spun down at 1.5k rpm, 
washed twice with PBS, and resuspended in Trizol Reagent (Invitrogen). Trizol samples were 
mixed with chloroform and spun down for 15 minutes at 11k rpm, and the upper, aqueous 
phase was purified using an RNeasy Mini Kit (QIAGEN). RNA concentrations were 
determined using a spectrophotometer (Tecan). Equal amounts of RNA were then reverse 
transcribed using poly d(T)12-18, and Superscript II reverse transcriptase (Invitrogen). 
Template cDNA was mixed with RT2 SYBR Green/ROX qPCR master mix (SABiosciences) 
and 25 µl of this mixture was added to each well of the 96-well PCR array containing specific 
primer sets.  The Human Apoptosis RT2Profiler PCR Array (SABiosciences) examines 84 
genes involved in the apoptotic pathway.  These genes include members of the caspase, 
BCL2, IAP, TRAF, CARD, CIDE, death domain, death effector domain, and TNF receptor 
and ligand families, as well as genes involved in the p53 and DNA damage pathways.  The 
array also contains primer sets for five housekeeping genes and reverse transcription and PCR 
positive controls, as well as a control for genomic DNA contamination. The PCR cycling 
program was performed using an ABI 7500 Fast Real-Time PCR System (Applied 
Biosystems).  The threshold cycle (Ct) values of each gene were used to calculate the fold 
changes in gene expression using the RT2 Profiler PCR Array Data Analysis software 
(http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php), yielding expression profiles 
of Huh7 cells infected with either dVV-L-ORF6 or dVV-L for 2 independent experiments 
 
Validation of QPCR Array results 
 
Huh7, Vero E6, CaCo2 and Huh7.5 cells were infected with dVV-L-ORF6 or dVV-L at an 
MOI of 5. At 24 hours post-infection, cells were scraped into a Falcon tube and spun down at 
1.5k rpm, washed twice with PBS, and resuspended in an appropriate amount of Trizol 
Reagent (Invitrogen). Trizol samples were mixed with chloroform and spun down for 15 
minutes at 11k rpm, and the upper, aqueous phase was purified using an RNeasy Mini Kit 
(Qiagen). RNA concentrations were determined using a spectrophotometer (Tecan). Equal 
amounts of RNA were then reverse transcribed using poly d(T)12-18, and Superscript II reverse 
transcriptase (Invitrogen). cDNA samples were subjected to quantitative realtime PCR using 
appropriate TaqMan Gene Expression Assays (Life Technologies) in an ABI Fast 7500 
Realtime PCR System (Life Technologies), using HPRT1 as a housekeeping control. Fold 
changes were calculated in Microsoft Excel using the ∆∆Ct method.  
 
Microarray Analysis 
  
 
Huh7 cells were infected with either dVV-L-ORF6 or dVV-L. At 12 hours post-infection, 
cells were scraped into a 15ml Falcon tube and spun down at 1.5k rpm, washed twice with 
PBS, and resuspended in Trizol Reagent (Invitrogen). Trizol samples were mixed with 
chloroform and spun down for 15 minutes at 11k rpm, and the upper, aqueous phase was 
purified using an RNeasy Mini Kit (QIAGEN). RNA concentrations were determined using a 
spectrophotometer (Tecan). 100ng of each RNA sample was then labelled for microarray 
hybridization using the GeneChip Whole Transcript Sense Target Labelling Assay 
(Affymetrix), according to manufacturer's instructions. Briefly, the protocol is as follows: the 
RNA sample is reverse transcribed twice to yield both positive and negative-strand cDNA. 
Random hexamers are then used to generate negative-stranded cRNA from the positive-strand 
cDNA template. cRNA then serves as a template for the production of multiple copies of 
dUTP-containing positive-stranded cDNA. From here, the cDNA is fragmented with uracil 
DNA glycosylase (UDG) and fragments are terminally labelled. Labelled fragments are then 
hybridized overnight to the microarray chip before washing and staining. Washed and stained 
chips are then scanned to yield signal values for each set of probes corresponding to 
individual genes in the human genome. Raw signal values were normalized using signal 
values from control probes in the chip using the Robust Multichip Algorithm and fold 
changes were calculated in Partek Genomics Suite (Partek Incorporated). 
 
 
 
Results 
 
Generation of a defective recombinant vaccinia virus expressing SARS-CoV ORF6 
 
A widely accepted method of introducing a viral gene into a host cell where the use of the 
virus of origin is not feasible or in order to express individual viral genes in isolation is to use 
various chemical or electrical transfection methods to transport an expression plasmid 
encoding the gene of interest across the plasma membrane of the host cell. While this method 
has enjoyed substantial popularity, there are drawbacks that do not make it ideal for all 
applications. The efficiency of transfection is typically in the region of 50-70 percent 
(unpublished observation), making for an incomplete background of expression when 
examining the effect of the transfected gene on whole cell populations where the isolation of 
a single transfected cell or the population of positively transfected cells is not feasible, 
complicating the analysis of results. Also, chemical and mechanical transfection methods are 
often cytotoxic to various degrees, compromising the viability of the cell or cells in which the 
effect of the gene of interest is to be studied. An alternative strategy to introduce a gene into a 
cell in trans while achieving a comprehensive expression background is to use a recombinant 
virus to infect the cells; this virus would express the gene of interest along with its other 
constituent genes. Several vaccine candidates employ the use of recombinant viruses that are 
replication-defective in order to introduce a potentially immunogenic gene from a pathogen 
into individuals in order to elicit a protective immune response. One such virus is the 
defective vaccinia (Lister) which is deficient in uracil DNA glycosylase (Holzer & Faulkner 
1997), preventing its replication while allowing for the expression of target genes introduced 
into the genomic locus previously occupied by this glycosylase, termed D4R. The SARS-CoV 
ORF6 protein was cloned into the pDW2-mh5 vector to yield pDW2-mh5-ORF6, which 
contains a recombination cassette in order to facilitate recombination of the ORF6 gene into 
the vaccina (Lister) genome at the D4R locus. This plasmid was then recombined with 
replicative vaccinia virus by means of infection/transfection in CV-1 cells. By means of gpt 
selection, defective viruses were obtained after 5 rounds of selection and subsequent 
amplification in RK-D4R-44.20 cells, which stably express the D4R gene to allow for 
replication and hence amplification of the recombinant virus. In parallel, an empty 
  
recombinant defective vaccinia virus was created and selected in the same manner to serve as 
a control for experiments involving the recombinant virus expressing ORF6.  
 
After amplification of these viruses, we sought to determine the expression and the 
prevalence of recombinant ORF6. Huh7 and Vero E6 cells were infected with either dVV-L-
ORF6 or dVV-L at an MOI of 5 for 6 and 12 hours and analysed by immunofluorescence 
using an antibody against the ORF6 protein. The results (Fig.1a) did not show a discernible 
difference between cells infected with the empty or recombinant viruses. It was suspected that 
the antibody against ORF6 might be cross-reacting with a vaccinia protein, and therefore a 
second infection was performed using dVV-L-7a, a defective recombinant vaccinia virus 
expressing the 7a protein of SARS. Immunofluorescence analysis of this infection compared 
to infection with dVV-L using a monoclonal antibody against the 7a protein showed a clear 
difference in signal between the 2 infections. In order to determine if the ORF6 protein was 
being expressed, Huh7 and E6 cells were infected with dVV-L-ORF6 or dVV-L and 
subjected to Western Blotting using the same antibody against ORF6. These results (Fig. 1b) 
showed the expression of the ORF6 protein at a molecular weight of around 7kDa. The 
Western blot also showed the presence of 2 non-specific bands recognized by the ORF6 
antibody at 82kDa and 30kDa, which might explain the lack of a specific ORF6 signal in the 
immunofluorescence assay. As an assay to determine the relative levels of either dVV-L-
ORF6 or dVV-L virus in infected cells, RNA extracted from a parallel set of Huh7 and E6 
cells infected with both of these viruses under the same conditions was analysed by 
quantitative realtime PCR for the rpo35 gene which encodes the canonical vaccinia DNA 
polymerase (Amegadzie et al 1991). As seen in Fig. 1c and 1d, the rpo35 fold change values 
for each infection are similar, indicating that the levels of defective virus used to infect each 
cell population are approximately the same. Uninfected cells show no rpo35 signal, indicating 
that the QPCR was specific for vaccinia-encoded rpo35.  
 
The ORF6 protein expressed by dVV-L-ORF6 is able to induce caspase activity 
 
A previous report has shown that the ORF6 protein from SARS-CoV is able to induce 
caspase-3-dependent apoptosis (Ye et al 2008) in Vero E6 and COS-7 cells transfected with a 
GFP-fusion plasmid expressing ORF6. We have also observed caspase-3-dependent apoptosis 
in Vero E6 cells transfected with a mammalian expression plasmid expressing an untagged 
form of the ORF6 protein (data not shown), confirming these results. One of the concerns 
with the use of a recombinant virus expressing a gene of interest is being able to assess 
whether the use of such a recombinant system compromises the function of the gene of 
interest; a functional assay is therefore needed to make this assessment. Given previous 
publication and our own confirmatory data showing the induction of apoptosis by the ORF6 
protein, we sought to use this knowledge in order to assess the function of the ORF6 protein 
expressed by the defective vaccinia system. Vero E6 and Huh7 cells were infected with dVV-
L-ORF6 and dVV-L at an MOI of 5. A similar virus, dVV-L-7a, expressing an untagged form 
of the 7a protein of SARS-CoV, was used as a positive control. At 6, 12 and 24 hours post-
infection, cells were subjected to a caspase-3 assay using the Caspase-Glo reagent (Promega). 
The results, normalized using a cell proliferation assay based on WST-1 (Promega), showed 
the induction of caspase activity in cells that had been infected with dVV-L-ORF6 and dVV-
L-7a in both Huh7 (Fig. 2a) and Vero E6 cells (Fig. 2b), as compared to cells infected with 
dVV-L. As the data indicates that the relative induction of caspase activity was significantly 
higher in cells infected with the recombinant dVV-L-ORF6 and dVV-L-7a viruses as 
compared to the empty virus, it can be concluded that recombinant ORF6 expressed via the 
defective vaccinia system is functionally intact in that it is able to induce caspase-dependent 
apoptosis. It is noteworthy, however, that there are differences in the timing of caspase 
activation between the 2 cell lines. E6 cells show little caspase activation until the 24hr 
timepoint, while significant caspase activity is observed in the Huh7 cells as early as 12 hours 
post-infection. It is likely that this difference is dependent on physiological differences 
between the 2 cell lines.  
  
 
 
ORF6 upregulates the extrinsic pathway of apoptosis 
 
Given that we have established a system where defective recombinant viruses are used to 
introduce virus genes into cell populations where the recombinant proteins are functionally 
intact, we sought to employ this system to characterize the induction of apoptosis by the 
ORF6 protein. Because of their ability to undergo caspase dependent apoptosis from a much 
earlier timepoint (12hrs) as opposed to Vero E6 cells, Huh7 cells were infected with dVV-L-
ORF6 or dVV-L at an MOI of 5. Total RNA was extracted from samples taken at 6hrs, 12hrs, 
and 24hrs post-infection and reverse-transcribed before being subjected to analysis using a 
Human Apoptosis RT2Profiler PCR Array (SA Biosciences). The QPCR array plate contained 
primers for 84 human genes in various apoptotic pathways, along with 5 housekeeping 
controls as well as other appropriate controls for reverse transcription PCR, as well as 
genomic DNA contamination. The Ct values obtained for each well was analysed using the 
RT2 Profiler PCR Array Data Analysis suite, an online analysis suite provided by the 
manufacturer (http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php). Using this 
analysis suite, fold changes for each of the 84 apoptotic genes were obtained for cells infected 
with dVV-L-ORF6 relative to those infected with dVV-L. This experiment was repeated once 
to provide a biological replicate. Based on the 2 data sets obtained (Fig. 3), a fold change cut-
off was set at 2 and genes which were either upregulated or downregulated by more than 2-
fold were identified, yielding a total of 14 genes for validation. Validation of the results was 
performed by quantitative realtime PCR using pre-fabricated Taqman-based assays specific to 
each gene (Life Technologies). HPRT1 was used as a housekeeping control for the validation, 
given that it was observed to be the most consistent housekeeping gene amongst the 5 
housekeeping controls from the QPCR array. Fold changes were calculated for each of the 14 
genes identified from the QPCR arrays as being upregulated. Of these, 7 genes were validated 
(see Fig. 4). The fold change directions of most of these genes were consistent with the 
literature, such as the observed upregulation of proapoptotic factors such as BNIP3, TNF and 
GADD45A. One result that stood out from the rest was the observed downregulation of the 
TP53 gene, which encodes for the pro-apoptotic p53 protein. Of the rest of the genes that 
were identified for validation, some showed a fold change in the opposite direction from the 
arrays, and others failed to amplify altogether.  
 
Given the genes observed to be either upregulated or downregulated in the context of ORF6 
expression in Huh7 cells, we sought to determine if there were any cell-specific differences 
when ORF6 was expressed in other cell lines known to be permissive to SARS-CoV 
infection. Vero E6, Huh7.5 and CaCo2 cells were infected in the same manner and at 24 
hours post-infection, RNA was extracted, reverse transcribed and the resulting cDNA 
subjected to QPCR using the same Taqman probe-based assays used for validation in Huh7 
cells. Using HPRT1 as a housekeeping gene, fold changes were calculated for each cell line 
using the ∆∆Ct method, and compared to the fold changes for 14 genes obtained for Huh7 
cells (Fig. 4). It was observed that most of the genes that were observed to be upregulated in 
the Huh7 cells, such as GADD45A, LTA, TNF and BNIP3 were also upregulated in Huh7.5 
and CaCo2 cells. Genes which were downregulated consistently in Huh7 cells such as 
DAPK1 were also observed to be downregulated in Huh7.5 and CaCo2 cells. Genes which 
failed to amplify in Huh7 cells such as CD27 and TNFSF8 also failed to amplify in these 2 
cell lines. However, there were also several differences in the expression of the 14 candidate 
genes between the 3 cell lines. The CIDEB gene, which was consistently observed to be 
downregulated in Huh7 cells, was also observed to be downregulated in CaCo2 cells, but 
failed to amplify in Huh7.5 cells. The FAS gene was not validated in Huh7 cells but was 
observed to be upregulated in both Huh7.5 and CaCo2 cells, which indicated further that 
ORF6 activated the extrinsic pathway of apoptosis independently of cell type. Surprisingly, 
TP53 was observed to be upregulated in CaCo2 cells as opposed to the significant 
downregulation observed in both Huh7 and Huh7.5 cells, albeit below the threshold of 2. 
  
None of the genes selected for validation were amplified in Vero E6 cells, possibly due to 
sequence differences as the Vero E6 line is of primate origin where the other cell lines were 
of human origin (data not shown).  
 
Microarray Analysis 
 
In order to further characterize the changes in the expression profile of cells infected with 
dVV-L-ORF6 beyond an examination of the apoptotic pathway, microarray analysis of the 
same infected cell populations as used in the QPCR array was carried out. RNA samples from 
Huh7 cells 12 hours post-infection were processed and eventual cRNA was hybridized to 
Affymetrix Human Gene 1.0 ST arrays (Affymetrix). Microarray signal values were 
normalized using RMA (Robust Multichip Average) and log2-transformed across the set of 
chips to account for differences in hybridization efficiency. Following fold change 
calculations, we sought to determine if the validated genes from the QPCR array showed the 
same fold changes or fold change trends in the microarrays. In order to determine if these 
genes showed the same patterns in the microarray as they did in the QPCR array, average fold 
changes for each probeset corresponding to these genes (seen in Fig. 4) were plotted (Fig. 5). 
The resulting graph shows that the fold change trend for the genes from the microarray data 
concurs with the trend seen from the QPCR array data. The CIDEB, DAPK1 and TP53 genes 
are seen to be downregulated and BNIP3, GADD45A, LTA and TNF genes are observed to be 
upregulated as in the QPCR array. The fold change magnitudes, however, are lower than 
those seen in the QPCR array, possibly due to the fact that the microarray samples were taken 
from 12hrs post-infection. Following this, a threshold fold change of 5 was selected and the 
set of genes exhibiting fold changes greater than 5 or lesser than -5 were intersected between 
2 biological replicates to yield a list of differentially expressed genes common to both 
replicates. In order to make a determination of the functional profile of these differentially 
expressed genes, lists were analyzed using DAVID, an online toolset for functional 
assignment and grouping of gene lists from microarray data (http://david.abcc.ncifcrf.gov). 
The DAVID toolset uses data from several publicly valuable datasets such as from GO 
(www.geneontology.org), Panther and Interpro in order to assign functional annotations to 
genes in a given gene list (Huang et al 2009a, Huang et al 2009b). Analysis was performed in 
DAVID using the GO_xx_FAT datasets (GO_MF_FAT, GO_BP_FAT and GO_CC_FAT), 
which provide high level functional assignments of molecular function, biological processes 
and cellular components in order to simplify the data output from these datasets. From the 
data output, a threshold was set at an enrichment score of 1.0, and these results are 
represented in Tables 1 & 2, and show the upregulation and downregulation (respectively) of 
genes in a few pathways. There were many similarities between the pathways affected by 
genes that were either upregulated or downregulated, indicating that the ORF6 protein was 
acting on specific pathways in cells infected with dVV-L-ORF6. Interestingly, 3 of the 
downregulated candidate genes – LRP1, MAPK8IP2, PTK2B - were annotated as being 
related to “positive regulation of anti-apoptosis” (GO:0045768), and these genes were not 
represented amongst the genes present in the QPCR array.  
 
 
 
Discussion 
 
Here we have attempted to characterise the induction of apoptosis by the SARS-CoV ORF6 
protein by introducing the ORF6 gene in trans using a defective recombinant vaccinia virus 
based on the Lister strain. One of the challenges associated with such studies is the 
homogeneity of expression in the cell population being studied. Conventional chemical and 
electrical transfection methods result in a low to medium efficiency of transduction. With the 
use of a replication-defective recombinant virus expressing ORF6, we were able to achieve a 
high transduction efficiency for recombinant ORF6, giving us a thorough and largely 
homogenous expression background in perform the characterisation. The expression, 
  
transduction efficiency and relative amounts of virus were tested for each infection and the 
result showed that these were adequate for the task of expression profiling of pro- and anti-
apoptotic factors in the chosen cell lines. As an assay of the functional viability of the 
recombinant ORF6 protein, we performed a caspase assay in both Vero E6 and Huh7 cell 
lines, which showed that in cells infected with dVV-L-ORF6, caspase activation was 
significantly higher than in cells infected with dVV-L. While this indicated that ORF6 
induced caspase-3-dependent apoptosis and was therefore functionally intact, the assay also 
threw up differences between the 2 cell lines as far as the activation of caspases was 
concerned. In Vero E6 cells, caspase activation was only seen at 24 hours post-infection, 
while in Huh7 cells, the induction of caspases was observed to occur much earlier, at the 12-
hour timepoint. This can be taken to be indicative of cell-type differences resulting in 
different responses to the same stimuli, a theme which is seen again in the comparison of the 
characterisation of apoptotic responses to ORF6 protein in different cell types.  
 
In order to arrive at a profile of the expression of apoptotic pathway genes in cells infected 
with the recombinant compared to cells which were infected with an empty virus, we 
employed the use of a commercially-available SYBR Green-based QPCR array, 14 genes 
from which were subsequently validated by using QPCR, employing a different set of primers 
and Taqman chemistry. The results of the array and subsequent validation showed that the 
expression of a total of 7 apoptotic genes were stimulated or repressed by the presence of 
ORF6 protein, when compared to RNA populations in cells infected with dVV-L, the empty 
defective virus. These genes were observed to fall into 2 categories – those related to the 
mitochondrial death pathway and others related to the extrinsic pathway of apoptotic 
induction. The genes BNIP3 and CIDEB are known to be pro-apoptotic factors in the 
mitochondrial death pathway, and it is indeed surprising to see a difference in the expression 
patterns of these pro-apoptotic genes. While BNIP3 is observed to be upregulated, CIDEB 
undergoes a significant downregulation, which would be at odds with the logic of the 
upregulation or activation of pro-apoptotic genes during the induction of apoptosis. A 
resolution to this apparent contradiction will probably require an examination of the protein 
levels of these 2 proteins – it is recognized that a large majority of the myriad of factors 
involved in apoptotic induction and execution are regulated at the protein level, and this can 
differ from patterns observed at the mRNA level.  
 
A few of the 7 genes validated from this study were identified as belonging to the extrinsic 
pathway of apoptotic activation: TNF, LTA and GADD45A. TNF encodes for the TNFα 
protein that binds to the TNF receptor, one of the major initiators of the extrinsic pathway of 
apoptosis signaling. The expression of the TNF gene here is very interesting, as a previous 
study on the induction of apoptosis by the ORF6 protein (Ye et al 2008) is indicative of JNK 
activation. The TNF gene is a known transcriptional target of both JNK and p38 MAPK, 
which are both mediators of apoptotic signaling in either direction – pro and anti-apoptotic, 
but in this case, pro-apoptotic. From here, the binding of TNFα to the TNF receptor initiates 
the activation of caspase-8, which eventually results in the execution of the death program by 
the activation of executor caspases such as caspase-3 and caspase-9. Further evidence of the 
involvement of this pathway in the apoptotic activity of the ORF6 protein comes from the 
results of the microarray studies. The pathway analysis of the most highly upregulated genes 
in the array point to a myriad of different cellular processes being activated by the ORF6 
protein. However, there does exist a commonality to these processes – these are largely 
calcium-dependent processes. A plausible explanation for the activation of so may calcium-
dependent processes in cells infected with dVV-L-ORF6 is that this is indicative of the 
presence of a large intracellular pool of calcium in these cells. A great deal of published work 
has implicated elevated calcium levels in the ER as a putative ‘trigger’ that initiates apoptotic 
signaling (Demaurex and Distelhorst 2003, Orrenius et al 2003, Timms et al 2009). Such 
work has also shown that JNK activation in apoptotic cells correlates to sustained elevated ER 
calcium levels, leading to the transcriptional activation of TNF, downstream signaling of the 
TNF receptor and subsequent caspase recruitment and activation (Brnjic et al 2009). The 
  
elevated levels of intracellular calcium correspond to the activation of the ER stress pathway, 
a commonality observed in the induction of apoptosis by many viral proteins (Foo et al 2002, 
Jordan et al 2002, Benali-Furet et al 2005), including the SARS-CoV 3a protein (Law et al 
2005, Minakshi et al 2009). In this pathway, ER stress signals initiate large influxes of 
calcium into cells, sustained levels of which initiate p38 MAPK and JNK signaling, resulting 
in the transcriptional activation of TNF and the eventual caspase signaling cascade leading to 
caspase-3 activation, as discussed above. To this end, we have observed the differential 
expression of several genes related to calcium influx and the cellular reponse to elevated 
intracellular calcium, such as those encoding for subunits for the L-type calcium channels, 
CACNA1D, CACNA1E, CACNA1F, CACNA1G, CACNA1S and other genes involved in the 
transduction of calcium signals such as CAPN3 (calpain 3) and (calmodulin-binding 
transactivation factor).  
 
The transduction of pro-apoptotic JNK signaling can occur via either the intrinsic or extrinsic 
pathways of apoptosis, or a combination of both. While we do observe some degree of 
activation of the mitochondrial pathway, as evidenced by the observed, reproducible 
upregulation of BNIP3, we also observe a downregulation of a key component of the intrinsic 
pathway, TP53, at the mRNA level in cells infected with dVV-L-ORF6. This could mean that 
ORF6 apoptosis occurs solely via the extrinsic pathway (downstream of ER stress and JNK 
activation) or via a p53-independent activation the intrinsic pathway, along with concomitant 
activation of the extrinsic pathway. The relationship between JNK and p53 is somewhat 
contentious from the literature, with conflicting reports that JNK either stabilizes and 
activates p53 transcription (Fuchs et al 1998 PNAS) or that JNK inhibits the activity of p53 
(Das et al 2007 PNAS). Given the pleiotropic nature of JNK itself, this relationship may be 
dependent on physiological context and therefore one could surmise, in this instance, that 
JNK might be inhibiting p53 and therefore apoptotic activation by the ORF6 gene, is 
independent of p53. It is however, necessary to examine the protein levels of p53 as the 
downregulation of TP53 expression need not necessarily indicate the lack of p53 activity, as 
the proapoptotic activity of p53 could only require the stabilization and nuclear accumulation 
of p53 already present in the cell. As such, the involvement of p53 in the induction of 
apoptosis by the ORF6 protein cannot be ruled out until such studies are performed.  
 
Indeed, it would be prudent to examine the protein products of the genes discussed here, as it 
is widely recognized that a large part of apoptotic regulation in eukaryotic cells occurs at the 
protein level. However, studies like this help to isolate targets for such further study at the 
protein level. An example of this would be factors upstream and downstream of JNK, such as 
TNF and GADD45A, and the protein products of downregulated anti-apoptotic genes such as 
LRP1, MAPK8IP2 and PTK2B. Further analysis of the microarray data may also shed light on 
the host expression changes induced by the ORF6 protein, which lead to its cellular effects.  
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Figure Legends 
 
1. Expression of recombinant ORF6 from a defective vaccinia virus. (a) Huh7 cells plated on 
glass coverslips were infected with dVV-L and  dVV-L-ORF6 or dVV-L and dVV-L7a at an 
MOI of 5 for either 6 or 12 hours. At the appropriate timepoints, coverslips were fixed in 
methanol and subjected to immunofluorescence analysis using antibodies against the ORF6 
and 7a proteins, and FITC-conjugated secondary antibodies, before being mounted on glass 
slides and imaged with a Zeiss LSM510Meta confocal microscope. (b) Western blot for 
expression analysis of ORF6 expressed from recombinant vaccinia virus. Huh7 and E6 cells 
were infected with dVV-L or dVV-L-ORF6 at an MOI of 5 for 6 or 12 hours. Cells were 
lysed at the appropriate timepoints and subjected to SDS-PAGE separation and Western 
blotting using an antibody against ORF6 (indicated by arrow). Comparison of virus levels 
used in each infection. (c) Huh7 cells and (d) Vero E6 cells were infected with dVV-L-ORF6 
or dVV-L at an MOI of 5 for 6 or 12 hours, after which cells were lysed and total RNA 
extracted and subjected to SYBR-Green QPCR using primers against the rpo35 gene of 
vaccinia. Relative quotients for each QPCR were calculated using the ∆∆Ct method, with 
GAPDH as a housekeeping gene.  
 
2. Induction of caspase activity by ORF6 expressed from a defective recombinant vaccinia 
virus. Huh7 cells (a) or Vero E6 cells (b) were infected with either dVV-L-ORF6 or dVV-L 
or dVV-L-7a (as a positive control for caspase induction) at an MOI of 5 for either 6, 12 or 24 
hours and were subjected to a luminescent assay for caspase-3 activity. A WST-1 assay for 
cell proliferation was used to normalize the readings from the caspase assay and the resulting 
values were plotted for each virus at each timepoint. 
 
3. The ORF protein induces differential expression of genes in the apoptotic pathway. Huh 7 
cells were infected at an MOI of 5 for 24 hrs in 2 independent experiments and resulting total 
cDNA was subjected to a commercially available SYBR-Green QPCR array for selected pro- 
and anti-apoptotic genes. Using the HPRT1 gene as a housekeeping control, fold changes 
were calculated by the ∆∆Ct method, using the manufacturer’s data analysis suite 
(http://pcrdataanalysis.sabiosciences.com/pcr/arrayanalysis.php). Genes exhibiting fold 
changes either greater than 2 or lower than -2 were plotted for 2 biological replicates, along 
with validation fold changes for these genes (see next figure).  
 
4. Validation of differentially expressed apoptotic genes in multiple cell lines. Huh7, Huh7.5, 
CaCo2 and Vero E6 cells were infected with either dVV-L-ORF6 or dVV-L for 24 hours and 
resulting total cDNA was subjected to QPCR analysis using alternative primer and probe sets 
for candidate genes based on Taqman chemistry, with HPRT1 as a housekeeping gene. Fold 
changes were calculated using the ∆∆Ct method and plotted for each cell line. E6 samples 
showed no amplification (not shown).  
 
5. Fold change comparison of validated genes from QPCR array with microarray results. 
Huh7 cells were infected with either dVV-L-ORF6 or dVV-L at an MOI of 5 for 12 hours and 
total RNA was subjected to microarray analysis using the HuGene 1.0 ST Gene array 
(Affymetrix). Fold changes were calculated in Partek Genomic Suite and these fold changes 
were plotted for genes found in the microarray data which were validated from the QPCR 
array results. Data is collated from 2 independent experiments.  
 
Table 1. Functional analysis of upregulated genes from microarray study. Genes from the 
microarray study which showed fold changes lower than -5 were selected and input into the 
DAVID functional annotation database to yield functional information on highly 
downregulated genes. A total of 161 genes were analysed in this manner and the results were 
filtered by setting a threshold enrichment score of 1.0 and collated into a table showing the 
genes clustered by functional annotation using the GO_xx_FAT databases. 
 
  
Table 2. Functional analysis of downregulated genes from microarray study. Genes from the 
microarray study which showed fold changes lower than -5 were selected and input into the 
DAVID functional annotation database to yield functional information on highly 
downregulated genes. A total of 175 genes were analysed in this manner and the results were 
filtered by setting a threshold enrichment score of 1.0 and collated into a table showing the 
genes clustered by functional annotation using the GO_xx_FAT databases. 
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Annotation No. of 
Genes 
Genes 
ATP-Binding and 
ATPase activity 
37 ABCA12, ABCA7, ABCB11, ABCC12, ACSM1, ADCY1, ALK, 
ATP8B2, DGKA, DHX30, DNAH1, DNAH11, DNAH6, DNAH8, 
GUCY2F, IFIH1, KDR, KIT, KSR1, LIMK2, LRGUK, MAST2, 
MCM7, MOV10L1, MSH4, MYH6, OBSCN, OXSR1, PAN3, 
PASK, PRKCG, RET, RUNX1, SLC22A4, STK32A, TTN, WNK2 
Ion Channel Activity 13 CACNA1G, CACNA1S, CACNA2D1, FXYD4, GRIK5, KCNK16, 
NALCN, RYR1, SCN3A, SCN4A, SCN7A, SCN10A, TRPM3,  
Plasma Membrane 62 ABCA7, ABCB11, ACTN2, ADCY1, ALK, ATP6V1G3, 
CACNA1G, CACNA1S, CACNA2D1, CALCR, CD163L1, CD44, 
CLTCL1, CSMD2, DGKA, DIAPH1, DYSF, EFNA5, EPB41, FAP, 
GRIK5, GUCY2F, HLA-F, IL1RL1, ITGA11, ITGAL, JAG2, KDR, 
KIT, LGR4, LILRB3, MAST2, MGAM, MRC1, MUC16, MYH6, 
NBEA, OBSCN, PCDH15, PDE6C, PDZD11, PDZD2, PKHD1, 
PLB1, PLXNA3, PLXND1, PTPRD, RASGRF1, RYR1, SCN10A, 
SCN3A, SCN4A, SCN7A, SECTM1, SHROOM3, SLC22A4, SPTB, 
TMEM67, TPO, VAMP1, ZAN 
Cation Binding 66 ACAP1, ACSM1, ACTN2, ADAM32, ADAMTS20, ADCY1, 
AMY2B, ATP8B2, BMP1, C20ORF12, CACNA1G, CACNA1S, 
CACNA2D1, CAPN3, COL9A1, DCHS2, DGKA, DNASE1, DZIP3, 
FBN2, FGD5, FOXP2, HMCN1, IFIH1, ITGA11, ITGAL, JAG2, 
KCNK16, KSR1, LIMK2, LMBRD1, LRP4, MAST2, MCTP2, MLL4, 
MOV10L1, MRC1, NALCN, NEBL, OBSCN, OXSR1, PCDH15, 
PHF8, POMGNT1, PRDM15, PRKCG, RABGGTB, RET, RNF160, 
RORB, RUNX1, RYR1, SCN10A, SCN3A, SCN4A, SCN7A, SFXN2, 
SLC22A4, STK32A, TP63, TPO, TRPM3, TTN, USP20, ZFYVE26, 
ZNF323, 
Cytoskeletal Protein 
Binding 
16 ACTN2, DAAM2, DIAPH1, DNASE1, EPB41, FHOD3, IPP, 
MYBPC1, MYH6, MYPN, NEBL, OBSCN, RET, SHROOM3, SPTB, 
TTN 
Structural Molecule 
Activity 
14 ACTN2, COL15A1, COL16A1, COL4A4, COL5A2, COL9A1, 
CYLD, EPB41, FBN2KRT31, IMPG2, MYBPC1,NEBL, OBSCN 
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Annotation No. of 
Genes 
Genes 
ATP-Binding and 
ATPase activity 
41 ABCA12, ABCA2, ABCC12, ACSM1, ADCY1, ALK, ATP10A, 
ATP8B2, ATR, DGKA, DGKD, DHX29, DHX30, DNAH1, DNAH6, 
KDR, KIF11, KIF15, KIF1A, KIF4A, KIF6, KIT, LIG3, MCM7, 
MKI67, MOV10L1, MYH14, MYH6, OBSCN, OPLAH, ORC1L, 
OXSR1, PASK, PTK2B, RECQL5, RET, STK32A, TEK, TEP1, TTN, 
UBE2J2, ULK2 
Ion Channel Activity 11 ANO7, CACNA1D, CACNA1G, CACNA1S, FXYD4, GRIK5, 
KCNK16, KCNQ1, NALCN, RASA3, SCN7A  
Microtubule/Cytoskel
eton 
23 ABCA2, CENPF, CEP152, DNAH1, DNAH6, DNASE1, HDAC6, 
IPP, KIF11, KIF15, KIF1A, KIF4A, KIF6, MED12, MYH14, MYH6, 
PKHD1, RAB3IP, SHROOM3, SPTB, TACC2, TTLL9, TTN 
Calcium Ion Binding 26 ACTN2, AMY2B, ANO7, BMP1, CACNA1D, CACNA1G, 
CACNA1S, CAPN3, DCHS2, DGKA, DNASE1, FBN2, HMCN1, 
ITGA2B, ITGAL, JAG2, LRP1, LRP4, LTBP2, MAN1B1, NELL2, 
PCDH15, PLCG2, RET, RYR1, TTN 
Muscle System 
Process 
7 CACNA1G, KCNQ1, MYH6, RYR1, SCN4A, SCN7A, TTN 
Positive Regulation of 
Anti-Apoptosis 
3 LRP1, MAPK8IP2, PTK2B 
 
 
Table 2 


